US20210079006A1 - Nitrogen-containing heterocyclic compounds as fxr modulators - Google Patents
Nitrogen-containing heterocyclic compounds as fxr modulators Download PDFInfo
- Publication number
- US20210079006A1 US20210079006A1 US17/108,644 US202017108644A US2021079006A1 US 20210079006 A1 US20210079006 A1 US 20210079006A1 US 202017108644 A US202017108644 A US 202017108644A US 2021079006 A1 US2021079006 A1 US 2021079006A1
- Authority
- US
- United States
- Prior art keywords
- compound
- group
- substituted
- alkyl
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 Nitrogen-containing heterocyclic compounds Chemical class 0.000 title claims description 91
- 150000001875 compounds Chemical class 0.000 claims abstract description 265
- 239000000203 mixture Substances 0.000 claims abstract description 130
- 102100038495 Bile acid receptor Human genes 0.000 claims abstract description 43
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 14
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 14
- 208000019423 liver disease Diseases 0.000 claims abstract description 14
- 230000001404 mediated effect Effects 0.000 claims abstract description 14
- 208000008589 Obesity Diseases 0.000 claims abstract description 13
- 235000020824 obesity Nutrition 0.000 claims abstract description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 12
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 11
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 10
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 10
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 10
- 208000010643 digestive system disease Diseases 0.000 claims abstract description 10
- 208000018685 gastrointestinal system disease Diseases 0.000 claims abstract description 10
- 208000017169 kidney disease Diseases 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 91
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 25
- 125000002947 alkylene group Chemical group 0.000 claims description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 125000000304 alkynyl group Chemical group 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 19
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 18
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 18
- 229910003827 NRaRb Inorganic materials 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 12
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 9
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 8
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 8
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 claims description 8
- 208000001088 cerebrotendinous xanthomatosis Diseases 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 7
- 125000003368 amide group Chemical group 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000004450 alkenylene group Chemical group 0.000 claims description 5
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 229910006069 SO3H Inorganic materials 0.000 claims description 4
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 4
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 2
- 229910052702 rhenium Inorganic materials 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 156
- 239000000243 solution Substances 0.000 description 148
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 146
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 85
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 70
- 239000007787 solid Substances 0.000 description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- TYIDIQSHMNIPKI-UHFFFAOYSA-N CC(C)(C)CC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl Chemical compound CC(C)(C)CC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl TYIDIQSHMNIPKI-UHFFFAOYSA-N 0.000 description 45
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 40
- 239000000741 silica gel Substances 0.000 description 40
- 229910002027 silica gel Inorganic materials 0.000 description 40
- 239000003208 petroleum Substances 0.000 description 35
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 34
- XCIWZNHTOAUIRL-UHFFFAOYSA-N CC(C)C1=C(CC(C)(C)C)C(C2=C(Cl)C=CC=C2Cl)=NO1 Chemical compound CC(C)C1=C(CC(C)(C)C)C(C2=C(Cl)C=CC=C2Cl)=NO1 XCIWZNHTOAUIRL-UHFFFAOYSA-N 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 0 [10*]C.[4*]C*1CC(C[W])C1 Chemical compound [10*]C.[4*]C*1CC(C[W])C1 0.000 description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
- 125000004432 carbon atom Chemical group C* 0.000 description 28
- 125000000623 heterocyclic group Chemical group 0.000 description 28
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- 239000012267 brine Substances 0.000 description 25
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 125000005843 halogen group Chemical group 0.000 description 24
- 229910052739 hydrogen Inorganic materials 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 22
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 21
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- ZADJOWHTVVNCNM-LLVKDONJSA-N C[C@@H]1CN(C(C)(C)C)CCN1C(C)(C)C Chemical compound C[C@@H]1CN(C(C)(C)C)CCN1C(C)(C)C ZADJOWHTVVNCNM-LLVKDONJSA-N 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000001257 hydrogen Substances 0.000 description 19
- 125000001424 substituent group Chemical group 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- SLRQZQPUXWCTDN-UHFFFAOYSA-N CC(C)(C)N1CCN(C(C)(C)C)CC1 Chemical compound CC(C)(C)N1CCN(C(C)(C)C)CC1 SLRQZQPUXWCTDN-UHFFFAOYSA-N 0.000 description 17
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 17
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 125000003710 aryl alkyl group Chemical group 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- ZADJOWHTVVNCNM-NSHDSACASA-N C[C@H]1CN(C(C)(C)C)CCN1C(C)(C)C Chemical compound C[C@H]1CN(C(C)(C)C)CCN1C(C)(C)C ZADJOWHTVVNCNM-NSHDSACASA-N 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- FYSHKKAWEGZUEY-TXEJJXNPSA-N C[C@H]1CN(C(C)(C)C)[C@H](C)CN1C(C)(C)C Chemical compound C[C@H]1CN(C(C)(C)C)[C@H](C)CN1C(C)(C)C FYSHKKAWEGZUEY-TXEJJXNPSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- DVAQLKVNVWANSR-UHFFFAOYSA-N methyl 2-chloro-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1 DVAQLKVNVWANSR-UHFFFAOYSA-N 0.000 description 8
- DMPZJACLHDWUFS-UHFFFAOYSA-N 1,3-benzothiazole-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CSC2=C1 DMPZJACLHDWUFS-UHFFFAOYSA-N 0.000 description 7
- DAZLXPUSMBNBGA-UHFFFAOYSA-N CC(C)(C)C1CCN(C(C)(C)C)CC1 Chemical compound CC(C)(C)C1CCN(C(C)(C)C)CC1 DAZLXPUSMBNBGA-UHFFFAOYSA-N 0.000 description 7
- 229940126062 Compound A Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 7
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- LNJKOZHBNRSQOR-UHFFFAOYSA-N CC(C)C1=C(CC(C)(C)C)N(C2=C(Cl)C=CC=C2Cl)N=C1 Chemical compound CC(C)C1=C(CC(C)(C)C)N(C2=C(Cl)C=CC=C2Cl)N=C1 LNJKOZHBNRSQOR-UHFFFAOYSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 125000004404 heteroalkyl group Chemical group 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000003613 bile acid Substances 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- GWTDMUYLKYOFOS-MRXNPFEDSA-N 2-[(2R)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-4-propan-2-yl-1,3-benzothiazole-6-carboxylic acid Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)CN1C[C@H](N(CC1)C=1SC2=C(N=1)C(=CC(=C2)C(=O)O)C(C)C)C GWTDMUYLKYOFOS-MRXNPFEDSA-N 0.000 description 4
- XHQAYLOZUUZRRD-CYBMUJFWSA-N 2-[(2R)-4-[[5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxamide Chemical compound C1=C(C2=C(C=C1C(=O)N)SC(=N2)N1CCN(CC=2C(C3=C(Cl)C=NC=C3Cl)=NOC=2C2CC2)C[C@H]1C)OC XHQAYLOZUUZRRD-CYBMUJFWSA-N 0.000 description 4
- DDKZVNGQZHZESD-UHFFFAOYSA-N 2-[1-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]piperidin-4-yl]-4-methoxy-1,3-benzothiazole-6-carboxylic acid Chemical compound C1=C(C2=C(SC(=N2)C2CCN(CC=3C(C4=C(Cl)C=CC=C4Cl)=NOC=3C(C)C)CC2)C=C1C(=O)O)OC DDKZVNGQZHZESD-UHFFFAOYSA-N 0.000 description 4
- OUUVSJOGZADEQK-UHFFFAOYSA-N 2-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]piperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carbonitrile Chemical compound ClC1=C(C(=CC=C1)Cl)C1=NOC(=C1CN1CCN(CC1)C=1SC2=C(N=1)C(=CC(=C2)C#N)OC)C(C)C OUUVSJOGZADEQK-UHFFFAOYSA-N 0.000 description 4
- WGOVDCOFGJIZQP-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazole-4-carbaldehyde Chemical compound O=CC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl WGOVDCOFGJIZQP-UHFFFAOYSA-N 0.000 description 4
- MDIQOYGWSCUHLL-IDBRGDLFSA-N CC(C)(C)C.CC(C)(C)C1=[2H]C2=CC=CC=C2C1 Chemical compound CC(C)(C)C.CC(C)(C)C1=[2H]C2=CC=CC=C2C1 MDIQOYGWSCUHLL-IDBRGDLFSA-N 0.000 description 4
- ZADJOWHTVVNCNM-UHFFFAOYSA-N CC1CN(C(C)(C)C)CCN1C(C)(C)C Chemical compound CC1CN(C(C)(C)C)CCN1C(C)(C)C ZADJOWHTVVNCNM-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000003081 coactivator Effects 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- DDTMYVRJHZZBBA-AAFJCEBUSA-N 2-[(2R)-4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]-2-methylpiperidin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylic acid Chemical compound ClC1=C(C(=CC=C1)Cl)C1=NOC(=C1CC1C[C@H](N(CC1)C=1SC2=C(N=1)C(=CC(=C2)C(=O)O)OC)C)C(C)C DDTMYVRJHZZBBA-AAFJCEBUSA-N 0.000 description 3
- WYQDCUVPPHJHML-CQSZACIVSA-N 2-[(2R)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methyl-3,6-dihydro-2H-pyridin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylic acid Chemical compound COC1=C2N=C(SC2=CC(=C1)C(O)=O)N1CC=C(CC2=C(ON=C2C2=C(Cl)C=CC=C2Cl)C2CC2)C[C@H]1C WYQDCUVPPHJHML-CQSZACIVSA-N 0.000 description 3
- LNBZNTXDGDLBTG-CYBMUJFWSA-N 2-[(2R)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-4-(trifluoromethoxy)-1,3-benzothiazole-6-carboxylic acid Chemical compound C[C@@H]1CN(CC2=C(ON=C2C2=C(Cl)C=CC=C2Cl)C2CC2)CCN1C1=NC2=C(OC(F)(F)F)C=C(C=C2S1)C(O)=O LNBZNTXDGDLBTG-CYBMUJFWSA-N 0.000 description 3
- HGCUAIIWGRIVPJ-AWEZNQCLSA-N 2-[(2S)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-7-methoxy-1,3-benzothiazole-5-carboxamide Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)CN1C[C@@H](N(CC1)C=1SC2=C(N=1)C=C(C=C2OC)C(=O)N)C HGCUAIIWGRIVPJ-AWEZNQCLSA-N 0.000 description 3
- KKDUNWVXDDCJAH-UHFFFAOYSA-N 2-[4-[[2-(2,6-dichlorophenyl)-4-propan-2-ylpyrazol-3-yl]methyl]piperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylic acid Chemical compound COC1=C2N=C(SC2=CC(=C1)C(O)=O)N1CCN(CC2=C(C=NN2C2=C(Cl)C=CC=C2Cl)C(C)C)CC1 KKDUNWVXDDCJAH-UHFFFAOYSA-N 0.000 description 3
- HTTNVLKTDLJLPM-UHFFFAOYSA-N 2-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]-2-(hydroxymethyl)piperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylic acid Chemical compound C1=C(C2=C(C=C1C(=O)O)SC(=N2)N1CCN(CC=2C(C3=C(Cl)C=CC=C3Cl)=NOC=2C(C)C)CC1CO)OC HTTNVLKTDLJLPM-UHFFFAOYSA-N 0.000 description 3
- AVFYXAIHFCRDIQ-UHFFFAOYSA-N 2-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]-3,3-dimethylpiperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylic acid Chemical compound COC1=C2N=C(SC2=CC(=C1)C(O)=O)N1CCN(CC2=C(ON=C2C2=C(Cl)C=CC=C2Cl)C(C)C)C(C)(C)C1 AVFYXAIHFCRDIQ-UHFFFAOYSA-N 0.000 description 3
- IFEYLBKLCAVCNW-UHFFFAOYSA-N 2-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]piperazin-1-yl]-1-benzofuran-5-carboxylic acid Chemical compound CC(C)C1=C(CN2CCN(CC2)C2=CC3=CC(=CC=C3O2)C(O)=O)C(=NO1)C1=C(Cl)C=CC=C1Cl IFEYLBKLCAVCNW-UHFFFAOYSA-N 0.000 description 3
- TUFZXCPMTCEOAG-UHFFFAOYSA-N CC(C)(C)CC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F Chemical compound CC(C)(C)CC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F TUFZXCPMTCEOAG-UHFFFAOYSA-N 0.000 description 3
- PJSDGMKPMWYVMM-UHFFFAOYSA-N CCC1CN(C(C)(C)C)CCN1C(C)(C)C Chemical compound CCC1CN(C(C)(C)C)CCN1C(C)(C)C PJSDGMKPMWYVMM-UHFFFAOYSA-N 0.000 description 3
- FYSHKKAWEGZUEY-VXGBXAGGSA-N C[C@@H]1CN(C(C)(C)C)[C@H](C)CN1C(C)(C)C Chemical compound C[C@@H]1CN(C(C)(C)C)[C@H](C)CN1C(C)(C)C FYSHKKAWEGZUEY-VXGBXAGGSA-N 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- JBAFDIUNNPEGBJ-UHFFFAOYSA-N methyl 2,4-dichloro-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(Cl)=C2N=C(Cl)SC2=C1 JBAFDIUNNPEGBJ-UHFFFAOYSA-N 0.000 description 3
- BWZYGMWPBFZOHH-OAHLLOKOSA-N methyl 2-[(2R)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methyl-3,6-dihydro-2H-pyridin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2N=C(SC2=C1)N1CC=C(CC2=C(ON=C2C2=C(Cl)C=CC=C2Cl)C2CC2)C[C@H]1C BWZYGMWPBFZOHH-OAHLLOKOSA-N 0.000 description 3
- PSGCIFLDXYKSSL-QGZVFWFLSA-N methyl 2-[(2R)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-4-propan-2-yl-1,3-benzothiazole-6-carboxylate Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)CN1C[C@H](N(CC1)C=1SC2=C(N=1)C(=CC(=C2)C(=O)OC)C(C)C)C PSGCIFLDXYKSSL-QGZVFWFLSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 2
- WLWNRAWQDZRXMB-YLFCFFPRSA-N (2r,3r,4r,5s)-n,3,4,5-tetrahydroxy-1-(4-phenoxyphenyl)sulfonylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 WLWNRAWQDZRXMB-YLFCFFPRSA-N 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 2
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 2
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 2
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 2
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 2
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 2
- MSSQOQPKGAMUSY-LEAFIULHSA-N 2-[1-[2-[(4r,6s)-8-chloro-6-(2,3-dimethoxyphenyl)-4,6-dihydropyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetic acid Chemical compound COC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N3C=CC=C3[C@@H](CC(=O)N3CCC(CC(O)=O)CC3)O2)=C1OC MSSQOQPKGAMUSY-LEAFIULHSA-N 0.000 description 2
- LHASZEBEQGPCFM-CJFMBICVSA-N 2-amino-4-[(1r)-1-[[(6r)-6-[(5-chloro-2-methoxyphenyl)methyl]-7-oxo-3-(phenoxyamino)-5,6-dihydro-2h-1,4-diazepine-1-carbonyl]amino]propyl]benzoic acid Chemical compound C([C@@H]1CNC(CN(C1=O)C(=O)N[C@H](CC)C=1C=C(N)C(C(O)=O)=CC=1)=NOC=1C=CC=CC=1)C1=CC(Cl)=CC=C1OC LHASZEBEQGPCFM-CJFMBICVSA-N 0.000 description 2
- SZHNMJRTGSYAEX-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-4-[[4-[4-methoxy-6-(2H-tetrazol-5-yl)-1,3-benzothiazol-2-yl]piperazin-1-yl]methyl]-5-propan-2-yl-1,2-oxazole Chemical compound C1=C(C2=C(C=C1C=1NN=NN=1)SC(=N2)N1CCN(CC=2C(C3=C(Cl)C=CC=C3Cl)=NOC=2C(C)C)CC1)OC SZHNMJRTGSYAEX-UHFFFAOYSA-N 0.000 description 2
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 2
- XDCOYBQVEVSNNB-UHFFFAOYSA-N 4-[(7-naphthalen-2-yl-1-benzothiophen-2-yl)methylamino]butanoic acid Chemical compound OC(=O)CCCNCc1cc2cccc(-c3ccc4ccccc4c3)c2s1 XDCOYBQVEVSNNB-UHFFFAOYSA-N 0.000 description 2
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 2
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 2
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- NZSQBRZWARZNQH-ZWOACCQCSA-N C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C Chemical compound C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C NZSQBRZWARZNQH-ZWOACCQCSA-N 0.000 description 2
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 2
- ZJTQMGIDPFXGNC-UHFFFAOYSA-N CC(C)(C)N1CC2CCC(C1)N2C(C)(C)C Chemical compound CC(C)(C)N1CC2CCC(C1)N2C(C)(C)C ZJTQMGIDPFXGNC-UHFFFAOYSA-N 0.000 description 2
- IGUBIBJJSFVADV-UHFFFAOYSA-N CC(C)(C)N1CCN(C(C)(C)C)C(C)(C)C1 Chemical compound CC(C)(C)N1CCN(C(C)(C)C)C(C)(C)C1 IGUBIBJJSFVADV-UHFFFAOYSA-N 0.000 description 2
- VULNZMIAAUDHCW-UHFFFAOYSA-N CC(C)(C)N1CCN(C(C)(C)C)C2(CC2)C1 Chemical compound CC(C)(C)N1CCN(C(C)(C)C)C2(CC2)C1 VULNZMIAAUDHCW-UHFFFAOYSA-N 0.000 description 2
- VNFJKEDKSFJODW-UHFFFAOYSA-N CC(C)C1CN(C(C)(C)C)CCN1C(C)(C)C Chemical compound CC(C)C1CN(C(C)(C)C)CCN1C(C)(C)C VNFJKEDKSFJODW-UHFFFAOYSA-N 0.000 description 2
- BGNQEPVIGNQKHJ-UHFFFAOYSA-N CC1CCN(C(C)(C)C)CCN1C(C)(C)C Chemical compound CC1CCN(C(C)(C)C)CCN1C(C)(C)C BGNQEPVIGNQKHJ-UHFFFAOYSA-N 0.000 description 2
- 125000006519 CCH3 Chemical group 0.000 description 2
- ZRMKQODKOYJRAG-UHFFFAOYSA-N COC(=O)C1=C(F)C=C2N=C(Cl)SC2=C1 Chemical compound COC(=O)C1=C(F)C=C2N=C(Cl)SC2=C1 ZRMKQODKOYJRAG-UHFFFAOYSA-N 0.000 description 2
- HSTWZXJDEICJAL-UHFFFAOYSA-N COC(=O)C1=CC=C2N=C(Cl)SC2=C1 Chemical compound COC(=O)C1=CC=C2N=C(Cl)SC2=C1 HSTWZXJDEICJAL-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- BYTNEISLBIENSA-MDZDMXLPSA-N GW 4064 Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(C=C1Cl)=CC=C1\C=C\C1=CC=CC(C(O)=O)=C1 BYTNEISLBIENSA-MDZDMXLPSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 2
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 2
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910019020 PtO2 Inorganic materials 0.000 description 2
- 229940125907 SJ995973 Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- KSQVGVMZECCPAT-AEFFLSMTSA-N [(1R)-4-phenyl-1-[[(2R)-2-(pyrazine-2-carbonylamino)pentanoyl]amino]butyl]boronic acid Chemical compound B([C@H](CCCC1=CC=CC=C1)NC(=O)[C@@H](CCC)NC(=O)C2=NC=CN=C2)(O)O KSQVGVMZECCPAT-AEFFLSMTSA-N 0.000 description 2
- NELWQUQCCZMRPB-UBPLGANQSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(4-amino-5-ethenyl-2-oxopyrimidin-1-yl)-2-methyloxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](C)O[C@H]1N1C(=O)N=C(N)C(C=C)=C1 NELWQUQCCZMRPB-UBPLGANQSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 2
- 150000001537 azepanes Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- LNAMMBFJMYMQTO-FNEBRGMMSA-N chloroform;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 LNAMMBFJMYMQTO-FNEBRGMMSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125876 compound 15a Drugs 0.000 description 2
- 229940125801 compound 7f Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000000117 diazepanes Chemical class 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 150000002357 guanidines Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- ZZMHBFGSQVJSER-UHFFFAOYSA-N methyl 2-chloro-1,3-benzoxazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2N=C(Cl)OC2=C1 ZZMHBFGSQVJSER-UHFFFAOYSA-N 0.000 description 2
- JLCAGOOQSDLHGB-UHFFFAOYSA-N methyl 2-chloro-1-methylindole-5-carboxylate Chemical compound ClC=1N(C2=CC=C(C=C2C=1)C(=O)OC)C JLCAGOOQSDLHGB-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- PHVXTQIROLEEDB-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-4-[[3-(2-methylphenyl)piperidin-1-yl]methyl]-n-pyrrolidin-3-ylbenzamide Chemical compound CC1=CC=CC=C1C1CN(CC=2C=CC(=CC=2)C(=O)N(CCC=2C(=CC=CC=2)Cl)C2CNCC2)CCC1 PHVXTQIROLEEDB-UHFFFAOYSA-N 0.000 description 2
- MUJNAWXXOJRNGK-UHFFFAOYSA-N n-[3-(6-methyl-1,2,3,4-tetrahydrocarbazol-9-yl)propyl]cyclohexanamine Chemical compound C1=2CCCCC=2C2=CC(C)=CC=C2N1CCCNC1CCCCC1 MUJNAWXXOJRNGK-UHFFFAOYSA-N 0.000 description 2
- BODLESUVCQEUII-UHFFFAOYSA-N n-[4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide Chemical compound C=12C=CC=CC2=NC(C)=CC=1COC(C=C1)=CC=C1C(=O)NC1(CC(=O)NO)CCNCC1 BODLESUVCQEUII-UHFFFAOYSA-N 0.000 description 2
- RCSBCWXPGSPJNF-UHFFFAOYSA-N n-[4-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]butyl]-4-(1,8-naphthyridin-2-yl)butanamide Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1C(O1)=NN=C1CCCCNC(=O)CCCC1=CC=C(C=CC=N2)C2=N1 RCSBCWXPGSPJNF-UHFFFAOYSA-N 0.000 description 2
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 2
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 2
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 229960001601 obeticholic acid Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000010399 physical interaction Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 108010094020 polyglycine Proteins 0.000 description 2
- 229920000232 polyglycine polymer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 150000003235 pyrrolidines Chemical class 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- DVWOYOSIEJRHKW-UIRZNSHLSA-M sodium (2S)-2-[[(2S)-2-[[(4,4-difluorocyclohexyl)-phenylmethoxy]carbonylamino]-4-methylpentanoyl]amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate Chemical compound FC1(CCC(CC1)C(OC(=O)N[C@H](C(=O)N[C@H](C(S(=O)(=O)[O-])O)C[C@H]1C(NCC1)=O)CC(C)C)C1=CC=CC=C1)F.[Na+] DVWOYOSIEJRHKW-UIRZNSHLSA-M 0.000 description 2
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000005208 trialkylammonium group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- CRDAMVZIKSXKFV-YFVJMOTDSA-N (2-trans,6-trans)-farnesol Chemical class CC(C)=CCC\C(C)=C\CC\C(C)=C\CO CRDAMVZIKSXKFV-YFVJMOTDSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
- JNGNKVHWGMVTGO-UHFFFAOYSA-N 1-(5-bromo-1-benzothiophen-2-yl)piperazine Chemical compound BrC1=CC=C2SC(=CC2=C1)N1CCNCC1 JNGNKVHWGMVTGO-UHFFFAOYSA-N 0.000 description 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- SBWQOSWAEFNRFE-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)-4-propan-2-ylpyrazole-3-carbaldehyde Chemical compound CC(C)C1=C(C=O)N(N=C1)C1=C(Cl)C=CC=C1Cl SBWQOSWAEFNRFE-UHFFFAOYSA-N 0.000 description 1
- QDIVOFQWYJBWCN-CYBMUJFWSA-N 2-[(2R)-4-[[5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylic acid Chemical compound C1=C(C2=C(C=C1C(=O)O)SC(=N2)N1CCN(CC=2C(=NOC=2C2CC2)C2=C(Cl)C=NC=C2Cl)C[C@H]1C)OC QDIVOFQWYJBWCN-CYBMUJFWSA-N 0.000 description 1
- KNSXFBJTMDXVOE-AWEZNQCLSA-N 2-[(2S)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-7-methoxy-1,3-benzothiazole-5-carboxylic acid Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)CN1C[C@@H](N(CC1)C=1SC2=C(N=1)C=C(C=C2OC)C(=O)O)C KNSXFBJTMDXVOE-AWEZNQCLSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LKDJYZBKCVSODK-UHFFFAOYSA-N 3,8-diazabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1N2 LKDJYZBKCVSODK-UHFFFAOYSA-N 0.000 description 1
- PJDJTXWCVQUXKZ-UHFFFAOYSA-N 3,9-diazabicyclo[3.3.1]nonane Chemical compound C1NCC2CCCC1N2 PJDJTXWCVQUXKZ-UHFFFAOYSA-N 0.000 description 1
- XHKPKRWUVHHDTH-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-4-[(2,2-dimethylpiperazin-1-yl)methyl]-5-propan-2-yl-1,2-oxazole Chemical compound CC(C)C1=C(CN2CCNCC2(C)C)C(=NO1)C1=C(Cl)C=CC=C1Cl XHKPKRWUVHHDTH-UHFFFAOYSA-N 0.000 description 1
- SHHLOSWWMUHSMY-PZORYLMUSA-N 3-(2,6-dichlorophenyl)-4-[[(2R)-2-methylpiperidin-4-yl]methyl]-5-propan-2-yl-1,2-oxazole Chemical compound ClC1=C(C(=CC=C1)Cl)C1=NOC(=C1CC1C[C@H](NCC1)C)C(C)C SHHLOSWWMUHSMY-PZORYLMUSA-N 0.000 description 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JMDLBQMKBBJSKK-UHFFFAOYSA-N 4-(chloromethyl)-3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazole Chemical compound ClCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl JMDLBQMKBBJSKK-UHFFFAOYSA-N 0.000 description 1
- MDFXZDUEXDDCOP-UHFFFAOYSA-N 4-(chloromethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole Chemical compound ClCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl MDFXZDUEXDDCOP-UHFFFAOYSA-N 0.000 description 1
- DCGCWCFAJURBBR-CYBMUJFWSA-N 4-[[(3R)-4-[6-bromo-4-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-3-methylpiperazin-1-yl]methyl]-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole Chemical compound BrC1=CC2=C(N=C(S2)N2[C@@H](CN(CC2)CC=2C(=NOC=2C2CC2)C2=C(C=CC=C2Cl)Cl)C)C(=C1)OC(F)(F)F DCGCWCFAJURBBR-CYBMUJFWSA-N 0.000 description 1
- CPYABLFFHCBHQZ-UHFFFAOYSA-N 4-[[4-(5-bromo-1-benzothiophen-2-yl)piperazin-1-yl]methyl]-3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazole Chemical compound CC(C)C1=C(CN2CCN(CC2)C2=CC3=CC(Br)=CC=C3S2)C(=NO1)C1=C(Cl)C=CC=C1Cl CPYABLFFHCBHQZ-UHFFFAOYSA-N 0.000 description 1
- QVILSWLYJYMGRN-UHFFFAOYSA-N 4-bromo-2-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(Br)C=C1OC(F)(F)F QVILSWLYJYMGRN-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- XEKXHTXFDKJSKM-UHFFFAOYSA-N 5-bromo-2-chloro-7-(trifluoromethoxy)-1,3-benzothiazole Chemical compound BrC=1C=C(C2=C(N=C(S2)Cl)C=1)OC(F)(F)F XEKXHTXFDKJSKM-UHFFFAOYSA-N 0.000 description 1
- GXOJIGFIISCLSK-UHFFFAOYSA-N 5-bromo-2-iodo-1-benzothiophene Chemical compound BrC1=CC=C2SC(I)=CC2=C1 GXOJIGFIISCLSK-UHFFFAOYSA-N 0.000 description 1
- YBQJXXSNQSMIHJ-UHFFFAOYSA-N 5-bromo-7-(trifluoromethoxy)-1,3-benzothiazol-2-amine Chemical compound BrC=1C=C(C2=C(N=C(S2)N)C=1)OC(F)(F)F YBQJXXSNQSMIHJ-UHFFFAOYSA-N 0.000 description 1
- WVULOKZMQJKUIQ-UHFFFAOYSA-N 5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carbaldehyde Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)C=O WVULOKZMQJKUIQ-UHFFFAOYSA-N 0.000 description 1
- KWGARIGHPISOAR-UHFFFAOYSA-N 5-cyclopropyl-3-(2,6-dichlorophenyl)-4,5-dihydro-1,2-oxazole-4-carbaldehyde Chemical compound ClC1=CC=CC(Cl)=C1C1=NOC(C2CC2)C1C=O KWGARIGHPISOAR-UHFFFAOYSA-N 0.000 description 1
- XZFZMIUXTNJIFD-LLVKDONJSA-N 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-[[(2R)-2-methyl-1,2,3,6-tetrahydropyridin-4-yl]methyl]-1,2-oxazole Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)CC=1C[C@H](NCC=1)C XZFZMIUXTNJIFD-LLVKDONJSA-N 0.000 description 1
- JFDQMDAGDHCNOL-LLVKDONJSA-N 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-[[(3R)-3-methylpiperazin-1-yl]methyl]-1,2-oxazole Chemical compound C[C@@H]1CN(CC2=C(ON=C2C2=C(Cl)C=CC=C2Cl)C2CC2)CCN1 JFDQMDAGDHCNOL-LLVKDONJSA-N 0.000 description 1
- JFDQMDAGDHCNOL-NSHDSACASA-N 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-[[(3S)-3-methylpiperazin-1-yl]methyl]-1,2-oxazole Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)CN1C[C@@H](NCC1)C JFDQMDAGDHCNOL-NSHDSACASA-N 0.000 description 1
- QCTIJERLQUTRHY-UHFFFAOYSA-N 5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)-1,2-oxazole-4-carbaldehyde Chemical compound ClC1=CN=CC(Cl)=C1C1=NOC(C2CC2)=C1C=O QCTIJERLQUTRHY-UHFFFAOYSA-N 0.000 description 1
- RRELDGDKULRRDM-UHFFFAOYSA-N 6-[2-chloro-4-nitro-5-(oxan-4-yloxy)anilino]-3,4-dihydro-1H-quinolin-2-one Chemical compound [O-][N+](=O)c1cc(Cl)c(Nc2ccc3NC(=O)CCc3c2)cc1OC1CCOCC1 RRELDGDKULRRDM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- YMXVFAYYZBSHIA-UHFFFAOYSA-N BrC1=CC=C2OC(I)=CC2=C1.BrC1=CC=C2SC(N3CCNCC3)=CC2=C1.C.CC(C)(C)OC(=O)N1CCN(C2=CC3=CC(Br)=CC=C3S2)CC1.CC(C)(C)OC(=O)N1CCNCC1.CC(C)C1=C(C=O)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CN2CCN(C3=CC4=CC(Br)=CC=C4S3)CC2)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CN2CCN(C3=CC4=CC(C(=O)O)=CC=C4S3)CC2)C(C2=C(Cl)C=CC=C2Cl)=NO1.[CH3-] Chemical compound BrC1=CC=C2OC(I)=CC2=C1.BrC1=CC=C2SC(N3CCNCC3)=CC2=C1.C.CC(C)(C)OC(=O)N1CCN(C2=CC3=CC(Br)=CC=C3S2)CC1.CC(C)(C)OC(=O)N1CCNCC1.CC(C)C1=C(C=O)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CN2CCN(C3=CC4=CC(Br)=CC=C4S3)CC2)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CN2CCN(C3=CC4=CC(C(=O)O)=CC=C4S3)CC2)C(C2=C(Cl)C=CC=C2Cl)=NO1.[CH3-] YMXVFAYYZBSHIA-UHFFFAOYSA-N 0.000 description 1
- WXMPHMALQWWSNP-GMPANMLDSA-M C.C.C=C(C)B(F)(F)(F)[K].C=C(C)C1=C2N=C(N3CCN(C(=O)OC(C)(C)C)C[C@H]3C)SC2=CC(C(=O)OC)=C1.CO.COC(=O)C1=CC(C(C)C)=C2N=C(N3CCN(C(=O)OC(C)(C)C)C[C@H]3C)SC2=C1.COC(=O)C1=CC(C(C)C)=C2N=C(N3CCN(CC4=C(C5CC5)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)SC2=C1.COC(=O)C1=CC(C(C)C)=C2N=C(N3CCNC[C@H]3C)SC2=C1.COC(=O)C1=CC(Cl)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(Cl)=C2N=C(N3CCN(C(=O)OC(C)(C)C)C[C@H]3C)SC2=C1.C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1.C[Pd].O=CC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl.O=COO[K].[KH] Chemical compound C.C.C=C(C)B(F)(F)(F)[K].C=C(C)C1=C2N=C(N3CCN(C(=O)OC(C)(C)C)C[C@H]3C)SC2=CC(C(=O)OC)=C1.CO.COC(=O)C1=CC(C(C)C)=C2N=C(N3CCN(C(=O)OC(C)(C)C)C[C@H]3C)SC2=C1.COC(=O)C1=CC(C(C)C)=C2N=C(N3CCN(CC4=C(C5CC5)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)SC2=C1.COC(=O)C1=CC(C(C)C)=C2N=C(N3CCNC[C@H]3C)SC2=C1.COC(=O)C1=CC(Cl)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(Cl)=C2N=C(N3CCN(C(=O)OC(C)(C)C)C[C@H]3C)SC2=C1.C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1.C[Pd].O=CC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl.O=COO[K].[KH] WXMPHMALQWWSNP-GMPANMLDSA-M 0.000 description 1
- NVURALVATHKPAC-UHFFFAOYSA-M C.CC(C)(C)OC(=O)N1CCNCC1.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCN(C(=O)OC(C)(C)C)CC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCN(CC4=C(C(C)C)C=NN4C4=C(Cl)C=CC=C4Cl)CC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCNCC3)SC2=C1.COC1=C(C(C)C)C=NN1C1=C(Cl)C=CC=C1Cl.COC1=C2N=C(N3CCN(CC4=C(C(C)C)C=NN4C4=C(Cl)C=CC=C4Cl)CC3)SC2=CC(C(=O)O)=C1.O=COO[K].[KH] Chemical compound C.CC(C)(C)OC(=O)N1CCNCC1.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCN(C(=O)OC(C)(C)C)CC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCN(CC4=C(C(C)C)C=NN4C4=C(Cl)C=CC=C4Cl)CC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCNCC3)SC2=C1.COC1=C(C(C)C)C=NN1C1=C(Cl)C=CC=C1Cl.COC1=C2N=C(N3CCN(CC4=C(C(C)C)C=NN4C4=C(Cl)C=CC=C4Cl)CC3)SC2=CC(C(=O)O)=C1.O=COO[K].[KH] NVURALVATHKPAC-UHFFFAOYSA-M 0.000 description 1
- IUDKPPZPDDVCQF-UHFFFAOYSA-M C.CC(C)C1=C(C=O)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CN2CCN(C(=O)OC(C)(C)C)CC2(C)C)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CN2CCNCC2(C)C)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC1(C)CN(C(=O)OC(C)(C)C)CCN1.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)C(C)(C)C3)SC2=C1.COC1=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)C(C)(C)C3)SC2=CC(C(=O)O)=C1.I[I-22].O[Na] Chemical compound C.CC(C)C1=C(C=O)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CN2CCN(C(=O)OC(C)(C)C)CC2(C)C)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CN2CCNCC2(C)C)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC1(C)CN(C(=O)OC(C)(C)C)CCN1.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)C(C)(C)C3)SC2=C1.COC1=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)C(C)(C)C3)SC2=CC(C(=O)O)=C1.I[I-22].O[Na] IUDKPPZPDDVCQF-UHFFFAOYSA-M 0.000 description 1
- WUQRYYSLECFELC-UHFFFAOYSA-M C.CCCC[N+](CCCC)(CCCC)CCCC.CI.CI.COC1=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3)SC2=CC(C#N)=C1.COC1=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3)SC2=CC(C(N)=O)=C1.COC1=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3)SC2=CC(C2=NN=NN2)=C1.C[Si](C)(C)N=[N+]=[N-].[F-] Chemical compound C.CCCC[N+](CCCC)(CCCC)CCCC.CI.CI.COC1=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3)SC2=CC(C#N)=C1.COC1=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3)SC2=CC(C(N)=O)=C1.COC1=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3)SC2=CC(C2=NN=NN2)=C1.C[Si](C)(C)N=[N+]=[N-].[F-] WUQRYYSLECFELC-UHFFFAOYSA-M 0.000 description 1
- RAMSRFQVMSQPRV-FBVBRAIOSA-M C.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC2=C(N=C(N3CCN(CC4=C(C5CC5)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@@H]3C)S2)C(OC)=C1.COC1=CC(C(=O)O)=CC2=C1N=C(N1CCN(CC3=C(C4CC4)ON=C3C3=C(Cl)C=CC=C3Cl)C[C@@H]1C)S2.COC1=CC(C(N)=O)=CC2=C1N=C(N1CCN(CC3=C(C4CC4)ON=C3C3=C(Cl)C=CC=C3Cl)C[C@@H]1C)S2.C[C@H]1CN(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)CCN1.C[C@H]1CN(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)CCN1C(=O)OC(C)(C)C.C[C@H]1CNCCN1C(=O)OC(C)(C)C.N.O.O=CC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl.O[Na] Chemical compound C.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC2=C(N=C(N3CCN(CC4=C(C5CC5)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@@H]3C)S2)C(OC)=C1.COC1=CC(C(=O)O)=CC2=C1N=C(N1CCN(CC3=C(C4CC4)ON=C3C3=C(Cl)C=CC=C3Cl)C[C@@H]1C)S2.COC1=CC(C(N)=O)=CC2=C1N=C(N1CCN(CC3=C(C4CC4)ON=C3C3=C(Cl)C=CC=C3Cl)C[C@@H]1C)S2.C[C@H]1CN(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)CCN1.C[C@H]1CN(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)CCN1C(=O)OC(C)(C)C.C[C@H]1CNCCN1C(=O)OC(C)(C)C.N.O.O=CC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl.O[Na] RAMSRFQVMSQPRV-FBVBRAIOSA-M 0.000 description 1
- OTYZRRNUAHEREV-UHFFFAOYSA-N C1=CNC=N1.CC(C)(C)OC(=O)N1CCNC(CO)C1.CC(C)C1=C(C=O)C(C2=C(Cl)C=CC=C2Cl)=NO1.CCC1CN(C(=O)OC(C)(C)C)CCN1.CCC1CN(C(=O)OC(C)(C)C)CCN1C1=NC2=C(OC)C=C(C(=O)OC)C=C2S1.CCC1CN(CC2=C(C(C)C)ON=C2C2=C(Cl)C=CC=C2Cl)CCN1C1=NC2=C(OC)C=C(C(=O)OC)C=C2S1.CCC1CNCCN1C1=NC2=C(OC)C=C(C(=O)OC)C=C2S1.CCO.CO.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3CO)SC2=C1.COC1=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3CO)SC2=CC(C(=O)O)=C1.Cl Chemical compound C1=CNC=N1.CC(C)(C)OC(=O)N1CCNC(CO)C1.CC(C)C1=C(C=O)C(C2=C(Cl)C=CC=C2Cl)=NO1.CCC1CN(C(=O)OC(C)(C)C)CCN1.CCC1CN(C(=O)OC(C)(C)C)CCN1C1=NC2=C(OC)C=C(C(=O)OC)C=C2S1.CCC1CN(CC2=C(C(C)C)ON=C2C2=C(Cl)C=CC=C2Cl)CCN1C1=NC2=C(OC)C=C(C(=O)OC)C=C2S1.CCC1CNCCN1C1=NC2=C(OC)C=C(C(=O)OC)C=C2S1.CCO.CO.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3CO)SC2=C1.COC1=C2N=C(N3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3CO)SC2=CC(C(=O)O)=C1.Cl OTYZRRNUAHEREV-UHFFFAOYSA-N 0.000 description 1
- WFOGBGXYEBSDAQ-UHFFFAOYSA-N C1CCOC1.COC(=O)C1=CC2=C(C=C1)N(C)C(Cl)=C2.COC(=O)C1=CC2=C(C=C1)NC(=O)C2.COC(=O)C1=CC2=C(C=C1)NC(Cl)=C2.O=P(Cl)(Cl)Cl Chemical compound C1CCOC1.COC(=O)C1=CC2=C(C=C1)N(C)C(Cl)=C2.COC(=O)C1=CC2=C(C=C1)NC(=O)C2.COC(=O)C1=CC2=C(C=C1)NC(Cl)=C2.O=P(Cl)(Cl)Cl WFOGBGXYEBSDAQ-UHFFFAOYSA-N 0.000 description 1
- ZHGZNKAHWWUSSU-UHFFFAOYSA-N CC(C)(C)C1CCN(C(C)(C)C)C1 Chemical compound CC(C)(C)C1CCN(C(C)(C)C)C1 ZHGZNKAHWWUSSU-UHFFFAOYSA-N 0.000 description 1
- MWKZMZLDGDPNSW-UHFFFAOYSA-N CC(C)(C)CC1=C(C2CC2)ON=C1C1=C(Cl)C=NC=C1Cl Chemical compound CC(C)(C)CC1=C(C2CC2)ON=C1C1=C(Cl)C=NC=C1Cl MWKZMZLDGDPNSW-UHFFFAOYSA-N 0.000 description 1
- AZEUSXAJLGOLHT-UHFFFAOYSA-N CC(C)(C)N1CC2(CC2)N(C)CC1 Chemical compound CC(C)(C)N1CC2(CC2)N(C)CC1 AZEUSXAJLGOLHT-UHFFFAOYSA-N 0.000 description 1
- SOLGBVOURCMXPK-UHFFFAOYSA-N CC(C)(C)N1CC2CCCC(C1)N2C(C)(C)C Chemical compound CC(C)(C)N1CC2CCCC(C1)N2C(C)(C)C SOLGBVOURCMXPK-UHFFFAOYSA-N 0.000 description 1
- GAHGOSRZYKHIQY-UHFFFAOYSA-N CC(C)(C)N1CCCN(C(C)(C)C)CC1 Chemical compound CC(C)(C)N1CCCN(C(C)(C)C)CC1 GAHGOSRZYKHIQY-UHFFFAOYSA-N 0.000 description 1
- QUWDQZQINWPPMF-UHFFFAOYSA-N CC(C)(C)N1CCN(C(C)(C)C)C2CCCCC21 Chemical compound CC(C)(C)N1CCN(C(C)(C)C)C2CCCCC21 QUWDQZQINWPPMF-UHFFFAOYSA-N 0.000 description 1
- CTKPKEVQIWQQDO-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CC=C(B2OC(C)(C)C(C)(C)O2)CC1.CC(C)C1=C(C=O)C(C2=C(Cl)C=CC=C2Cl)=NO1.CCOC(C)=O.COC(=O)C1=CC(OC)=C2N=C(C3=CCN(C(=O)OC(C)(C)C)CC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(C3CCN(C(=O)OC(C)(C)C)CC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(C3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(C3CCNCC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC1=C2N=C(C3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3)SC2=CC(C(=O)O)=C1.I[I-47] Chemical compound CC(C)(C)OC(=O)N1CC=C(B2OC(C)(C)C(C)(C)O2)CC1.CC(C)C1=C(C=O)C(C2=C(Cl)C=CC=C2Cl)=NO1.CCOC(C)=O.COC(=O)C1=CC(OC)=C2N=C(C3=CCN(C(=O)OC(C)(C)C)CC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(C3CCN(C(=O)OC(C)(C)C)CC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(C3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(C3CCNCC3)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC1=C2N=C(C3CCN(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)CC3)SC2=CC(C(=O)O)=C1.I[I-47] CTKPKEVQIWQQDO-UHFFFAOYSA-N 0.000 description 1
- IHEDEIUXXZVYEA-UHFFFAOYSA-N CC(C)C(C)Cc1c(C(C)C)[o]nc1-c(c(Cl)ccc1)c1Cl Chemical compound CC(C)C(C)Cc1c(C(C)C)[o]nc1-c(c(Cl)ccc1)c1Cl IHEDEIUXXZVYEA-UHFFFAOYSA-N 0.000 description 1
- NIGJGQALHONHCE-UHFFFAOYSA-N CC(C)C1=C(CC(C)(C)C)C(C2=C(Cl)C=NC=C2Cl)=NO1 Chemical compound CC(C)C1=C(CC(C)(C)C)C(C2=C(Cl)C=NC=C2Cl)=NO1 NIGJGQALHONHCE-UHFFFAOYSA-N 0.000 description 1
- WTNNPKMOPRXFQG-UHFFFAOYSA-N CC(C)C1=C(CC(C)(C)C)C(C2=CC=CC=C2OC(F)(F)F)=NO1 Chemical compound CC(C)C1=C(CC(C)(C)C)C(C2=CC=CC=C2OC(F)(F)F)=NO1 WTNNPKMOPRXFQG-UHFFFAOYSA-N 0.000 description 1
- OQDFJDYBIHNKIM-FEZHAGOJSA-N CC(C)C1=C(CC2=C[C@@H](C)N(C(=O)OC(C)(C)C)CC2)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CCl)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CO)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(F)(F)S(=O)N(C1=CC=CC=C1)S(=O)C(F)(F)F.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1=C[C@@H](C)N(C(=O)OC(C)(C)C)CC1.CCOC(C)=O.C[C@@H]1C=C(B2OC(C)(C)C(C)(C)O2)CCN1C(=O)OC(C)(C)C.C[C@@H]1C=C(B2OC(C)(C)C(C)(C)O2)CCN1C(=O)OC(C)(C)C.C[C@@H]1CC(=O)CCN1C(=O)OC(C)(C)C.O=S(Cl)Cl Chemical compound CC(C)C1=C(CC2=C[C@@H](C)N(C(=O)OC(C)(C)C)CC2)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CCl)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CO)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(F)(F)S(=O)N(C1=CC=CC=C1)S(=O)C(F)(F)F.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.CC1=C[C@@H](C)N(C(=O)OC(C)(C)C)CC1.CCOC(C)=O.C[C@@H]1C=C(B2OC(C)(C)C(C)(C)O2)CCN1C(=O)OC(C)(C)C.C[C@@H]1C=C(B2OC(C)(C)C(C)(C)O2)CCN1C(=O)OC(C)(C)C.C[C@@H]1CC(=O)CCN1C(=O)OC(C)(C)C.O=S(Cl)Cl OQDFJDYBIHNKIM-FEZHAGOJSA-N 0.000 description 1
- RHFMVBXCCAXHMZ-VIRRENSUSA-M CC(C)C1=C(CC2CCN(C(=O)OC(C)(C)C)[C@H](C)C2)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CC2CCN[C@H](C)C2)C(C2=C(Cl)C=CC=C2Cl)=NO1.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCC(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)SC2=C1.COC1=C2N=C(N3CCC(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)SC2=CC(C(=O)O)=C1.I[I-45].O[Na] Chemical compound CC(C)C1=C(CC2CCN(C(=O)OC(C)(C)C)[C@H](C)C2)C(C2=C(Cl)C=CC=C2Cl)=NO1.CC(C)C1=C(CC2CCN[C@H](C)C2)C(C2=C(Cl)C=CC=C2Cl)=NO1.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CCC(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)SC2=C1.COC1=C2N=C(N3CCC(CC4=C(C(C)C)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)SC2=CC(C(=O)O)=C1.I[I-45].O[Na] RHFMVBXCCAXHMZ-VIRRENSUSA-M 0.000 description 1
- LAPNPLBNAYDNPC-NMZACMJESA-M CC(C)CCON=O.CC1=C(C2=NOC(C3CC3)=C2CN2CCN[C@H](C)C2)C(Cl)=CC=C1.CO.COC(=O)C1=CC(OC(F)(F)F)=C2SC(N3CCN(CC4=C(C5CC5)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)=NC2=C1.C[C@@H]1CN(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)CCN1C1=NC2=CC(Br)=CC(OC(F)(F)F)=C2S1.C[C@@H]1CN(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)CCN1C1=NC2=CC(C(=O)O)=CC(OC(F)(F)F)=C2S1.FC(F)(F)OC1=C2SC(Cl)=NC2=CC(Br)=C1.N#CS[Na].NC1=C(OC(F)(F)F)C=C(Br)C=C1.NC1=NC2=CC(Br)=CC(OC(F)(F)F)=C2S1 Chemical compound CC(C)CCON=O.CC1=C(C2=NOC(C3CC3)=C2CN2CCN[C@H](C)C2)C(Cl)=CC=C1.CO.COC(=O)C1=CC(OC(F)(F)F)=C2SC(N3CCN(CC4=C(C5CC5)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)=NC2=C1.C[C@@H]1CN(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)CCN1C1=NC2=CC(Br)=CC(OC(F)(F)F)=C2S1.C[C@@H]1CN(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)CCN1C1=NC2=CC(C(=O)O)=CC(OC(F)(F)F)=C2S1.FC(F)(F)OC1=C2SC(Cl)=NC2=CC(Br)=C1.N#CS[Na].NC1=C(OC(F)(F)F)C=C(Br)C=C1.NC1=NC2=CC(Br)=CC(OC(F)(F)F)=C2S1 LAPNPLBNAYDNPC-NMZACMJESA-M 0.000 description 1
- YIYAWRLXGOBIJI-UHFFFAOYSA-M CC(C)CCON=O.COC(=O)C1=CC(OC)=C(N)C=C1.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N)SC2=C1.N#CS[Na] Chemical compound CC(C)CCON=O.COC(=O)C1=CC(OC)=C(N)C=C1.COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N)SC2=C1.N#CS[Na] YIYAWRLXGOBIJI-UHFFFAOYSA-M 0.000 description 1
- HXEUZLAJYXRJNI-UHFFFAOYSA-N CC(C)Cc1c(C(C)C)[o]nc1-c(c(Cl)ccc1)c1Cl Chemical compound CC(C)Cc1c(C(C)C)[o]nc1-c(c(Cl)ccc1)c1Cl HXEUZLAJYXRJNI-UHFFFAOYSA-N 0.000 description 1
- DMWXUQSWJMYCFW-UHFFFAOYSA-N CC(C)Cc1c(C2CC2)[o]nc1-c(c(Cl)ccc1)c1Cl Chemical compound CC(C)Cc1c(C2CC2)[o]nc1-c(c(Cl)ccc1)c1Cl DMWXUQSWJMYCFW-UHFFFAOYSA-N 0.000 description 1
- NZQRDRWUCVXCNF-NSHDSACASA-N CC(C)N(CC1)C[C@H](C)N1C(C)(C)C Chemical compound CC(C)N(CC1)C[C@H](C)N1C(C)(C)C NZQRDRWUCVXCNF-NSHDSACASA-N 0.000 description 1
- NUOIPBTYGPCXGC-UHFFFAOYSA-N CCCN/C(=N/C)NCC.CCCN/C(=N\CC)NC Chemical compound CCCN/C(=N/C)NCC.CCCN/C(=N\CC)NC NUOIPBTYGPCXGC-UHFFFAOYSA-N 0.000 description 1
- FGDYGBIFCWLWAO-UHFFFAOYSA-N CCCc1c(C(C)C)[o]nc1-c(c(Cl)ccc1)c1Cl Chemical compound CCCc1c(C(C)C)[o]nc1-c(c(Cl)ccc1)c1Cl FGDYGBIFCWLWAO-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- XISSCVMIXDMKLH-UHFFFAOYSA-N CCOC(=O)C1=CC=C2N=C(Cl)SC2=C1 Chemical compound CCOC(=O)C1=CC=C2N=C(Cl)SC2=C1 XISSCVMIXDMKLH-UHFFFAOYSA-N 0.000 description 1
- WZGTWSQJGKRQCC-UHFFFAOYSA-N COC(=O)C1=C(C)C=C2N=C(Cl)SC2=C1 Chemical compound COC(=O)C1=C(C)C=C2N=C(Cl)SC2=C1 WZGTWSQJGKRQCC-UHFFFAOYSA-N 0.000 description 1
- BOLDVAFZLUCRKJ-UHFFFAOYSA-N COC(=O)C1=CC(C)=C2N=C(Cl)SC2=C1 Chemical compound COC(=O)C1=CC(C)=C2N=C(Cl)SC2=C1 BOLDVAFZLUCRKJ-UHFFFAOYSA-N 0.000 description 1
- MBCZXROTRSIJOK-UHFFFAOYSA-N COC(=O)C1=CC(F)=C2N=C(Cl)SC2=C1 Chemical compound COC(=O)C1=CC(F)=C2N=C(Cl)SC2=C1 MBCZXROTRSIJOK-UHFFFAOYSA-N 0.000 description 1
- YDIVBVYYRZAMMJ-LPDKITAGSA-M COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CC=C(CC4=C(C5CC5)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)SC2=C1.COC1=C2N=C(N3CC=C(CC4=C(C5CC5)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)SC2=CC(C(=O)O)=C1.C[C@@H]1CC(B2OC(C)(C)C(C)(C)O2)=CCN1C(=O)OC(C)(C)C.C[C@@H]1CC(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)=CCN1.C[C@@H]1CC(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)=CCN1C(=O)OC(C)(C)C.ClCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl.I[I-46].O=S(Cl)Cl.OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl.O[Na] Chemical compound COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1.COC(=O)C1=CC(OC)=C2N=C(N3CC=C(CC4=C(C5CC5)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)SC2=C1.COC1=C2N=C(N3CC=C(CC4=C(C5CC5)ON=C4C4=C(Cl)C=CC=C4Cl)C[C@H]3C)SC2=CC(C(=O)O)=C1.C[C@@H]1CC(B2OC(C)(C)C(C)(C)O2)=CCN1C(=O)OC(C)(C)C.C[C@@H]1CC(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)=CCN1.C[C@@H]1CC(CC2=C(C3CC3)ON=C2C2=C(Cl)C=CC=C2Cl)=CCN1C(=O)OC(C)(C)C.ClCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl.I[I-46].O=S(Cl)Cl.OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl.O[Na] YDIVBVYYRZAMMJ-LPDKITAGSA-M 0.000 description 1
- GRBCZHNRZDDLOT-UHFFFAOYSA-N COC(=O)C1=CC2=C(C=C1)N(C)C(Cl)=N2 Chemical compound COC(=O)C1=CC2=C(C=C1)N(C)C(Cl)=N2 GRBCZHNRZDDLOT-UHFFFAOYSA-N 0.000 description 1
- ZWJRTNXVWAZIJL-XTHFKZNKSA-N COC(=O)C1=CC2=C(N=C(N3CCN(CC4=C(C5CC5)ON=C4C4=C(Cl)C=NC=C4Cl)C[C@H]3C)S2)C(OC)=C1.COC(=O)C1=CC2=C(N=C(N3CCNC[C@H]3C)S2)C(OC)=C1.COC1=C2N=C(N3CCN(CC4=C(C5CC5)ON=C4C4=C(Cl)C=NC=C4Cl)C[C@H]3C)SC2=CC(C(N)=O)=C1.COC1=CC(C(=O)O)=CC2=C1N=C(N1CCN(CC3=C(C4CC4)ON=C3C3=C(Cl)C=NC=C3Cl)C[C@H]1C)S2.N.O.O=CC1=C(C2CC2)ON=C1C1=C(Cl)C=NC=C1Cl Chemical compound COC(=O)C1=CC2=C(N=C(N3CCN(CC4=C(C5CC5)ON=C4C4=C(Cl)C=NC=C4Cl)C[C@H]3C)S2)C(OC)=C1.COC(=O)C1=CC2=C(N=C(N3CCNC[C@H]3C)S2)C(OC)=C1.COC1=C2N=C(N3CCN(CC4=C(C5CC5)ON=C4C4=C(Cl)C=NC=C4Cl)C[C@H]3C)SC2=CC(C(N)=O)=C1.COC1=CC(C(=O)O)=CC2=C1N=C(N1CCN(CC3=C(C4CC4)ON=C3C3=C(Cl)C=NC=C3Cl)C[C@H]1C)S2.N.O.O=CC1=C(C2CC2)ON=C1C1=C(Cl)C=NC=C1Cl ZWJRTNXVWAZIJL-XTHFKZNKSA-N 0.000 description 1
- SWWIJOGOQCCYER-YGJXFZMTSA-N COC(=O)C1=CC=C(N)C(O)=C1.COC(=O)C1=CC=C2N=C(Cl)OC2=C1.COC(=O)C1=CC=C2N=C(S)OC2=C1.O=S(Cl)Cl.OC#CC=S.[2H]CF.[KH] Chemical compound COC(=O)C1=CC=C(N)C(O)=C1.COC(=O)C1=CC=C2N=C(Cl)OC2=C1.COC(=O)C1=CC=C2N=C(S)OC2=C1.O=S(Cl)Cl.OC#CC=S.[2H]CF.[KH] SWWIJOGOQCCYER-YGJXFZMTSA-N 0.000 description 1
- WVGMSEJDODWFPO-PXYINDEMSA-N C[C@H]1CC(C(C)(C)C)CCN1C(C)(C)C Chemical compound C[C@H]1CC(C(C)(C)C)CCN1C(C)(C)C WVGMSEJDODWFPO-PXYINDEMSA-N 0.000 description 1
- FYSHKKAWEGZUEY-RYUDHWBXSA-N C[C@H]1CN(C(C)(C)C)[C@@H](C)CN1C(C)(C)C Chemical compound C[C@H]1CN(C(C)(C)C)[C@@H](C)CN1C(C)(C)C FYSHKKAWEGZUEY-RYUDHWBXSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical group ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- QKFSDLYZZTWMQG-UHFFFAOYSA-N [3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methanol Chemical compound OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl QKFSDLYZZTWMQG-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- KRGFOUGVZFEEBW-UHFFFAOYSA-N [5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methanol Chemical compound OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl KRGFOUGVZFEEBW-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002202 anti-cholestatic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000012971 dimethylpiperazine Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 150000003620 farnesol derivatives Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000002192 heptalenyl group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 150000002461 imidazolidines Chemical class 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 102000004311 liver X receptors Human genes 0.000 description 1
- 108090000865 liver X receptors Proteins 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- CMQKHOIAOJXPRK-CQSZACIVSA-N methyl 2-[(2R)-2-methyl-4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-4-propan-2-yl-1,3-benzothiazole-6-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C[C@H](N(CC1)C=1SC2=C(N=1)C(=CC(=C2)C(=O)OC)C(C)C)C CMQKHOIAOJXPRK-CQSZACIVSA-N 0.000 description 1
- BZBLGTQCRPGCPH-TZHYSIJRSA-N methyl 2-[(2R)-4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]-2-methylpiperidin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound ClC1=C(C(=CC=C1)Cl)C1=NOC(=C1CC1C[C@H](N(CC1)C=1SC2=C(N=1)C(=CC(=C2)C(=O)OC)OC)C)C(C)C BZBLGTQCRPGCPH-TZHYSIJRSA-N 0.000 description 1
- HLDCFSDXSFPCHP-CQSZACIVSA-N methyl 2-[(2R)-4-[[5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2N=C(SC2=C1)N1CCN(CC2=C(ON=C2C2=C(Cl)C=NC=C2Cl)C2CC2)C[C@H]1C HLDCFSDXSFPCHP-CQSZACIVSA-N 0.000 description 1
- AZPBRLVDOCUUAU-HNNXBMFYSA-N methyl 2-[(2S)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-7-methoxy-1,3-benzothiazole-5-carboxylate Chemical compound C1(CC1)C1=C(C(=NO1)C1=C(C=CC=C1Cl)Cl)CN1C[C@@H](N(CC1)C=1SC2=C(N=1)C=C(C=C2OC)C(=O)OC)C AZPBRLVDOCUUAU-HNNXBMFYSA-N 0.000 description 1
- FJWMQQNDTHSQFE-UHFFFAOYSA-N methyl 2-[1-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]piperidin-4-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound ClC1=C(C(=CC=C1)Cl)C1=NOC(=C1CN1CCC(CC1)C=1SC2=C(N=1)C(=CC(=C2)C(=O)OC)OC)C(C)C FJWMQQNDTHSQFE-UHFFFAOYSA-N 0.000 description 1
- RFIBKGKMAYQODL-UHFFFAOYSA-N methyl 2-[2-[[tert-butyl(diphenyl)silyl]oxymethyl]-4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CC(N(CC1)C=1SC2=C(N=1)C(=CC(=C2)C(=O)OC)OC)CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C RFIBKGKMAYQODL-UHFFFAOYSA-N 0.000 description 1
- NRJJNLUNJZWGIX-UHFFFAOYSA-N methyl 2-[2-[[tert-butyl(diphenyl)silyl]oxymethyl]-4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]piperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)OCC1N(CCN(C1)CC=1C(=NOC=1C(C)C)C1=C(C=CC=C1Cl)Cl)C=1SC2=C(N=1)C(=CC(=C2)C(=O)OC)OC NRJJNLUNJZWGIX-UHFFFAOYSA-N 0.000 description 1
- FNGPWTDZUCILCE-UHFFFAOYSA-N methyl 2-[2-[[tert-butyl(diphenyl)silyl]oxymethyl]piperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)OCC1N(CCNC1)C=1SC2=C(N=1)C(=CC(=C2)C(=O)OC)OC FNGPWTDZUCILCE-UHFFFAOYSA-N 0.000 description 1
- NSHREZXHOYWBIM-UHFFFAOYSA-N methyl 2-[4-[[2-(2,6-dichlorophenyl)-4-propan-2-ylpyrazol-3-yl]methyl]piperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2N=C(SC2=C1)N1CCN(CC2=C(C=NN2C2=C(Cl)C=CC=C2Cl)C(C)C)CC1 NSHREZXHOYWBIM-UHFFFAOYSA-N 0.000 description 1
- WSKVDMMGYMINKJ-UHFFFAOYSA-N methyl 2-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]-2-(hydroxymethyl)piperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2N=C(SC2=C1)N1CCN(CC2=C(ON=C2C2=C(Cl)C=CC=C2Cl)C(C)C)CC1CO WSKVDMMGYMINKJ-UHFFFAOYSA-N 0.000 description 1
- SSBMZYHRPXOQQM-UHFFFAOYSA-N methyl 2-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]-3,3-dimethylpiperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2N=C(SC2=C1)N1CCN(CC2=C(ON=C2C2=C(Cl)C=CC=C2Cl)C(C)C)C(C)(C)C1 SSBMZYHRPXOQQM-UHFFFAOYSA-N 0.000 description 1
- SYZNSAWWLCRFFT-UHFFFAOYSA-N methyl 2-amino-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2N=C(N)SC2=C1 SYZNSAWWLCRFFT-UHFFFAOYSA-N 0.000 description 1
- SUGWVPJSFIQOPB-UHFFFAOYSA-N methyl 2-chloro-1H-indole-5-carboxylate Chemical compound ClC=1NC2=CC=C(C=C2C=1)C(=O)OC SUGWVPJSFIQOPB-UHFFFAOYSA-N 0.000 description 1
- NDTQMLBKLTTZTI-UHFFFAOYSA-N methyl 2-chloro-7-methoxy-1,3-benzothiazole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2SC(Cl)=NC2=C1 NDTQMLBKLTTZTI-UHFFFAOYSA-N 0.000 description 1
- CYBPPDZFRDSSME-UHFFFAOYSA-N methyl 2-oxo-1,3-dihydroindole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC(=O)CC2=C1 CYBPPDZFRDSSME-UHFFFAOYSA-N 0.000 description 1
- FMCZQIFKXIGAFL-UHFFFAOYSA-N methyl 2-sulfanylidene-3h-1,3-benzoxazole-6-carboxylate Chemical compound COC(=O)C1=CC=C2NC(=S)OC2=C1 FMCZQIFKXIGAFL-UHFFFAOYSA-N 0.000 description 1
- OCZXDVNSNDITBS-UHFFFAOYSA-N methyl 4-amino-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(O)=C1 OCZXDVNSNDITBS-UHFFFAOYSA-N 0.000 description 1
- DJLFOMMCQBAMAA-UHFFFAOYSA-N methyl 4-amino-3-methoxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(OC)=C1 DJLFOMMCQBAMAA-UHFFFAOYSA-N 0.000 description 1
- LLMBDHCEJWKNME-LLVKDONJSA-N methyl 4-chloro-2-[(2R)-2-methyl-4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-1,3-benzothiazole-6-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1C[C@H](N(CC1)C=1SC2=C(N=1)C(=CC(=C2)C(=O)OC)Cl)C LLMBDHCEJWKNME-LLVKDONJSA-N 0.000 description 1
- NBEUOTRFVRUDML-SECBINFHSA-N methyl 4-methoxy-2-[(2R)-2-methylpiperazin-1-yl]-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2N=C(SC2=C1)N1CCNC[C@H]1C NBEUOTRFVRUDML-SECBINFHSA-N 0.000 description 1
- FZXNBFYXWMNDHR-UHFFFAOYSA-N methyl 4-methoxy-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]-3,6-dihydro-2H-pyridin-4-yl]-1,3-benzothiazole-6-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC(=CC1)C=1SC2=C(N=1)C(=CC(=C2)C(=O)OC)OC FZXNBFYXWMNDHR-UHFFFAOYSA-N 0.000 description 1
- XGYBROPQYJPANL-UHFFFAOYSA-N methyl 4-methoxy-2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]-1,3-benzothiazole-6-carboxylate Chemical compound O(C)C1=C2C(=CC(C(=O)OC)=C1)SC(=N2)C1CCN(CC1)C(=O)OC(C)(C)C XGYBROPQYJPANL-UHFFFAOYSA-N 0.000 description 1
- AGLBYEJJCOPDTM-UHFFFAOYSA-N methyl 4-methoxy-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-1,3-benzothiazole-6-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)C=1SC2=C(N=1)C(=CC(=C2)C(=O)OC)OC AGLBYEJJCOPDTM-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- JCBJVAJGLKENNC-UHFFFAOYSA-M potassium ethyl xanthate Chemical compound [K+].CCOC([S-])=S JCBJVAJGLKENNC-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- MARFGAOIFGKRBE-GFCCVEGCSA-N tert-butyl (2R)-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](CC(=CC1)B1OC(C(O1)(C)C)(C)C)C MARFGAOIFGKRBE-GFCCVEGCSA-N 0.000 description 1
- LDWLRHUQFRJABG-AAFJCEBUSA-N tert-butyl (2R)-4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]-2-methylpiperidine-1-carboxylate Chemical compound ClC1=C(C(=CC=C1)Cl)C1=NOC(=C1CC1C[C@H](N(CC1)C(=O)OC(C)(C)C)C)C(C)C LDWLRHUQFRJABG-AAFJCEBUSA-N 0.000 description 1
- PGZRVOJLWSDDSO-CQSZACIVSA-N tert-butyl (2R)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methyl-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC1=C(C=2C(CC3=CCN([C@@H](C3)C)C(=O)OC(C)(C)C)=C(C3CC3)ON=2)C(Cl)=CC=C1 PGZRVOJLWSDDSO-CQSZACIVSA-N 0.000 description 1
- LOSISIFLTCDATK-AWEZNQCLSA-N tert-butyl (2S)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazine-1-carboxylate Chemical compound ClC1=C(C=2C(CN3CCN([C@@H](C)C3)C(=O)OC(C)(C)C)=C(C3CC3)ON=2)C(Cl)=CC=C1 LOSISIFLTCDATK-AWEZNQCLSA-N 0.000 description 1
- HQMYWQCBINPHBB-MRVPVSSYSA-N tert-butyl (2r)-2-methyl-4-oxopiperidine-1-carboxylate Chemical compound C[C@@H]1CC(=O)CCN1C(=O)OC(C)(C)C HQMYWQCBINPHBB-MRVPVSSYSA-N 0.000 description 1
- DATRVIMZZZVHMP-QMMMGPOBSA-N tert-butyl (2s)-2-methylpiperazine-1-carboxylate Chemical compound C[C@H]1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-QMMMGPOBSA-N 0.000 description 1
- FMLPQHJYUZTHQS-MRVPVSSYSA-N tert-butyl (3r)-3-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-MRVPVSSYSA-N 0.000 description 1
- IYCDTBUPJIRCBD-OAHLLOKOSA-N tert-butyl (6R)-4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]-6-methyl-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound ClC1=C(C(=CC=C1)Cl)C1=NOC(=C1CC1=C[C@H](N(CC1)C(=O)OC(C)(C)C)C)C(C)C IYCDTBUPJIRCBD-OAHLLOKOSA-N 0.000 description 1
- YPYJUPOKIAKWHW-GFCCVEGCSA-N tert-butyl (6R)-6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound C[C@@H]1C=C(CCN1C(=O)OC(C)(C)C)B1OC(C)(C)C(C)(C)O1 YPYJUPOKIAKWHW-GFCCVEGCSA-N 0.000 description 1
- UAAWMAOUVZMVKN-MRVPVSSYSA-N tert-butyl (6r)-6-methyl-4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C[C@@H]1C=C(OS(=O)(=O)C(F)(F)F)CCN1C(=O)OC(C)(C)C UAAWMAOUVZMVKN-MRVPVSSYSA-N 0.000 description 1
- LBAIYWWWORXVEQ-UHFFFAOYSA-N tert-butyl 3,3-dimethylpiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(C)(C)C1 LBAIYWWWORXVEQ-UHFFFAOYSA-N 0.000 description 1
- NSILYQWHARROMG-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(CO)C1 NSILYQWHARROMG-UHFFFAOYSA-N 0.000 description 1
- KSWWMUDRJLPFKQ-UHFFFAOYSA-N tert-butyl 4-(5-bromo-1-benzothiophen-2-yl)piperazine-1-carboxylate Chemical compound BrC=1C=CC2=C(C=C(S2)N2CCN(CC2)C(=O)OC(C)(C)C)C=1 KSWWMUDRJLPFKQ-UHFFFAOYSA-N 0.000 description 1
- JPHPCZBOZXDUMU-UHFFFAOYSA-N tert-butyl 4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methyl]-3,3-dimethylpiperazine-1-carboxylate Chemical compound C1(CN(CCN1CC=1C(C2=C(Cl)C=CC=C2Cl)=NOC=1C(C)C)C(=O)OC(C)(C)C)(C)C JPHPCZBOZXDUMU-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005944 tetrahydroimidazopyridyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present technology is directed to compounds, compositions, and methods related to modulation of farnesoid X receptor (FXR).
- FXR farnesoid X receptor
- the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, and renal disease.
- the Farnesoid X receptor (FXR, NR1H4) is an orphan member of the nuclear receptor gene family that is activated by farnesol metabolites (Forman et al. “Identification of a nuclear receptor that is activated by farnesol metabolites” Cell 1995, 81, 687-693; Seol et al. “Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors” Mol. Endocrinol. 1995, 9, 72-85). FXR is highly expressed in the liver, gall bladder, intestine, kidney and adrenal glands.
- bile acids were identified as natural ligands for FXR.
- Bile acid has many physiological functions and plays a critical role in the digestion, absorption, transportation, distribution of fat and lipid-soluble vitamins; maintain homeostasis of cholesterol and glucose.
- FXR serves as a key controller of bile acid homeostasis. Therefore, FXR modulation is expected to provide treatments for diseases such as cholestasis, liver fibrosis, liver cancer, atherosclerosis, diabetes and the like.
- FXR agonists were also reported as a treatment option for HBV infection (Radreau et al. “Reciprocal regulation of farnesoid X receptor a activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes” FASEB J, 2016, 30, 3146-3154).
- the present technology provides a compound according to formula I
- the present technology provides a compound according to formula IA, IB, or IC:
- composition in a related aspect, includes the compound of any one of the compounds disclosed herein (including but not limited to compounds of formulae I, IA, IB, and IC) and a pharmaceutically accepT carrier.
- a pharmaceutical composition including an effective amount of the compound of any one of the above embodiments for treating an FXR-mediated disorder or condition.
- a method in another aspect, includes administering an effective amount of a compound of any one of the above embodiments, or administering a pharmaceutical composition including an effective amount of a compound of any one of the above embodiments, to a subject suffering from an FXR-mediated disorder or condition.
- a method in another aspect, includes modulating FXR in a subject by contacting FXR with an effective amount of a compound of any one of the compounds of described herein, including but not limited to compounds of formulae I, IA, IB, and IC.
- the present technology provides compounds and methods for modulating FXR and the treatment of FXR-mediated disorders and conditions.
- the compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods. Also provided is the use of the compounds in preparing pharmaceutical formulations and medicaments.
- references to a certain element such as hydrogen or H is meant to include all isotopes of that element.
- an R group is defined to include hydrogen or H, it also includes deuterium and tritium.
- Compounds comprising radioisotopes such as tritium, C 14 , P 32 and S 35 are thus within the scope of the present technology. Procedures for inserting such labels into the compounds of the present technology will be readily apparent to those skilled in the art based on the disclosure herein.
- substituted refers to an organic group as defined below (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms.
- Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom.
- a substituted group is substituted with one or more substituents, unless otherwise specified.
- a substituted group is substituted with 1, 2, 3, 4, 5, or 6 substituents.
- substituent groups include: halogens (i.e., F, Cl, Br, and I); CF 3 ; hydroxyls; alkoxy, alkenoxy, aryloxy, aralkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, and heterocyclylalkoxy groups; carbonyls (oxo); carboxylates; esters; urethanes; oximes; hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sulfides; sulfoxides; sulfones; sulfonyls; pentafluorosulfanyl (i.e., SF 5 ), sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; amines; ureas; amidines; guanidines; enamines; imides
- Substituted ring groups such as substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups also include rings and ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups may also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined below.
- Alkyl groups include straight chain and branched chain alkyl groups having from 1 to 12 carbon atoms, and typically from 1 to 10 carbons or, in some embodiments, from 1 to 8, 1 to 6, or 1 to 4 carbon atoms.
- straight chain alkyl groups include groups such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups.
- branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups.
- Representative substituted alkyl groups may be substituted one or more times with substituents such as those listed above, and include without limitation haloalkyl (e.g., trifluoromethyl), hydroxyalkyl, thioalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, carboxyalkyl, and the like.
- Cycloalkyl groups include mono-, bi- or tricyclic alkyl groups having from 3 to 12 carbon atoms in the ring(s), or, in some embodiments, 3 to 10, 3 to 8, or 3 to 4, 5, or 6 carbon atoms.
- Exemplary monocyclic cycloalkyl groups include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
- the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 3 to 6, or 3 to 7.
- Bi- and tricyclic ring systems include both bridged cycloalkyl groups and fused rings, such as, but not limited to, bicyclo[2.1.1]hexane, adamantyl, decalinyl, and the like.
- Substituted cycloalkyl groups may be substituted one or more times with, non-hydrogen and non-carbon groups as defined above.
- substituted cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above.
- Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4-, 2,5- or 2,6-disubstituted cyclohexyl groups, which may be substituted with substituents such as those listed above.
- Cycloalkylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a cycloalkyl group as defined above.
- cycloalkylalkyl groups have from 4 to 16 carbon atoms, 4 to 12 carbon atoms, and typically 4 to 10 carbon atoms.
- Substituted cycloalkylalkyl groups may be substituted at the alkyl, the cycloalkyl or both the alkyl and cycloalkyl portions of the group.
- Representative substituted cycloalkylalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
- Alkenyl groups include straight and branched chain alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Alkenyl groups have from 2 to 12 carbon atoms, and typically from 2 to 10 carbons or, in some embodiments, from 2 to 8, 2 to 6, or 2 to 4 carbon atoms. In some embodiments, the alkenyl group has one, two, or three carbon-carbon double bonds. Examples include, but are not limited to vinyl, allyl, —CH ⁇ CH(CH 3 ), —CH ⁇ C(CH 3 ) 2 , —C(CH 3 ) ⁇ CH 2 , —C(CH 3 ) ⁇ CH(CH 3 ), —C(CH 2 CH 3 ) ⁇ CH 2 , among others. Representative substituted alkenyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
- Cycloalkenyl groups include cycloalkyl groups as defined above, having at least one double bond between two carbon atoms. In some embodiments the cycloalkenyl group may have one, two or three double bonds but does not include aromatic compounds. Cycloalkenyl groups have from 4 to 14 carbon atoms, or, in some embodiments, 5 to 14 carbon atoms, 5 to 10 carbon atoms, or even 5, 6, 7, or 8 carbon atoms. Examples of cycloalkenyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, cyclobutadienyl, and cyclopentadienyl.
- Cycloalkenylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above. Substituted cycloalkenylalkyl groups may be substituted at the alkyl, the cycloalkenyl or both the alkyl and cycloalkenyl portions of the group. Representative substituted cycloalkenylalkyl groups may be substituted one or more times with substituents such as those listed above.
- Alkynyl groups include straight and branched chain alkyl groups as defined above, except that at least one triple bond exists between two carbon atoms.
- Alkynyl groups have from 2 to 12 carbon atoms, and typically from 2 to 10 carbons or, in some embodiments, from 2 to 8, 2 to 6, or 2 to 4 carbon atoms.
- the alkynyl group has one, two, or three carbon-carbon triple bonds. Examples include, but are not limited to —C ⁇ CH, —C ⁇ CCH 3 , —CH 2 C ⁇ CCH 3 , —C ⁇ CCH 2 CH(CH 2 CH 3 ) 2 , among others.
- Representative substituted alkynyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
- Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms.
- Aryl groups herein include monocyclic, bicyclic and tricyclic ring systems.
- aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, fluorenyl, phenanthrenyl, anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups.
- aryl groups contain 6-14 carbons, and in others from 6 to 12 or even 6-10 carbon atoms in the ring portions of the groups.
- the aryl groups are phenyl or naphthyl.
- aryl groups includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like), it does not include aryl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, groups such as tolyl are referred to as substituted aryl groups.
- Representative substituted aryl groups may be mono-substituted or substituted more than once.
- monosubstituted aryl groups include, but are not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl groups, which may be substituted with substituents such as those listed above.
- Aralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
- aralkyl groups contain 7 to 16 carbon atoms, 7 to 14 carbon atoms, or 7 to 10 carbon atoms.
- Substituted aralkyl groups may be substituted at the alkyl, the aryl or both the alkyl and aryl portions of the group.
- Representative aralkyl groups include but are not limited to benzyl and phenethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-indanylethyl.
- Representative substituted aralkyl groups may be substituted one or more times with substituents such as those listed above.
- Heteroalkyl groups are alkyl groups in which 1 or 2 carbons are replaced with a heteroatom selected from N, O or S.
- heteroalkyl groups may include straight chain and branched chain heteroalkyl groups having from 1 to 11 carbon atoms, and typically from 1 to 10 carbons or, in some embodiments, from 1 to 8, 1 to 6, or 1 to 4 carbon atoms.
- Heteroalkyl groups include for example, methoxy, methoxyethyl, methylthio, methylthiopropyl, ethyloxymethyl, and methylaminobutyl.
- Heteroalkyl groups may be substituted one or more times just as alkyl groups are with substituents such as those listed above.
- Heterocyclyl groups include aromatic (also referred to as heteroaryl) and non-aromatic ring compounds containing 3 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, and S.
- the heterocyclyl group contains 1, 2, 3 or 4 heteroatoms.
- heterocyclyl groups include mono-, bi- and tricyclic rings having 3 to 16 ring members, whereas other such groups have 3 to 6, 3 to 10, 3 to 12, or 3 to 14 ring members.
- Heterocyclyl groups encompass aromatic, partially unsaturated and saturated ring systems, such as, for example, imidazolyl, imidazolinyl and imidazolidinyl groups.
- heterocyclyl group includes fused ring species including those comprising fused aromatic and non-aromatic groups, such as, for example, benzotriazolyl, 2,3-dihydrobenzo[1,4]dioxinyl, and benzo[1,3]dioxolyl.
- the phrase also includes bridged polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl.
- the phrase does not include heterocyclyl groups that have other groups, such as alkyl, oxo or halo groups, bonded to one of the ring members. Rather, these are referred to as “substituted heterocyclyl groups”.
- Heterocyclyl groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrothiophenyl, tetrahydrofuranyl, dioxolyl, furanyl, thiophenyl, pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, oxadiazolonyl (including 1,2,4-oxazol-5(4H)-one-3-yl), isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidyl, piperazinyl, morpholinyl,
- substituted heterocyclyl groups may be mono-substituted or substituted more than once, such as, but not limited to, pyridyl or morpholinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with various substituents such as those listed above.
- Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S.
- Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, benzothiophenyl, furanyl, benzofuranyl, indolyl, azaindolyl (pyrrolopyridinyl), indazolyl, benzimidazolyl, imidazopyridinyl (azabenzimidazolyl), pyrazolopyridinyl, triazolopyridinyl, benzotriazolyl, benzoxazolyl, benzo
- Heteroaryl groups include fused ring compounds in which all rings are aromatic such as indolyl groups and include fused ring compounds in which only one of the rings is aromatic, such as 2,3-dihydro indolyl groups.
- heteroaryl groups includes fused ring compounds, the phrase does not include heteroaryl groups that have other groups bonded to one of the ring members, such as alkyl groups. Rather, heteroaryl groups with such substitution are referred to as “substituted heteroaryl groups.” Representative substituted heteroaryl groups may be substituted one or more times with various substituents such as those listed above.
- Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above. Substituted heterocyclylalkyl groups may be substituted at the alkyl, the heterocyclyl or both the alkyl and heterocyclyl portions of the group.
- Representative heterocyclyl alkyl groups include, but are not limited to, morpholin-4-yl-ethyl, furan-2-yl-methyl, imidazol-4-yl-methyl, pyridin-3-yl-methyl, tetrahydrofuran-2-yl-ethyl, and indol-2-yl-propyl.
- Representative substituted heterocyclylalkyl groups may be substituted one or more times with substituents such as those listed above.
- Heteroaralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above. Substituted heteroaralkyl groups may be substituted at the alkyl, the heteroaryl or both the alkyl and heteroaryl portions of the group. Representative substituted heteroaralkyl groups may be substituted one or more times with substituents such as those listed above.
- Groups described herein having two or more points of attachment i.e., divalent, trivalent, or polyvalent
- divalent alkyl groups are alkylene groups
- divalent aryl groups are arylene groups
- divalent heteroalkyl groups are heteroalkylene groups
- heteroaryl groups are divalent heteroarylene groups
- Substituted groups having a single point of attachment to the compound of the present technology are not referred to using the “ene” designation.
- chloroethyl is not referred to herein as chloroethylene.
- Alkoxy groups are hydroxyl groups (—OH) in which the bond to the hydrogen atom is replaced by a bond to a carbon atom of a substituted or unsubstituted alkyl group as defined above.
- linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, and the like.
- branched alkoxy groups include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy, and the like.
- cycloalkoxy groups include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
- Representative substituted alkoxy groups may be substituted one or more times with substituents such as those listed above.
- alkanoyl and alkanoyloxy can refer, respectively, to —C(O)-alkyl groups and —O—C(O)-alkyl groups, each containing 2-5 carbon atoms.
- aryloyl and aryloyloxy refer to —C(O)-aryl groups and —O—C(O)-aryl groups.
- aryloxy and arylalkoxy refer to, respectively, a substituted or unsubstituted aryl group bonded to an oxygen atom and a substituted or unsubstituted aralkyl group bonded to the oxygen atom at the alkyl. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy. Representative substituted aryloxy and arylalkoxy groups may be substituted one or more times with substituents such as those listed above.
- carboxylate refers to a —COOH group.
- esters refers to —COOR 70 and —C(O)O-G groups.
- R 70 is a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
- G is a carboxylate protecting group.
- Carboxylate protecting groups are well known to one of ordinary skill in the art. An extensive list of protecting groups for the carboxylate group functionality may be found in Protective Groups in Organic Synthesis, Greene, T. W.; Wuts, P. G.
- amide includes C- and N-amide groups, i.e., —C(O)NR 71 R 72 , and —NR 71 C(O)R 72 groups, respectively.
- R 71 and R 72 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
- Amido groups therefore include but are not limited to carbamoyl groups (—C(O)NH 2 ) and formamide groups (—NHC(O)H).
- the amide is —NR 71 C(O)—(C 1-5 alkyl) and the group is termed “carbonylamino,” and in others the amide is —NHC(O)-alkyl and the group is termed “alkanoylamino.”
- nitrile or “cyano” as used herein refers to the —CN group.
- Urethane groups include N- and O-urethane groups, i.e., —NR 73 C(O)OR 74 and —OC(O)NR 73 R 74 groups, respectively.
- R 73 and R 74 are independently a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, or heterocyclyl group as defined herein.
- R 73 may also be H.
- amine refers to —NR 75 R 76 groups, wherein R 75 and R 76 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
- the amine is alkylamino, dialkylamino, arylamino, or alkylarylamino.
- the amine is NH 2 , methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino, phenylamino, or benzylamino.
- sulfonamido includes S- and N-sulfonamide groups, i.e., —SO 2 NR 78 R 79 and —NR 78 SO 2 R 79 groups, respectively.
- R 78 and R 79 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, or heterocyclyl group as defined herein.
- Sulfonamido groups therefore include but are not limited to sulfamoyl groups (—SO 2 NH 2 ).
- the sulfonamido is —NHSO 2 -alkyl and is referred to as the “alkylsulfonylamino” group.
- thiol refers to —SH groups
- sulfides include —SR 80 groups
- sulfoxides include —S(O)R 81 groups
- sulfones include —SO 2 R 82 groups
- sulfonyls include —SO 2 OR 83 .
- R 80 , R 81 , R 82 , and R 83 are each independently a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- the sulfide is an alkylthio group, —S-alkyl.
- urea refers to —NR 84 —C(O)—NR 85 R 86 groups.
- R 84 , R 85 , and R 86 groups are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclyl, or heterocyclylalkyl group as defined herein.
- amidine refers to —C(NR 87 )NR 88 R 89 and —NR 87 C(NR 88 )R 89 , wherein R 87 , R 88 , and R 89 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- guanidine refers to —NR 90 C(NR 91 )NR 92 R 93 , wherein R 90 , R 91 , R 92 and R 93 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- enamine refers to —C(R 94 ) ⁇ C(R 95 )NR 96 R 97 and —NR 94 C(R 95 ) ⁇ C(R 96 )R 97 , wherein R 94 , R 95 , R 96 and R 97 are each independently hydrogen, a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- halogen refers to bromine, chlorine, fluorine, or iodine. In some embodiments, the halogen is fluorine. In other embodiments, the halogen is chlorine or bromine.
- hydroxyl as used herein can refer to —OH or its ionized form, —O—.
- a “hydroxyalkyl” group is a hydroxyl-substituted alkyl group, such as HO—CH 2 —.
- imide refers to —C(O)NR 98 C(O)R 99 , wherein R 98 and R 99 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- the term “imine” refers to —CR 100 (NR 100 ) and —N(CR 100 R 101 ) groups, wherein R 100 and R 101 are each independently hydrogen or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein, with the proviso that R 100 and R 101 are not both simultaneously hydrogen.
- nitro refers to an —NO 2 group.
- trifluoromethyl refers to —CF 3 .
- trifluoromethoxy refers to —OCF 3 .
- azido refers to —N 3 .
- trialkyl ammonium refers to a —N(alkyl) 3 group.
- a trialkylammonium group is positively charged and thus typically has an associated anion, such as halogen anion.
- isocyano refers to —NC.
- isothiocyano refers to —NCS.
- phrase “selectively modulates” as used herein will be understood by persons of ordinary skill in the art and will vary to some extent depending upon the context in which the phrase is used. If there are uses of the phrase which are not clear to persons of ordinary skill in the art, given the context in which the phrase is used, the phrase at minimum refers to the compounds acting through a specific mechanism of action, resulting in fewer off-target effects because the compounds target a particular receptor over other receptors, such as an FXR over a GR receptor, LXR, PPAR ⁇ , TGR5 or PXR. This phrase may further be modified as discussed herein.
- a range includes each individual member.
- a group having 1-3 atoms refers to groups having 1, 2, or 3 atoms.
- a group having 1-5 atoms refers to groups having 1, 2, 3, 4, or 5 atoms, and so forth.
- Pharmaceutically acceptable salts of compounds described herein are within the scope of the present technology and include acid or base addition salts which retain the desired pharmacological activity and is not biologically undesirable (e.g., the salt is not unduly toxic, allergenic, or irritating, and is bioavailable).
- pharmaceutically acceptable salts can be formed with inorganic acids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g.
- alginate formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalene sulfonic acid, and p-toluenesulfonic acid) or acidic amino acids (such as aspartic acid and glutamic acid).
- an acidic group such as for example, a carboxylic acid group
- it can form salts with metals, such as alkali and earth alkali metals (e.g.
- salts can be prepared in situ during isolation and purification of the compounds or by separately reacting the purified compound in its free base or free acid form with a suitable acid or base, respectively, and isolating the salt thus formed.
- Tautomers refers to isomeric forms of a compound that are in equilibrium with each other. The presence and concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, guanidines may exhibit the following isomeric forms in protic organic solution, also referred to as tautomers of each other:
- Stereoisomers of compounds include all chiral, diastereomeric, and racemic forms of a structure, unless the specific stereochemistry is expressly indicated.
- compounds used in the present technology include enriched or resolved optical isomers at any or all asymmetric atoms as are apparent from the depictions.
- racemic and diastereomeric mixtures, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these stereoisomers are all within the scope of the present technology.
- the present technology provides heterocyclic derivatives such as pyrrolidines, imidazolidines, piperidines, piperazines, azepanes and diazepanes that modulate FXR and intermediates for making such compounds.
- heterocyclic derivatives such as pyrrolidines, imidazolidines, piperidines, piperazines, azepanes and diazepanes that modulate FXR and intermediates for making such compounds.
- the compounds include, but are not limited to compounds of formulae I, IA, IB, and IC as described herein.
- L is N. In other embodiments, L is CR 7 .
- X, M, Z, W, R 4 , R 10 , n, r, and t may have any of the values of any of the aspects or embodiments of compounds described herein.
- M is N. In other embodiments, M is CR 7 .
- r and t are each independently 1, 2, or 3, as noted above.
- r is 1 or 2.
- r is 2.
- t is 1.
- t is 2.
- t is 3.
- the sum of r+t is greater than 2 but less than 6 (i.e., 2 ⁇ r+t ⁇ 6).
- the present compounds include but are not limited to pyrrolidines, piperidines, piperazines, azepanes and diazepanes.
- n is 1 or 2. In some embodiments, n is 0.
- R 10 at each occurrence is independently halo, CO 2 R c , or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group.
- R 10 at each occurrence is independently CO 2 H, substituted or unsubstituted C 1 -C 3 alkyl, C 1 -C 3 hydroxyalkyl, or C 3 -C 6 cycloalkyl group.
- R 10 at each occurrence is independently CO 2 H, CH 3 , CH 2 OH, or a cyclopropyl group. In other embodiments, R 10 at each occurrence is independently CH 3 , CH 2 CH 3 , or CH(CH 3 ) 2 . In certain embodiments, when n is 2 or 3, two of the R 10 groups together may be a substituted or unsubstituted C2-C5 (i.e., a C2, C3, C4, or C5 alkylene group) alkylene, heteroalkylene, alkenylene or heteroalkenylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached.
- C2-C5 i.e., a C2, C3, C4, or C5 alkylene group
- R 10 may be a substituted or unsubstituted C2-C5 alkylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached.
- R 10 is an unsubstituted C2-C5 alkylene group having 2 separate points of attachment to the same carbon, thus forming a spirocyclic group (e.g., a spirocyclic cyclopropyl group, spirocyclic cyclobutyl group, spirocyclic cyclopentyl group, spirocyclic cyclohexyl group).
- a spirocyclic group e.g., a spirocyclic cyclopropyl group, spirocyclic cyclobutyl group, spirocyclic cyclopentyl group, spirocyclic cyclohexyl group.
- R 10 is an unsubstituted C2, C3, C4 or C5 alkylene group having 2 separate points of attachment to different carbons, thus forming fused bicyclic rings, e.g., octahydroquinoxaline, 3,8-diazabicyclo[3.2.1]octane, and 3,9-diazabicyclo[3.3.1]nonane.
- the compounds of formula I have the formulae IIA, IIB and IIC:
- R 4 is CO 2 H, CN, CONH 2 , SO 2 NH 2 , or a substituted or unsubstituted CO 2 —C 1 -C 6 alkyl, CO 2 —C 3 -C 6 cycloalkyl, CONH—C 1 -C 6 alkyl, CONH—C 3 -C 6 cycloalkyl, NH—SO 2 —C 1 -C 6 alkyl, or tetrazolyl group.
- R 4 is CO 2 H, CN, CONH 2 , or a substituted or unsubstituted CO 2 —C 1 -C 6 alkyl, CONH—C 1 -C 6 alkyl, or tetrazolyl group. In yet other embodiments, R 4 is CO 2 H, or an unsubstituted CO 2 —C 1 -C 6 alkyl, CONH 2 , or tetrazolyl group. In some embodiments, R 4 is CO 2 H.
- X may be
- X is attached to R 4 via the open valence on the left side of the structure, and X is attached to the central nitrogen-containing heterocycle via the open valence on the right side of the structure.
- one of G 1 , G 2 , G 3 , and G 4 is CR 13 and the others are CH (it being understood that R 4 is attached in place of H at one of the G variables defined as CH).
- one of G 1 , G 2 , G 3 , and G 4 is CR 13 and one is CR 11 .
- D is N and in others, D is CR 9 .
- Q is S. In others, Q is O, and in still others, Q is NR 12 .
- D is N and Q is S. In others, D is N and Q is NR 12 .
- D is CR 9 and Q is S, or D is CR 9 and Q is NR 12 .
- X is
- R 9 and R 13 are independently H, halo, or a substituted or unsubstituted C 1 -C 4 alkyl, or O—(C 1 -C 4 alkyl) group.
- R 9 is H, F, or Cl.
- R 13 is H, F, or a substituted or unsubstituted C 1 -C 3 alkyl, or O—(C 1 -C 3 alkyl) group.
- R 13 is H, F, CH 3 , or OCH 3 .
- R 9 is H.
- R 11 at each occurrence is independently halo, CF 3 , or a substituted or unsubstituted alkyl or alkoxy group. In certain embodiments, R 11 is F, Cl, or CF 3 . In some embodiments, R 12 is H or a substituted or unsubstituted C 1 -C 6 alkyl group. In some embodiments, R 12 is H or CH 3 .
- Z is a substituted or unsubstituted C 1 -C 4 alkylene or O—C 1 -C 4 alkylene group. In some embodiments, Z is a substituted or unsubstituted C 1 -C 2 alkylene or O—C 1 -C 2 alkylene group. In some embodiments, Z is a substituted or unsubstituted C 1 -C 4 alkylene group. In some embodiments, Z is a substituted or unsubstituted C 1 -C 2 alkylene group. In some embodiments, Z is a substituted or unsubstituted methylene, e.g., —CH 2 —.
- Z is a substituted or unsubstituted cyclopropylalkylene group. In some embodiments, Z may be substituted with halo or OH. In some embodiments, Z may be substituted with F or OH. In some embodiments, Z may be substituted with F, OH, or CF 3 .
- W is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
- R 1 and R 2 are independently halo, CN, CO 2 R e , NR e R f , or a substituted or unsubstituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or C 1 -C 6 hydroxyalkyl group; and wherein R e and R f at each occurrence are independently H or a substituted or unsubstituted C 1 -C 6 alkyl group.
- R 1 and R 2 are independently H, F, Cl, CN, CO 2 H, NR e R f , or a substituted or unsubstituted C 1 -C 3 alkyl, C 1 -C 3 alkoxy, or C 1 -C 3 hydroxyalkyl group.
- R 1 and R 2 are independently H, F, Cl, CN, CO 2 H, NH 2 , CH 3 , CH 2 NH 2 , OCF 3 , or OCH 3 .
- R 1 and R 2 are both Cl.
- one of R 1 and R 2 is H and the other is OCF 3 .
- R 3 is a substituted or unsubstituted C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl group.
- R 3 is CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH(CH 3 ) 2 , CH(CH 2 CH 3 ) 2 , CH(CH 2 CH 3 )(CH 3 ), C(CH 3 ) 3 , or cyclopropyl.
- R 3 is an isopropyl or cyclopropyl group.
- the present technology provides a compound according to formula IA, IB, or IC:
- a composition in an aspect of the present technology, includes any one of the aspects and embodiments of compounds of formulas I-III and a pharmaceutically acceptable carrier.
- a pharmaceutical composition which includes an effective amount of the compound of any one of the aspects and embodiments of compounds of formulas I-IV for treating an FXR-mediated disorder or condition.
- the FXR-mediated disorder or condition may be liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, or renal disease.
- the disorder or condition may be a liver disease selected from the group consisting of primary biliary cirrhosis (PBC), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, and liver cirrhosis.
- PBC primary biliary cirrhosis
- CCTX cerebrotendinous xanthomatosis
- PSC primary sclerosing cholangitis
- NAFLD nonalcoholic fatty liver disease
- NASH nonalcoholic steatohepatitis
- liver fibrosis liver cirrhosis
- a method in a further related aspect, includes administering an effective amount of a compound of any one of the aspects and embodiments of compounds of formulas I-IV or administering a pharmaceutical composition comprising an effective amount of a compound of any one of the aspects and embodiments of compounds of formula I-IV to a subject suffering from an FXR-mediated disorder or condition.
- the FXR-mediated disorder or condition may be liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, or renal disease.
- the disorder or condition is the disorder or condition may be a liver disease selected from the group consisting of primary biliary cirrhosis (PBC), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, and liver cirrhosis.
- PBC primary biliary cirrhosis
- CCTX cerebrotendinous xanthomatosis
- PSC primary sclerosing cholangitis
- NAFLD nonalcoholic fatty liver disease
- NASH nonalcoholic steatohepatitis
- liver fibrosis liver fibrosis
- liver cirrhosis liver cirrhosis
- Effective amount refers to the amount of a compound or composition required to produce a desired effect.
- One example of an effective amount includes amounts or dosages that yield acceptable toxicity and bioavailability levels for therapeutic (pharmaceutical) use including, but not limited to, the treatment of hyperlipidemia.
- Another example of an effective amount includes amounts or dosages that are capable of reducing symptoms associated with metabolic syndrome, such as, for example, obesity and/or metabolic syndrome.
- the effective amount of the compound may selectively modulate FXR.
- a “subject” or “patient” is a mammal, such as a cat, dog, rodent or primate. Typically the subject is a human, and, preferably, a human suffering from or suspected of suffering from an FXR-mediated disorder or condition.
- the term “subject” and “patient” can be used interchangeably.
- the present technology provides methods of modulating FXR by contacting FXR with an effective amount of any compound as described herein, including but not limited to a compound of formula I, II, III, or IV.
- compositions and medicaments comprising any of the compounds disclosed herein (e.g., compounds of formulas I-IV) and a pharmaceutically acceptable carrier or one or more excipients or fillers.
- the compositions may be used in the methods and treatments described herein.
- Such compositions and medicaments include a theapeutically effective amount of any compound as described herein, including but not limited to a compound of formula I, II, III, or IV.
- the pharmaceutical composition may be packaged in unit dosage form.
- compositions and medicaments may be prepared by mixing one or more compounds of the present technology, stereoisomers thereof, and/or pharmaceutically acceptable salts thereof, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like to prevent and treat disorders associated with the effects of increased plasma and/or hepatic lipid levels.
- the compounds and compositions described herein may be used to prepare formulations and medicaments that prevent or treat a variety of disorders associated with or mediated by FXR, including but not limited to liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis and renal disease.
- compositions can be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions.
- the instant compositions can be formulated for various routes of administration, for example, by oral, parenteral, topical, rectal, nasal, vaginal administration, or via implanted reservoir.
- Parenteral or systemic administration includes, but is not limited to, subcutaneous, intravenous, intraperitoneal, and intramuscular, injections.
- the following dosage forms are given by way of example and should not be construed as limiting the instant present technology.
- powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more compounds of the instant present technology, or pharmaceutically acceptable salts or tautomers thereof, with at least one additive such as a starch or other additive.
- Suitable additives are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides.
- oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, thickeners, buffers, sweeteners, flavoring agents or perfuming agents. Tablets and pills may be further treated with suitable coating materials known in the art.
- suitable coating materials known in the art.
- Liquid dosage forms for oral administration may be in the form of pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, and solutions, which may contain an inactive diluent, such as water.
- Pharmaceutical formulations and medicaments may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these.
- Pharmaceutically suitable surfactants, suspending agents, emulsifying agents may be added for oral or parenteral administration.
- suspensions may include oils.
- oils include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil.
- Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides.
- Suspension formulations may include alcohols, such as, but not limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol.
- Ethers such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil and petrolatum; and water may also be used in suspension formulations.
- Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or suspending agents. Typically, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
- the pharmaceutical formulation and/or medicament may be a powder suitable for reconstitution with an appropriate solution as described above.
- these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates.
- the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
- Compounds of the present technology may be administered to the lungs by inhalation through the nose or mouth.
- suitable pharmaceutical formulations for inhalation include solutions, sprays, dry powders, or aerosols containing any appropriate solvents and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
- the carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.
- Aqueous and nonaqueous (e.g., in a fluorocarbon propellant) aerosols are typically used for delivery of compounds of the present technology by inhalation.
- Dosage forms for the topical (including buccal and sublingual) or transdermal administration of compounds of the present technology include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, and patches.
- the active component may be mixed under sterile conditions with a pharmaceutically-acceptable carrier or excipient, and with any preservatives, or buffers, which may be required.
- Powders and sprays can be prepared, for example, with excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- the ointments, pastes, creams and gels may also contain excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Absorption enhancers can also be used to increase the flux of the compounds of the present technology across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane (e.g., as part of a transdermal patch) or dispersing the compound in a polymer matrix or gel.
- excipients and carriers are generally known to those skilled in the art and are thus included in the instant present technology. Such excipients and carriers are described, for example, in “Remingtons Pharmaceutical Sciences” Mack Pub. Co., New Jersey (1991), which is incorporated herein by reference.
- the formulations of the present technology may be designed to be short-acting, fast-releasing, long-acting, and sustained-releasing as described below.
- the pharmaceutical formulations may also be formulated for controlled release or for slow release.
- compositions may also comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the pharmaceutical formulations and medicaments may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers.
- Specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, and diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant present technology.
- a compound of the present technology is readily able to determine an effective amount by simply administering a compound of the present technology to a patient in increasing amounts until for example, (for metabolic syndrome and/or obesity) the elevated plasma or elevated white blood cell count or hepatic cholesterol or triglycerides or progression of the disease state is reduced or stopped.
- the progression of the disease state can be assessed using in vivo imaging, as described, or by taking a tissue sample from a patient and observing the target of interest therein.
- the compounds of the present technology can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kg, a dosage in the range of about 0.01 to about 100 mg per kg of body weight per day is sufficient.
- the specific dosage used can vary or may be adjusted as considered appropriate by those of ordinary skill in the art. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to those skilled in the art.
- Effectiveness of the compositions and methods of the present technology may also be demonstrated by a decrease in the symptoms of hyperlipidemia, such as, for example, a decrease in triglycerides in the blood stream. Effectiveness of the compositions and methods of the present technology may also be demonstrated by a decrease in the signs and symptoms of liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, or renal disease.
- test subjects will exhibit a 10%, 20%, 30%, 50% or greater reduction, up to a 75-90%, or 95% or greater, reduction, in one or more symptom(s) caused by, or associated with, the disorder in the subject, compared to placebo—treated or other suitable control subjects.
- the compounds of the present technology can also be administered to a patient along with other conventional therapeutic agents that may be useful in the treatment of liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, or renal disease.
- the administration may include oral administration, parenteral administration, or nasal administration.
- the administration may include subcutaneous injections, intravenous injections, intraperitoneal injections, or intramuscular injections.
- the administration may include oral administration.
- the methods of the present technology can also comprise administering, either sequentially or in combination with one or more compounds of the present technology, a conventional therapeutic agent in an amount that can potentially be effective for the treatment of liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, or renal disease.
- a compound of the present technology is administered to a patient in an amount or dosage suitable for therapeutic use.
- a unit dosage comprising a compound of the present technology will vary depending on patient considerations. Such considerations include, for example, age, protocol, condition, sex, extent of disease, contraindications, concomitant therapies and the like.
- An exemplary unit dosage based on these considerations can also be adjusted or modified by a physician skilled in the art.
- a unit dosage for a patient comprising a compound of the present technology can vary from 1 ⁇ 10 ⁇ 4 g/kg to 1 g/kg, preferably, 1 ⁇ 10 ⁇ 3 g/kg to 1.0 g/kg. Dosage of a compound of the present technology can also vary from 0.01 mg/kg to 100 mg/kg or, preferably, from 0.1 mg/kg to 10 mg/kg.
- a compound of the present technology can also be modified, for example, by the covalent attachment of an organic moiety or conjugate to improve pharmacokinetic properties, toxicity or bioavailability (e.g., increased in vivo half-life).
- the conjugate can be a linear or branched hydrophilic polymeric group, fatty acid group or fatty acid ester group.
- a polymeric group can comprise a molecular weight that can be adjusted by one of ordinary skill in the art to improve, for example, pharmacokinetic properties, toxicity or bioavailability.
- Exemplary conjugates can include a polyalkane glycol (e.g., polyethylene glycol (PEG), polypropylene glycol (PPG)), carbohydrate polymer, amino acid polymer or polyvinyl pyrolidone and a fatty acid or fatty acid ester group, each of which can independently comprise from about eight to about seventy carbon atoms.
- a polyalkane glycol e.g., polyethylene glycol (PEG), polypropylene glycol (PPG)
- carbohydrate polymer e.g., amino acid polymer or polyvinyl pyrolidone and a fatty acid or fatty acid ester group, each of which can independently comprise from about eight to about seventy carbon atoms.
- Conjugates for use with a compound of the present technology can also serve as linkers to, for example, any suitable substituents or groups, radiolabels (marker or tags), halogens, proteins, enzymes, polypeptides, other therapeutic agents (for example, a pharmaceutical or drug), nucleosides, dyes, oligonucleotides, lipids, phospholipids and/or liposomes.
- conjugates can include polyethylene amine (PEI), polyglycine, hybrids of PEI and polyglycine, polyethylene glycol (PEG) or methoxypolyethylene glycol (mPEG).
- a conjugate can also link a compound of the present technology to, for example, a label (fluorescent or luminescent) or marker (radionuclide, radioisotope and/or isotope) to comprise a probe of the present technology.
- Conjugates for use with a compound of the present technology can, in one aspect, improve in vivo half-life.
- Other exemplary conjugates for use with a compound of the present technology as well as applications thereof and related techniques include those generally described by U.S. Pat. No. 5,672,662, which is hereby incorporated by reference herein.
- the present technology provides methods of identifying a target of interest including contacting the target of interest with a detectable or imaging effective quantity of a labeled compound of the present technology.
- a detectable or imaging effective quantity is a quantity of a labeled compound of the present technology necessary to be detected by the detection method chosen.
- a detectable quantity can be an administered amount sufficient to enable detection of binding of the labeled compound to a target of interest including, but not limited to, a KOR.
- Suitable labels are known by those skilled in the art and can include, for example, radioisotopes, radionuclides, isotopes, fluorescent groups, biotin (in conjunction with streptavidin complexation), and chemoluminescent groups.
- the target may be isolated, purified and further characterized such as by determining the amino acid sequence.
- association can mean a chemical or physical interaction, for example, between a compound of the present technology and a target of interest.
- associations or interactions include covalent bonds, ionic bonds, hydrophilic-hydrophilic interactions, hydrophobic-hydrophobic interactions and complexes.
- Associated can also refer generally to “binding” or “affinity” as each can be used to describe various chemical or physical interactions. Measuring binding or affinity is also routine to those skilled in the art.
- compounds of the present technology can bind to or interact with a target of interest or precursors, portions, fragments and peptides thereof and/or their deposits.
- the examples herein are provided to illustrate advantages of the present technology and to further assist a person of ordinary skill in the art with preparing or using the compounds of the present technology or salts, pharmaceutical compositions, derivatives, solvates, metabolites, prodrugs, racemic mixtures or tautomeric forms thereof.
- the examples herein are also presented in order to more fully illustrate the preferred aspects of the present technology. The examples should in no way be construed as limiting the scope of the present technology, as defined by the appended claims.
- the examples can include or incorporate any of the variations, aspects or aspects of the present technology described above.
- the variations, aspects or aspects described above may also further each include or incorporate the variations of any or all other variations, aspects or aspects of the present technology.
- Methyl 2-chloro-4-methoxybenzo[d]thiazole-6-carboxylate (Compound INT-001): To a suspension of Compound 1a (22.5 g, 94 mmol) in MeCN (320 mL) was added CuCl 2 (25 g, 188 mmol). The mixture was stirred for 5 min at room temperature before 3-methylbutyl nitrite (16.5 g, 141 mmol) was added dropwise at room temperature. The reaction was stirred for another 1 h at 60° C. The reaction was then quenched by the addition of 60 mL of water. The resulting mixture was extracted with ethyl acetate several times. The organic layers were combined. The organic phase was washed with water and brine.
- Methyl 2-mercaptobenzo[d]oxazole-6-carboxylate (Compound 2a): To a stirring solution of methyl 4-amino-3-hydroxybenzoate (5 g, 29.91 mmol) in pyridine (60 mL) was added ethoxy(potassiosulfanyl)methanethione (5 g, 31.19 mmol). The resulting solution was stirred for 5 h at 115° C. The reaction was quenched with water. The resulting solution was extracted with 3'30 mL of dichloromethane. The organic layers were combined and washed successively with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. This resulted in 3.5 g (56%) of the title compound as a yellow solid.
- Methyl 2-chlorobenzo[d]oxazole-6-carboxylate (Compound INT-011): To a suspension of Compound 2a (1 g, 4.78 mmol) in thionyl dichloride (5 mL) was added DMF (0.1 mL). The resulting solution was stirred for 15 min at 80° C. The reaction solution was concentrated under vacuum. The crude was diluted with DCM and washed successively with saturated NaHCO 3 solution, water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (23:77). This resulted in 520 mg (51%) of the title compound as a white solid.
- Methyl 2-chloro-1-methyl-1H-indole-5-carboxylate (Compound INT-012): To a solution of Compound 3a (150 mg, 0.72 mmol) in THF (5 mL) was added sodium hydride (71 mg, 2.96 mmol) batchwise at 0° C. The mixture was stirred for 30 min at room temperature then CH 3 I (254 mg, 1.79 mmol) was added. The mixture was stirred for 6 h at room temperature. The reaction was quenched by adding 5 mL of water. The resulting solution was extracted with 3 ⁇ 5 mL of ethyl acetate and the organic layers were combined. The resulted organic phase was washed successively with water and brine.
- tert-Butyl 3-[[1(tert-butyldiphenylsilyl)oxy]methyl]piperazine-1-carboxylate (Compound 5a): To a solution of tert-butyl 3-(hydroxymethyl) piperazine-1-carboxylate (1 g, 4.62 mmol) in dichloromethane (10 mL) was added 1H-imidazole (629 mg, 9.24 mmol). This was followed by addition of a solution of TBDPSCl (1.18 mL, 1.30 mmol) in dichloromethane (10 mL) dropwise with stirring. The mixture was allowed warm to room temperature and stirred for 3 h.
- tert-Butyl 4-[[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methyl]-3,3-dimethylpiperazine-1-carboxylate (Compound 6a): To a solution of tert-butyl 3,3-dimethylpiperazine-1-carboxylate (150 mg, 0.70 mmol) in dichloromethane (5 mL) was added 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carbaldehyde (180 mg, 0.63 mmol) and sodium acetate (87 mg, 1.06 mmol).
- V-02 F 6 561.2 DMSO-d 6 ⁇ 13.10 (s, 1H), 8.24 (m, 1H), 7.64 (m, 2H), 7.53-7.50 (m, 1H), 7.23- 7.19 (m, 1H), 4.15 (s, 1H), 3.75 (m, 1H), 3.19-3.15 (m, 3H), 2.80-2.77 (m, 1H), 2.50-2.49 (m, 1H), 2.34- 2.32 (m, 1H), 2.24-2.21 (m. 1H), 1.95-1.92 (m, 1H), 1.16-1.11 (m, 4H), 0.96- 0.93 (m, 3H).
- *It is to be understood that ring A attaches to the thiazole ring at the open valence on the left-hand side of ring A and to the B-ring at the open valence on the right-hand side of ring A.
- VI-02 4 546.7 DMSO-d 6 ⁇ 12.94 (brs, 1H), 8.23-8.22 (m, 1H), 7.65-7.52 (m, 4H), 3.45-3.43 (m, 4H), 3.32-3.30 (m, 2H), 2.39-2.34 (m, 5H), 1.15-1.09 (m, 4H).
- tert-Butyl (2S)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazine-1-carboxylate (Compound 12a): To a solution of tert-butyl (2S)-2-methylpiperazine-1-carboxylate (400 mg, 2.00 mmol) in dichloromethane (6 mL) was added acetic acid (120 mg, 2.0 mmol) and 5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carbaldehyde (562 mg, 1.99 mmol).
- the compounds of the present technology may be assayed using the following procedures and show or will be shown to have FXR binding activity.
- FXR FXR Transactivation Coactivator Assay Assay Compound (EC 50 ) (EC 50 ) II-01 B A II-02 A A II-03 B A II-04 B A II-05 A A II-06 A — II-07 C — II-08 A A II-09 A A II-10 B — II-11 B A II-12 A — II-13 A A II-14 C — II-15 A — II-16 B A II-17 C — II-18 A A II-19 B A II-20 B A II-21 B — II-22 B A II-23 C — II-24 A A II-25 B — II-26 A A II-27 A — II-28 B A II-29 C — II-30 B A II-31 C — II-32 A A II-33 B A II-34 A — II-35 C — II-36 A — II-37 B — II-38 C — II-39 B — II-40 B A II-41 C — II-42 B A
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present technology is directed to compounds, compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/346807, filed on May 1, 2019, which is a U.S. National Stage Application under 35 U.S.C. § 371 of International Application No. PCT/US2017/058802, filed on Oct. 27, 2017, which claims the benefit of claims priority to U.S. Provisional Application No. 62/424813, filed on Nov. 21, 2016, and Chinese Application No. 201610974016.1, filed on Nov. 4, 2016, each of which is incorporated by reference in their entirity.
- The present technology is directed to compounds, compositions, and methods related to modulation of farnesoid X receptor (FXR). In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, and renal disease.
- The Farnesoid X receptor (FXR, NR1H4) is an orphan member of the nuclear receptor gene family that is activated by farnesol metabolites (Forman et al. “Identification of a nuclear receptor that is activated by farnesol metabolites” Cell 1995, 81, 687-693; Seol et al. “Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors” Mol. Endocrinol. 1995, 9, 72-85). FXR is highly expressed in the liver, gall bladder, intestine, kidney and adrenal glands.
- Subsequently, bile acids were identified as natural ligands for FXR. Bile acid has many physiological functions and plays a critical role in the digestion, absorption, transportation, distribution of fat and lipid-soluble vitamins; maintain homeostasis of cholesterol and glucose. Through regulation of gene expression of bile acids, FXR serves as a key controller of bile acid homeostasis. Therefore, FXR modulation is expected to provide treatments for diseases such as cholestasis, liver fibrosis, liver cancer, atherosclerosis, diabetes and the like. FXR agonists were also reported as a treatment option for HBV infection (Radreau et al. “Reciprocal regulation of farnesoid X receptor a activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes” FASEB J, 2016, 30, 3146-3154).
- In recent years, a variety of primary and secondary bile acids such as chenodeoxycholic acid (CDCA) that can activate FXR have been found. In 2002, Pellicciari et al. reported the first synthesis of highly active steroid FXR agonist, 6-ethyl-CDCA (Pellicciari et al. “6a-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity” J. Med. Chem. 2002, 45, 3569-72). 6-EDCA, also known as obeticholic acid, is in clinical trials for treatment of NAFLD, NASH, liver cirrhosis and other liver conditions. It has been approved for treatment in the US for the treatment of primary biliary cholangitis. Thus, FXR modulators have been shown to be therapeutically effective in a number of FXR-mediated diseases and disorders.
- In one aspect, the present technology provides a compound according to formula I
- stereoisomers, and/or salts thereof; wherein
- L and M are independently selected from N and CR7, provided that at least one of L and M is N;
- Z is a substituted or unsubstituted C1-C4 alkylene, O—C1-C4 alkylene, cyclopropylalkylene, or oxetanylalkylene group;
- W is
- X is
- D is N or CR9;
- one of G1, G2, G3, and G4 is CR13 and the others are selected from the group consisting of CH and CR11;
- Q is O, S, or NR12;
- R1 and R2 are independently H, OH, halo, CN, carboxyl, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, or hydroxyalkyl group;
- R3 is a substituted or unsubstituted alkyl or cycloalkyl group;
- R4 is CN, SO3H, CONRaRb, SO2NRaRb, NHSO2Rb, SO2NHCORa, CO2Rc, or a substituted or unsubstituted tetrazolyl or 1,2,4-oxadiazol-5(4H)-one-3-yl group;
- R7 is H, OH, halo, CN, carboxyl, amido, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, or aminoalkyl group;
- R9 and R13 are independently H, halo, or a substituted or unsubstituted C1-C6 alkyl, or O—(C1-C6 alkyl) group;
- R10 at each occurrence is independently halo, CO2Rc, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group, or, when n is 2 or 3, two of the R10 groups together may be a substituted or unsubstituted C2-C5 alkylene, heteroalkylene, alkenylene or heteroalkenylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached;
- R11 at each occurrence are independently OH, halo, CF3, CN, carboxyl, NRaRb, or a substituted or unsubstituted alkyl, alkoxy group, or phenyl group;
- R12 is H or a substituted or unsubstituted C1-C6 alkyl group; and
- Ra at each occurrence is independently H, or a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, or SO2-alkyl group;
- Rb at each occurrence is H or a substituted or unsubstituted alkyl, or haloalkyl group;
- Rc is H or a substituted or unsubstituted alkyl, alkenyl, alkynyl, or cycloalkyl group;
- n is 0, 1, 2, 3, or 4; and
- r and t are each independently 1, 2, or 3.
- In a second aspect, the present technology provides a compound according to formula IA, IB, or IC:
- stereoisomers, and/or salts thereof; wherein
- A1, A2, A3, and A4 are independently selected from the group consisting of CR5R6 and NR8, or when involved in a double bond, are selected from the group consisting of CR5 and N, provided that not more than two of A1, A2, A3, and A4 are N or NR8;
- L and M are independently N or CR7;
- Z is a substituted or unsubstituted C1-C4 alkylene, O—C1-C4 alkylene, cyclopropylalkylene, or oxetanylalkylene group;
- W is
- X is
- D is N or CR9;
- D1, D2 and D3 are independently selected from CH or CR14, and optionally one of D1, D2 and D3 is N;
- one of G1, G2, G3, and G4 is CR13 and the others are selected from the group consisting of CH, CR11, and N, provided that not more than one of G1, G2, G3, and G4 is N;
- Q is O, S, or NR12;
- R1 and R2 are independently H, OH, halo, CN, carboxyl, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, or hydroxyalkyl group;
- R3 is a substituted or unsubstituted alkyl or cycloalkyl group;
- R4 is CN, SO3H, CONRaRb, SO2NRaRb, NHSO2Rb, SO2NHCORa, CO2Rc, or a substituted or unsubstituted tetrazolyl or 1,2,4-oxadiazol-5(4H)-one-3-yl group;
- R5 and R7 are independently H, OH, halo, CN, carboxyl, amido, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, or aminoalkyl group;
- R6 at each occurrence is independently H, OH, halo, CN, carboxyl, amido, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, or aminoalkyl group;
- R8 at each occurrence is independently H or a substituted or unsubstituted alkyl group;
- R9 and R13 are independently H, halo, or a substituted or unsubstituted C1-C6 alkyl, or O—(C1-C6 alkyl) group;
- R10 at each occurrence is independently halo, CO2Rc, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group;
- R11 and R14 at each occurrence are independently OH, halo, CF3, CN, carboxyl, NRaRb, or a substituted or unsubstituted alkyl, alkoxy group, or phenyl group;
- R12 is H or a substituted or unsubstituted C1-C6 alkyl group; and
- Ra at each occurrence is independently H, or a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, or SO2-alkyl group;
- Rb at each occurrence is H or a substituted or unsubstituted alkyl, or haloalkyl group;
- Rc is H or a substituted or unsubstituted alkyl, alkenyl, alkynyl, or cycloalkyl group;
- n is 0, 1, 2, 3, or 4;
- r and t are each independently 1, 2, or 3; and
- indicates a single or double bond.
- In a related aspect, a composition is provided that includes the compound of any one of the compounds disclosed herein (including but not limited to compounds of formulae I, IA, IB, and IC) and a pharmaceutically accepT carrier.
- In another aspect, a pharmaceutical composition is provided, the pharmaceutical composition including an effective amount of the compound of any one of the above embodiments for treating an FXR-mediated disorder or condition.
- In another aspect, a method is provided that includes administering an effective amount of a compound of any one of the above embodiments, or administering a pharmaceutical composition including an effective amount of a compound of any one of the above embodiments, to a subject suffering from an FXR-mediated disorder or condition.
- In another aspect, a method is provided that includes modulating FXR in a subject by contacting FXR with an effective amount of a compound of any one of the compounds of described herein, including but not limited to compounds of formulae I, IA, IB, and IC.
- In various aspects, the present technology provides compounds and methods for modulating FXR and the treatment of FXR-mediated disorders and conditions. The compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods. Also provided is the use of the compounds in preparing pharmaceutical formulations and medicaments.
- The following terms are used throughout as defined below.
- As used herein and in the appended claims, singular articles such as “a” and “an” and “the” and similar referents in the context of describing the elements (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the embodiments and does not pose a limitation on the scope of the claims unless otherwise stated. No language in the specification should be construed as indicating any non-claimed element as essential.
- As used herein, “about” will be understood by persons of ordinary skill in the art and will vary to some extent depending upon the context in which it is used. If there are uses of the term which are not clear to persons of ordinary skill in the art, given the context in which it is used, “about” will mean up to plus or minus 10% of the particular term.
- Generally, reference to a certain element such as hydrogen or H is meant to include all isotopes of that element. For example, if an R group is defined to include hydrogen or H, it also includes deuterium and tritium. Compounds comprising radioisotopes such as tritium, C14, P32 and S35 are thus within the scope of the present technology. Procedures for inserting such labels into the compounds of the present technology will be readily apparent to those skilled in the art based on the disclosure herein.
- In general, “substituted” refers to an organic group as defined below (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms. Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom. Thus, a substituted group is substituted with one or more substituents, unless otherwise specified. In some embodiments, a substituted group is substituted with 1, 2, 3, 4, 5, or 6 substituents. Examples of substituent groups include: halogens (i.e., F, Cl, Br, and I); CF3; hydroxyls; alkoxy, alkenoxy, aryloxy, aralkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, and heterocyclylalkoxy groups; carbonyls (oxo); carboxylates; esters; urethanes; oximes; hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sulfides; sulfoxides; sulfones; sulfonyls; pentafluorosulfanyl (i.e., SF5), sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; amines; ureas; amidines; guanidines; enamines; imides; isocyanates; isothiocyanates; cyanates; thiocyanates; imines; nitro groups; nitriles (i.e., CN); and the like.
- Substituted ring groups such as substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups also include rings and ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups may also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined below.
- Alkyl groups include straight chain and branched chain alkyl groups having from 1 to 12 carbon atoms, and typically from 1 to 10 carbons or, in some embodiments, from 1 to 8, 1 to 6, or 1 to 4 carbon atoms. Examples of straight chain alkyl groups include groups such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups. Representative substituted alkyl groups may be substituted one or more times with substituents such as those listed above, and include without limitation haloalkyl (e.g., trifluoromethyl), hydroxyalkyl, thioalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, carboxyalkyl, and the like.
- Cycloalkyl groups include mono-, bi- or tricyclic alkyl groups having from 3 to 12 carbon atoms in the ring(s), or, in some embodiments, 3 to 10, 3 to 8, or 3 to 4, 5, or 6 carbon atoms. Exemplary monocyclic cycloalkyl groups include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 3 to 6, or 3 to 7. Bi- and tricyclic ring systems include both bridged cycloalkyl groups and fused rings, such as, but not limited to, bicyclo[2.1.1]hexane, adamantyl, decalinyl, and the like. Substituted cycloalkyl groups may be substituted one or more times with, non-hydrogen and non-carbon groups as defined above. However, substituted cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above. Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4-, 2,5- or 2,6-disubstituted cyclohexyl groups, which may be substituted with substituents such as those listed above.
- Cycloalkylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a cycloalkyl group as defined above. In some embodiments, cycloalkylalkyl groups have from 4 to 16 carbon atoms, 4 to 12 carbon atoms, and typically 4 to 10 carbon atoms. Substituted cycloalkylalkyl groups may be substituted at the alkyl, the cycloalkyl or both the alkyl and cycloalkyl portions of the group. Representative substituted cycloalkylalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
- Alkenyl groups include straight and branched chain alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Alkenyl groups have from 2 to 12 carbon atoms, and typically from 2 to 10 carbons or, in some embodiments, from 2 to 8, 2 to 6, or 2 to 4 carbon atoms. In some embodiments, the alkenyl group has one, two, or three carbon-carbon double bonds. Examples include, but are not limited to vinyl, allyl, —CH═CH(CH3), —CH═C(CH3)2, —C(CH3)═CH2, —C(CH3)═CH(CH3), —C(CH2CH3)═CH2, among others. Representative substituted alkenyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
- Cycloalkenyl groups include cycloalkyl groups as defined above, having at least one double bond between two carbon atoms. In some embodiments the cycloalkenyl group may have one, two or three double bonds but does not include aromatic compounds. Cycloalkenyl groups have from 4 to 14 carbon atoms, or, in some embodiments, 5 to 14 carbon atoms, 5 to 10 carbon atoms, or even 5, 6, 7, or 8 carbon atoms. Examples of cycloalkenyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, cyclobutadienyl, and cyclopentadienyl.
- Cycloalkenylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above. Substituted cycloalkenylalkyl groups may be substituted at the alkyl, the cycloalkenyl or both the alkyl and cycloalkenyl portions of the group. Representative substituted cycloalkenylalkyl groups may be substituted one or more times with substituents such as those listed above.
- Alkynyl groups include straight and branched chain alkyl groups as defined above, except that at least one triple bond exists between two carbon atoms. Alkynyl groups have from 2 to 12 carbon atoms, and typically from 2 to 10 carbons or, in some embodiments, from 2 to 8, 2 to 6, or 2 to 4 carbon atoms. In some embodiments, the alkynyl group has one, two, or three carbon-carbon triple bonds. Examples include, but are not limited to —C≡CH, —C≡CCH3, —CH2C≡CCH3, —C≡CCH2CH(CH2CH3)2, among others. Representative substituted alkynyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
- Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms. Aryl groups herein include monocyclic, bicyclic and tricyclic ring systems. Thus, aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, fluorenyl, phenanthrenyl, anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups. In some embodiments, aryl groups contain 6-14 carbons, and in others from 6 to 12 or even 6-10 carbon atoms in the ring portions of the groups. In some embodiments, the aryl groups are phenyl or naphthyl. Although the phrase “aryl groups” includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like), it does not include aryl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, groups such as tolyl are referred to as substituted aryl groups. Representative substituted aryl groups may be mono-substituted or substituted more than once. For example, monosubstituted aryl groups include, but are not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl groups, which may be substituted with substituents such as those listed above.
- Aralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above. In some embodiments, aralkyl groups contain 7 to 16 carbon atoms, 7 to 14 carbon atoms, or 7 to 10 carbon atoms. Substituted aralkyl groups may be substituted at the alkyl, the aryl or both the alkyl and aryl portions of the group. Representative aralkyl groups include but are not limited to benzyl and phenethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-indanylethyl. Representative substituted aralkyl groups may be substituted one or more times with substituents such as those listed above.
- Heteroalkyl groups are alkyl groups in which 1 or 2 carbons are replaced with a heteroatom selected from N, O or S. Thus, heteroalkyl groups may include straight chain and branched chain heteroalkyl groups having from 1 to 11 carbon atoms, and typically from 1 to 10 carbons or, in some embodiments, from 1 to 8, 1 to 6, or 1 to 4 carbon atoms. Heteroalkyl groups include for example, methoxy, methoxyethyl, methylthio, methylthiopropyl, ethyloxymethyl, and methylaminobutyl. Heteroalkyl groups may be substituted one or more times just as alkyl groups are with substituents such as those listed above.
- Heterocyclyl groups include aromatic (also referred to as heteroaryl) and non-aromatic ring compounds containing 3 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, and S. In some embodiments, the heterocyclyl group contains 1, 2, 3 or 4 heteroatoms. In some embodiments, heterocyclyl groups include mono-, bi- and tricyclic rings having 3 to 16 ring members, whereas other such groups have 3 to 6, 3 to 10, 3 to 12, or 3 to 14 ring members. Heterocyclyl groups encompass aromatic, partially unsaturated and saturated ring systems, such as, for example, imidazolyl, imidazolinyl and imidazolidinyl groups. The phrase “heterocyclyl group” includes fused ring species including those comprising fused aromatic and non-aromatic groups, such as, for example, benzotriazolyl, 2,3-dihydrobenzo[1,4]dioxinyl, and benzo[1,3]dioxolyl. The phrase also includes bridged polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl. However, the phrase does not include heterocyclyl groups that have other groups, such as alkyl, oxo or halo groups, bonded to one of the ring members. Rather, these are referred to as “substituted heterocyclyl groups”. Heterocyclyl groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrothiophenyl, tetrahydrofuranyl, dioxolyl, furanyl, thiophenyl, pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, oxadiazolonyl (including 1,2,4-oxazol-5(4H)-one-3-yl), isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydrothiopyranyl, oxathiane, dioxyl, dithianyl, pyranyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, dihydropyridyl, dihydrodithiinyl, dihydrodithionyl, homopiperazinyl, quinuclidyl, indolyl, indolinyl, isoindolyl,azaindolyl (pyrrolopyridyl), indazolyl, indolizinyl, benzotriazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benzthiazolyl, benzoxadiazolyl, benzoxazinyl, benzodithiinyl, benzoxathiinyl, benzothiazinyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[1,3]dioxolyl, pyrazolopyridyl, imidazopyridyl (azabenzimidazolyl), triazolopyridyl, isoxazolopyridyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, quinolizinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, pteridinyl, thianaphthyl, dihydrobenzothiazinyl, dihydrobenzofuranyl, dihydroindolyl, dihydrobenzodioxinyl, tetrahydroindolyl, tetrahydroindazolyl, tetrahydrobenzimidazolyl, tetrahydrobenzotriazolyl, tetrahydropyrrolopyridyl, tetrahydropyrazolopyridyl, tetrahydroimidazopyridyl, tetrahydrotriazolopyridyl, and tetrahydroquinolinyl groups. Representative substituted heterocyclyl groups may be mono-substituted or substituted more than once, such as, but not limited to, pyridyl or morpholinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with various substituents such as those listed above.
- Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, benzothiophenyl, furanyl, benzofuranyl, indolyl, azaindolyl (pyrrolopyridinyl), indazolyl, benzimidazolyl, imidazopyridinyl (azabenzimidazolyl), pyrazolopyridinyl, triazolopyridinyl, benzotriazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. Heteroaryl groups include fused ring compounds in which all rings are aromatic such as indolyl groups and include fused ring compounds in which only one of the rings is aromatic, such as 2,3-dihydro indolyl groups. Although the phrase “heteroaryl groups” includes fused ring compounds, the phrase does not include heteroaryl groups that have other groups bonded to one of the ring members, such as alkyl groups. Rather, heteroaryl groups with such substitution are referred to as “substituted heteroaryl groups.” Representative substituted heteroaryl groups may be substituted one or more times with various substituents such as those listed above.
- Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above. Substituted heterocyclylalkyl groups may be substituted at the alkyl, the heterocyclyl or both the alkyl and heterocyclyl portions of the group. Representative heterocyclyl alkyl groups include, but are not limited to, morpholin-4-yl-ethyl, furan-2-yl-methyl, imidazol-4-yl-methyl, pyridin-3-yl-methyl, tetrahydrofuran-2-yl-ethyl, and indol-2-yl-propyl. Representative substituted heterocyclylalkyl groups may be substituted one or more times with substituents such as those listed above.
- Heteroaralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above. Substituted heteroaralkyl groups may be substituted at the alkyl, the heteroaryl or both the alkyl and heteroaryl portions of the group. Representative substituted heteroaralkyl groups may be substituted one or more times with substituents such as those listed above.
- Groups described herein having two or more points of attachment (i.e., divalent, trivalent, or polyvalent) within the compound of the present technology are designated by use of the suffix, “ene.” For example, divalent alkyl groups are alkylene groups; divalent aryl groups are arylene groups; divalent heteroalkyl groups are heteroalkylene groups; heteroaryl groups are divalent heteroarylene groups; and so forth. Substituted groups having a single point of attachment to the compound of the present technology are not referred to using the “ene” designation. Thus, e.g., chloroethyl is not referred to herein as chloroethylene.
- Alkoxy groups are hydroxyl groups (—OH) in which the bond to the hydrogen atom is replaced by a bond to a carbon atom of a substituted or unsubstituted alkyl group as defined above. Examples of linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, and the like. Examples of branched alkoxy groups include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy, and the like. Examples of cycloalkoxy groups include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like. Representative substituted alkoxy groups may be substituted one or more times with substituents such as those listed above.
- The terms “alkanoyl” and “alkanoyloxy” as used herein can refer, respectively, to —C(O)-alkyl groups and —O—C(O)-alkyl groups, each containing 2-5 carbon atoms. Similarly, “aryloyl” and “aryloyloxy” refer to —C(O)-aryl groups and —O—C(O)-aryl groups.
- The terms “aryloxy” and “arylalkoxy” refer to, respectively, a substituted or unsubstituted aryl group bonded to an oxygen atom and a substituted or unsubstituted aralkyl group bonded to the oxygen atom at the alkyl. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy. Representative substituted aryloxy and arylalkoxy groups may be substituted one or more times with substituents such as those listed above.
- The term “carboxylate” as used herein refers to a —COOH group.
- The term “ester” as used herein refers to —COOR70 and —C(O)O-G groups. R70 is a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein. G is a carboxylate protecting group. Carboxylate protecting groups are well known to one of ordinary skill in the art. An extensive list of protecting groups for the carboxylate group functionality may be found in Protective Groups in Organic Synthesis, Greene, T. W.; Wuts, P. G. M., John Wiley & Sons, New York, N.Y., (3rd Edition, 1999) which can be added or removed using the procedures set forth therein and which is hereby incorporated by reference in its entirety and for any and all purposes as if fully set forth herein.
- The term “amide” (or “amido”) includes C- and N-amide groups, i.e., —C(O)NR71R72, and —NR71C(O)R72 groups, respectively. R71 and R72 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein. Amido groups therefore include but are not limited to carbamoyl groups (—C(O)NH2) and formamide groups (—NHC(O)H). In some embodiments, the amide is —NR71C(O)—(C1-5 alkyl) and the group is termed “carbonylamino,” and in others the amide is —NHC(O)-alkyl and the group is termed “alkanoylamino.”
- The term “nitrile” or “cyano” as used herein refers to the —CN group.
- Urethane groups include N- and O-urethane groups, i.e., —NR73C(O)OR74 and —OC(O)NR73R74 groups, respectively. R73 and R74 are independently a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, or heterocyclyl group as defined herein. R73 may also be H.
- The term “amine” (or “amino”) as used herein refers to —NR75R76 groups, wherein R75 and R76 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein. In some embodiments, the amine is alkylamino, dialkylamino, arylamino, or alkylarylamino. In other embodiments, the amine is NH2, methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino, phenylamino, or benzylamino.
- The term “sulfonamido” includes S- and N-sulfonamide groups, i.e., —SO2NR78R79 and —NR78SO2R79 groups, respectively. R78 and R79 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, or heterocyclyl group as defined herein. Sulfonamido groups therefore include but are not limited to sulfamoyl groups (—SO2NH2). In some embodiments herein, the sulfonamido is —NHSO2-alkyl and is referred to as the “alkylsulfonylamino” group.
- The term “thiol” refers to —SH groups, while “sulfides” include —SR80 groups, “sulfoxides” include —S(O)R81 groups, “sulfones” include —SO2R82 groups, and “sulfonyls” include —SO2OR83. R80, R81, R82, and R83 are each independently a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein. In some embodiments the sulfide is an alkylthio group, —S-alkyl.
- The term “urea” refers to —NR84—C(O)—NR85R86 groups. R84, R85, and R86 groups are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclyl, or heterocyclylalkyl group as defined herein.
- The term “amidine” refers to —C(NR87)NR88R89 and —NR87C(NR88)R89, wherein R87, R88, and R89 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- The term “guanidine” refers to —NR90C(NR91)NR92R93, wherein R90, R91, R92 and R93 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- The term “enamine” refers to —C(R94)═C(R95)NR96R97 and —NR94C(R95)═C(R96)R97, wherein R94, R95, R96 and R97 are each independently hydrogen, a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- The term “halogen” or “halo” as used herein refers to bromine, chlorine, fluorine, or iodine. In some embodiments, the halogen is fluorine. In other embodiments, the halogen is chlorine or bromine.
- The term “hydroxyl” as used herein can refer to —OH or its ionized form, —O—. A “hydroxyalkyl” group is a hydroxyl-substituted alkyl group, such as HO—CH2—.
- The term “imide” refers to —C(O)NR98C(O)R99, wherein R98 and R99 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
- The term “imine” refers to —CR100(NR100) and —N(CR100R101) groups, wherein R100 and R101 are each independently hydrogen or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein, with the proviso that R100 and R101 are not both simultaneously hydrogen.
- The term “nitro” as used herein refers to an —NO2 group.
- The term “trifluoromethyl” as used herein refers to —CF3.
- The term “trifluoromethoxy” as used herein refers to —OCF3.
- The term “azido” refers to —N3.
- The term “trialkyl ammonium” refers to a —N(alkyl)3 group. A trialkylammonium group is positively charged and thus typically has an associated anion, such as halogen anion.
- The term “isocyano” refers to —NC.
- The term “isothiocyano” refers to —NCS.
- The phrase “selectively modulates” as used herein will be understood by persons of ordinary skill in the art and will vary to some extent depending upon the context in which the phrase is used. If there are uses of the phrase which are not clear to persons of ordinary skill in the art, given the context in which the phrase is used, the phrase at minimum refers to the compounds acting through a specific mechanism of action, resulting in fewer off-target effects because the compounds target a particular receptor over other receptors, such as an FXR over a GR receptor, LXR, PPARγ, TGR5 or PXR. This phrase may further be modified as discussed herein.
- As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as “up to,” “at least,” “greater than,” “less than,” and the like include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 atoms refers to groups having 1, 2, or 3 atoms. Similarly, a group having 1-5 atoms refers to groups having 1, 2, 3, 4, or 5 atoms, and so forth.
- Pharmaceutically acceptable salts of compounds described herein are within the scope of the present technology and include acid or base addition salts which retain the desired pharmacological activity and is not biologically undesirable (e.g., the salt is not unduly toxic, allergenic, or irritating, and is bioavailable). When the compound of the present technology has a basic group, such as, for example, an amino group, pharmaceutically acceptable salts can be formed with inorganic acids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g. alginate, formic acid, acetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalene sulfonic acid, and p-toluenesulfonic acid) or acidic amino acids (such as aspartic acid and glutamic acid). When the compound of the present technology has an acidic group, such as for example, a carboxylic acid group, it can form salts with metals, such as alkali and earth alkali metals (e.g. Na+, Li+, K+, Ca2+, Mg2+, Zn2+), ammonia or organic amines (e.g. dicyclohexylamine, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine) or basic amino acids (e.g. arginine, lysine and ornithine). Such salts can be prepared in situ during isolation and purification of the compounds or by separately reacting the purified compound in its free base or free acid form with a suitable acid or base, respectively, and isolating the salt thus formed.
- Those of skill in the art will appreciate that compounds of the present technology may exhibit the phenomena of tautomerism, conformational isomerism, geometric isomerism and/or stereoisomerism. As the formula drawings within the specification and claims can represent only one of the possible tautomeric, conformational isomeric, stereochemical or geometric isomeric forms, it should be understood that the present technology encompasses any tautomeric, conformational isomeric, stereochemical and/or geometric isomeric forms of the compounds having one or more of the utilities described herein, as well as mixtures of these various different forms.
- “Tautomers” refers to isomeric forms of a compound that are in equilibrium with each other. The presence and concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, guanidines may exhibit the following isomeric forms in protic organic solution, also referred to as tautomers of each other:
- Because of the limits of representing compounds by structural formulas, it is to be understood that all chemical formulas of the compounds described herein represent all tautomeric forms of compounds and are within the scope of the present technology.
- Stereoisomers of compounds (also known as optical isomers) include all chiral, diastereomeric, and racemic forms of a structure, unless the specific stereochemistry is expressly indicated. Thus, compounds used in the present technology include enriched or resolved optical isomers at any or all asymmetric atoms as are apparent from the depictions. Both racemic and diastereomeric mixtures, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these stereoisomers are all within the scope of the present technology.
- In one aspect, the present technology provides heterocyclic derivatives such as pyrrolidines, imidazolidines, piperidines, piperazines, azepanes and diazepanes that modulate FXR and intermediates for making such compounds. The compounds include, but are not limited to compounds of formulae I, IA, IB, and IC as described herein.
- In some aspects or embodiments of compounds of the present technology, compounds of formula IA are provided:
- wherein X, L, Z, W, R4, R10, n, r, and t may have any of the values of any of the aspects or embodiments of compounds described herein. In certain such embodiments, L is N. In other embodiments, L is CR7.
- In some aspects or embodiments of compounds of the present technology, compounds of formula IB are provided:
- wherein X, M, Z, W, R4, R10, n, r, and t may have any of the values of any of the aspects or embodiments of compounds described herein. In certain embodiments of compounds of formula IB, M is N. In other embodiments, M is CR7.
- In some aspects and embodiments of the present compounds (including but not limited to compounds of formulae I, IA, IB, and IC), r and t are each independently 1, 2, or 3, as noted above. In certain embodiments, r is 1 or 2. In some embodiments, r is 2. In some embodiments, t is 1. In other embodiments t is 2. In some embodiments t is 3. In some embodiments, the sum of r+t is greater than 2 but less than 6 (i.e., 2<r+t<6). Thus, in some embodiments the present compounds include but are not limited to pyrrolidines, piperidines, piperazines, azepanes and diazepanes. For example, in some embodiments compounds of formula I include, but are not limited to, compounds of formulas IA1 (r=1, t=2, L=CH), IA2 (r=2, t=2, L=CH), IA3 (r=2, t=2, L=N), IA4 (r=2, t=3, L=CH), and IA5 (r=2, t=3, L=N), below. In other embodiments, compounds of formula I include but are not limited to compounds of formulas IB1 (r=1, t=2, M=CH), IB2 (r=1, t=2, M=N), IB3 (r=2, t=2, M=CH), and IB4 (r=2, t=3, M=CH), below.
- In some embodiments, n is 1 or 2. In some embodiments, n is 0. In some embodiments, R10 at each occurrence is independently halo, CO2Rc, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group. For example, in some embodiments, R10 at each occurrence is independently CO2H, substituted or unsubstituted C1-C3 alkyl, C1-C3 hydroxyalkyl, or C3-C6 cycloalkyl group. In some embodiments, R10 at each occurrence is independently CO2H, CH3, CH2OH, or a cyclopropyl group. In other embodiments, R10 at each occurrence is independently CH3, CH2CH3, or CH(CH3)2. In certain embodiments, when n is 2 or 3, two of the R10 groups together may be a substituted or unsubstituted C2-C5 (i.e., a C2, C3, C4, or C5 alkylene group) alkylene, heteroalkylene, alkenylene or heteroalkenylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached. In some such embodiments, R10 may be a substituted or unsubstituted C2-C5 alkylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached. In some such embodiments, R10 is an unsubstituted C2-C5 alkylene group having 2 separate points of attachment to the same carbon, thus forming a spirocyclic group (e.g., a spirocyclic cyclopropyl group, spirocyclic cyclobutyl group, spirocyclic cyclopentyl group, spirocyclic cyclohexyl group). In some embodiments, R10 is an unsubstituted C2, C3, C4 or C5 alkylene group having 2 separate points of attachment to different carbons, thus forming fused bicyclic rings, e.g., octahydroquinoxaline, 3,8-diazabicyclo[3.2.1]octane, and 3,9-diazabicyclo[3.3.1]nonane. Thus, in some embodiments, the compounds of formula I have the formulae IIA, IIB and IIC:
- In some embodiments of the present compounds, R4 is CO2H, CN, CONH2, SO2NH2, or a substituted or unsubstituted CO2—C1-C6 alkyl, CO2—C3-C6 cycloalkyl, CONH—C1-C6 alkyl, CONH—C3-C6 cycloalkyl, NH—SO2—C1-C6 alkyl, or tetrazolyl group. In some embodiments, R4 is CO2H, CN, CONH2, or a substituted or unsubstituted CO2—C1-C6 alkyl, CONH—C1-C6 alkyl, or tetrazolyl group. In yet other embodiments, R4 is CO2H, or an unsubstituted CO2—C1-C6 alkyl, CONH2, or tetrazolyl group. In some embodiments, R4 is CO2H.
- In the present compounds, X may be
- It will be understood that as depicted, X is attached to R4 via the open valence on the left side of the structure, and X is attached to the central nitrogen-containing heterocycle via the open valence on the right side of the structure.
- In some embodiments, one of G1, G2, G3, and G4 is CR13 and the others are CH (it being understood that R4 is attached in place of H at one of the G variables defined as CH). In other embodiments, one of G1, G2, G3, and G4 is CR13 and one is CR11. In some embodiments, D is N and in others, D is CR9. In some embodiments, Q is S. In others, Q is O, and in still others, Q is NR12. In some embodiments, D is N and Q is S. In others, D is N and Q is NR12. In some embodiments D is CR9 and Q is S, or D is CR9 and Q is NR12.
- Thus, in some embodiments, X is
- wherein q is 0, 1, or 2. In some such embodiments, q is 0. In other embodiments, q is 1. In the foregoing embodiments of X, R9, R11, R12 and R13 may have any of the values described herein for compounds of the present technology.
- In some embodiments of the present compounds, R9 and R13 are independently H, halo, or a substituted or unsubstituted C1-C4 alkyl, or O—(C1-C4 alkyl) group. In some embodiments, R9 is H, F, or Cl. In some embodiments, R13 is H, F, or a substituted or unsubstituted C1-C3 alkyl, or O—(C1-C3 alkyl) group. In some embodiments, R13 is H, F, CH3, or OCH3. In some embodiments, R9 is H.
- In some embodiments, R11 at each occurrence is independently halo, CF3, or a substituted or unsubstituted alkyl or alkoxy group. In certain embodiments, R11 is F, Cl, or CF3. In some embodiments, R12 is H or a substituted or unsubstituted C1-C6 alkyl group. In some embodiments, R12 is H or CH3.
- In some embodiments, Z is a substituted or unsubstituted C1-C4 alkylene or O—C1-C4 alkylene group. In some embodiments, Z is a substituted or unsubstituted C1-C2 alkylene or O—C1-C2 alkylene group. In some embodiments, Z is a substituted or unsubstituted C1-C4 alkylene group. In some embodiments, Z is a substituted or unsubstituted C1-C2 alkylene group. In some embodiments, Z is a substituted or unsubstituted methylene, e.g., —CH2—. In some embodiments, Z is a substituted or unsubstituted cyclopropylalkylene group. In some embodiments, Z may be substituted with halo or OH. In some embodiments, Z may be substituted with F or OH. In some embodiments, Z may be substituted with F, OH, or CF3.
- In some embodiments, W is
- In some embodiments of the present compounds, R1 and R2 are independently halo, CN, CO2Re, NReRf, or a substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl group; and wherein Re and Rf at each occurrence are independently H or a substituted or unsubstituted C1-C6 alkyl group. In some embodiments, R1 and R2 are independently H, F, Cl, CN, CO2H, NReRf, or a substituted or unsubstituted C1-C3 alkyl, C1-C3 alkoxy, or C1-C3 hydroxyalkyl group. In some embodiments, R1 and R2 are independently H, F, Cl, CN, CO2H, NH2, CH3, CH2NH2, OCF3, or OCH3. In some embodiments, R1 and R2 are both Cl. In some embodiments, one of R1 and R2 is H and the other is OCF3.
- In some embodiments, R3 is a substituted or unsubstituted C1-C6 alkyl or C3-C6 cycloalkyl group. In some embodiments, R3 is CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, CH(CH2CH3)2, CH(CH2CH3)(CH3), C(CH3)3, or cyclopropyl. In some embodiments, R3 is an isopropyl or cyclopropyl group.
- In a third aspect, the present technology provides a compound according to formula IA, IB, or IC:
- stereoisomers, and/or salts thereof; wherein
- L and M are independently N or CR7;
- Z is a substituted or unsubstituted C1-C4 alkylene, O—C1-C4 alkylene, cyclopropylalkylene, or oxetanylalkylene group;
- W is
- X is
- D is N or CR9;
- one of G1, G2, G3, and G4 is CR13 and the others are selected from the group consisting of CH and CR11;
- Q is O, S, or NR12;
- R1 and R2 are independently H, OH, halo, CN, carboxyl, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, or hydroxyalkyl group;
- R3 is a substituted or unsubstituted alkyl or cycloalkyl group;
- R4 is SO3H, CONRaRb, SO2NRaRb, NHSO2Rb, SO2NHCORa, CO2Rc, or an unsubstituted tetrazolyl group;
- R7 is H, OH, halo, CN, carboxyl, amido, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, or aminoalkyl group;
- R9 and R13 are independently H, halo, or a substituted or unsubstituted C1-C6 alkyl, or O—(C1-C6 alkyl) group;
- R10 at each occurrence is independently halo, CO2Rc, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group, or, when n is 2 or 3, two of the R10 groups together may be a substituted or unsubstituted C2-C5 alkylene or alkenylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached;
- R11 is OH, halo, CF3, CN, carboxyl, NRaRb,or a substituted or unsubstituted alkyl or alkoxy group;
- R12 is H or a substituted or unsubstituted C1-C6 alkyl group; and
- Ra at each occurrence is independently H, or a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, or SO2-alkyl group;
- Rb at each occurrence is H or a substituted or unsubstituted alkyl, or haloalkyl group;
- Rc is H or a substituted or unsubstituted alkyl, alkenyl, or cycloalkyl group;
- n is 0, 1, 2, 3, or 4; and
- r and t are each independently 1, 2, or 3.
- In an aspect of the present technology, a composition is provided that includes any one of the aspects and embodiments of compounds of formulas I-III and a pharmaceutically acceptable carrier. In a related aspect, a pharmaceutical composition is provided which includes an effective amount of the compound of any one of the aspects and embodiments of compounds of formulas I-IV for treating an FXR-mediated disorder or condition. The FXR-mediated disorder or condition may be liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, or renal disease. For example, the disorder or condition may be a liver disease selected from the group consisting of primary biliary cirrhosis (PBC), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, and liver cirrhosis.
- In a further related aspect, a method is provided that includes administering an effective amount of a compound of any one of the aspects and embodiments of compounds of formulas I-IV or administering a pharmaceutical composition comprising an effective amount of a compound of any one of the aspects and embodiments of compounds of formula I-IV to a subject suffering from an FXR-mediated disorder or condition. The FXR-mediated disorder or condition may be liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, or renal disease. In some embodiments, the disorder or condition is the disorder or condition may be a liver disease selected from the group consisting of primary biliary cirrhosis (PBC), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, and liver cirrhosis.
- “Effective amount” refers to the amount of a compound or composition required to produce a desired effect. One example of an effective amount includes amounts or dosages that yield acceptable toxicity and bioavailability levels for therapeutic (pharmaceutical) use including, but not limited to, the treatment of hyperlipidemia. Another example of an effective amount includes amounts or dosages that are capable of reducing symptoms associated with metabolic syndrome, such as, for example, obesity and/or metabolic syndrome. The effective amount of the compound may selectively modulate FXR. As used herein, a “subject” or “patient” is a mammal, such as a cat, dog, rodent or primate. Typically the subject is a human, and, preferably, a human suffering from or suspected of suffering from an FXR-mediated disorder or condition. The term “subject” and “patient” can be used interchangeably.
- In still another aspect, the present technology provides methods of modulating FXR by contacting FXR with an effective amount of any compound as described herein, including but not limited to a compound of formula I, II, III, or IV.
- Thus, the instant present technology provides pharmaceutical compositions and medicaments comprising any of the compounds disclosed herein (e.g., compounds of formulas I-IV) and a pharmaceutically acceptable carrier or one or more excipients or fillers. The compositions may be used in the methods and treatments described herein. Such compositions and medicaments include a theapeutically effective amount of any compound as described herein, including but not limited to a compound of formula I, II, III, or IV. The pharmaceutical composition may be packaged in unit dosage form.
- The pharmaceutical compositions and medicaments may be prepared by mixing one or more compounds of the present technology, stereoisomers thereof, and/or pharmaceutically acceptable salts thereof, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like to prevent and treat disorders associated with the effects of increased plasma and/or hepatic lipid levels. The compounds and compositions described herein may be used to prepare formulations and medicaments that prevent or treat a variety of disorders associated with or mediated by FXR, including but not limited to liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis and renal disease. Such compositions can be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions. The instant compositions can be formulated for various routes of administration, for example, by oral, parenteral, topical, rectal, nasal, vaginal administration, or via implanted reservoir. Parenteral or systemic administration includes, but is not limited to, subcutaneous, intravenous, intraperitoneal, and intramuscular, injections. The following dosage forms are given by way of example and should not be construed as limiting the instant present technology.
- For oral, buccal, and sublingual administration, powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more compounds of the instant present technology, or pharmaceutically acceptable salts or tautomers thereof, with at least one additive such as a starch or other additive. Suitable additives are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides. Optionally, oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, thickeners, buffers, sweeteners, flavoring agents or perfuming agents. Tablets and pills may be further treated with suitable coating materials known in the art.
- Liquid dosage forms for oral administration may be in the form of pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, and solutions, which may contain an inactive diluent, such as water. Pharmaceutical formulations and medicaments may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these. Pharmaceutically suitable surfactants, suspending agents, emulsifying agents, may be added for oral or parenteral administration.
- As noted above, suspensions may include oils. Such oils include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil. Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides. Suspension formulations may include alcohols, such as, but not limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol. Ethers, such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil and petrolatum; and water may also be used in suspension formulations.
- Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or suspending agents. Typically, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
- For injection, the pharmaceutical formulation and/or medicament may be a powder suitable for reconstitution with an appropriate solution as described above. Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates. For injection, the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
- Compounds of the present technology may be administered to the lungs by inhalation through the nose or mouth. Suitable pharmaceutical formulations for inhalation include solutions, sprays, dry powders, or aerosols containing any appropriate solvents and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these. The carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aqueous and nonaqueous (e.g., in a fluorocarbon propellant) aerosols are typically used for delivery of compounds of the present technology by inhalation.
- Dosage forms for the topical (including buccal and sublingual) or transdermal administration of compounds of the present technology include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, and patches. The active component may be mixed under sterile conditions with a pharmaceutically-acceptable carrier or excipient, and with any preservatives, or buffers, which may be required. Powders and sprays can be prepared, for example, with excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. The ointments, pastes, creams and gels may also contain excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Absorption enhancers can also be used to increase the flux of the compounds of the present technology across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane (e.g., as part of a transdermal patch) or dispersing the compound in a polymer matrix or gel.
- Besides those representative dosage forms described above, pharmaceutically acceptable excipients and carriers are generally known to those skilled in the art and are thus included in the instant present technology. Such excipients and carriers are described, for example, in “Remingtons Pharmaceutical Sciences” Mack Pub. Co., New Jersey (1991), which is incorporated herein by reference.
- The formulations of the present technology may be designed to be short-acting, fast-releasing, long-acting, and sustained-releasing as described below. Thus, the pharmaceutical formulations may also be formulated for controlled release or for slow release.
- The instant compositions may also comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the pharmaceutical formulations and medicaments may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers.
- Specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, and diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant present technology.
- Those skilled in the art are readily able to determine an effective amount by simply administering a compound of the present technology to a patient in increasing amounts until for example, (for metabolic syndrome and/or obesity) the elevated plasma or elevated white blood cell count or hepatic cholesterol or triglycerides or progression of the disease state is reduced or stopped. For metabolic syndrome and/or obesity, the progression of the disease state can be assessed using in vivo imaging, as described, or by taking a tissue sample from a patient and observing the target of interest therein.
- The compounds of the present technology can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kg, a dosage in the range of about 0.01 to about 100 mg per kg of body weight per day is sufficient. The specific dosage used, however, can vary or may be adjusted as considered appropriate by those of ordinary skill in the art. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to those skilled in the art.
- Various assays and model systems can be readily employed to determine the therapeutic effectiveness of the treatment according to the present technology.
- Effectiveness of the compositions and methods of the present technology may also be demonstrated by a decrease in the symptoms of hyperlipidemia, such as, for example, a decrease in triglycerides in the blood stream. Effectiveness of the compositions and methods of the present technology may also be demonstrated by a decrease in the signs and symptoms of liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, or renal disease.
- For each of the indicated conditions described herein, test subjects will exhibit a 10%, 20%, 30%, 50% or greater reduction, up to a 75-90%, or 95% or greater, reduction, in one or more symptom(s) caused by, or associated with, the disorder in the subject, compared to placebo—treated or other suitable control subjects.
- The compounds of the present technology can also be administered to a patient along with other conventional therapeutic agents that may be useful in the treatment of liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, or renal disease. The administration may include oral administration, parenteral administration, or nasal administration. In any of these embodiments, the administration may include subcutaneous injections, intravenous injections, intraperitoneal injections, or intramuscular injections. In any of these embodiments, the administration may include oral administration. The methods of the present technology can also comprise administering, either sequentially or in combination with one or more compounds of the present technology, a conventional therapeutic agent in an amount that can potentially be effective for the treatment of liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, or renal disease.
- In one aspect, a compound of the present technology is administered to a patient in an amount or dosage suitable for therapeutic use. Generally, a unit dosage comprising a compound of the present technology will vary depending on patient considerations. Such considerations include, for example, age, protocol, condition, sex, extent of disease, contraindications, concomitant therapies and the like. An exemplary unit dosage based on these considerations can also be adjusted or modified by a physician skilled in the art. For example, a unit dosage for a patient comprising a compound of the present technology can vary from 1×10−4 g/kg to 1 g/kg, preferably, 1×10−3g/kg to 1.0 g/kg. Dosage of a compound of the present technology can also vary from 0.01 mg/kg to 100 mg/kg or, preferably, from 0.1 mg/kg to 10 mg/kg.
- A compound of the present technology can also be modified, for example, by the covalent attachment of an organic moiety or conjugate to improve pharmacokinetic properties, toxicity or bioavailability (e.g., increased in vivo half-life). The conjugate can be a linear or branched hydrophilic polymeric group, fatty acid group or fatty acid ester group. A polymeric group can comprise a molecular weight that can be adjusted by one of ordinary skill in the art to improve, for example, pharmacokinetic properties, toxicity or bioavailability. Exemplary conjugates can include a polyalkane glycol (e.g., polyethylene glycol (PEG), polypropylene glycol (PPG)), carbohydrate polymer, amino acid polymer or polyvinyl pyrolidone and a fatty acid or fatty acid ester group, each of which can independently comprise from about eight to about seventy carbon atoms. Conjugates for use with a compound of the present technology can also serve as linkers to, for example, any suitable substituents or groups, radiolabels (marker or tags), halogens, proteins, enzymes, polypeptides, other therapeutic agents (for example, a pharmaceutical or drug), nucleosides, dyes, oligonucleotides, lipids, phospholipids and/or liposomes. In one aspect, conjugates can include polyethylene amine (PEI), polyglycine, hybrids of PEI and polyglycine, polyethylene glycol (PEG) or methoxypolyethylene glycol (mPEG). A conjugate can also link a compound of the present technology to, for example, a label (fluorescent or luminescent) or marker (radionuclide, radioisotope and/or isotope) to comprise a probe of the present technology. Conjugates for use with a compound of the present technology can, in one aspect, improve in vivo half-life. Other exemplary conjugates for use with a compound of the present technology as well as applications thereof and related techniques include those generally described by U.S. Pat. No. 5,672,662, which is hereby incorporated by reference herein.
- In another aspect, the present technology provides methods of identifying a target of interest including contacting the target of interest with a detectable or imaging effective quantity of a labeled compound of the present technology. A detectable or imaging effective quantity is a quantity of a labeled compound of the present technology necessary to be detected by the detection method chosen. For example, a detectable quantity can be an administered amount sufficient to enable detection of binding of the labeled compound to a target of interest including, but not limited to, a KOR. Suitable labels are known by those skilled in the art and can include, for example, radioisotopes, radionuclides, isotopes, fluorescent groups, biotin (in conjunction with streptavidin complexation), and chemoluminescent groups. Upon binding of the labeled compound to the target of interest, the target may be isolated, purified and further characterized such as by determining the amino acid sequence.
- The terms “associated” and/or “binding” can mean a chemical or physical interaction, for example, between a compound of the present technology and a target of interest. Examples of associations or interactions include covalent bonds, ionic bonds, hydrophilic-hydrophilic interactions, hydrophobic-hydrophobic interactions and complexes. Associated can also refer generally to “binding” or “affinity” as each can be used to describe various chemical or physical interactions. Measuring binding or affinity is also routine to those skilled in the art. For example, compounds of the present technology can bind to or interact with a target of interest or precursors, portions, fragments and peptides thereof and/or their deposits.
- The examples herein are provided to illustrate advantages of the present technology and to further assist a person of ordinary skill in the art with preparing or using the compounds of the present technology or salts, pharmaceutical compositions, derivatives, solvates, metabolites, prodrugs, racemic mixtures or tautomeric forms thereof. The examples herein are also presented in order to more fully illustrate the preferred aspects of the present technology. The examples should in no way be construed as limiting the scope of the present technology, as defined by the appended claims. The examples can include or incorporate any of the variations, aspects or aspects of the present technology described above. The variations, aspects or aspects described above may also further each include or incorporate the variations of any or all other variations, aspects or aspects of the present technology.
-
-
- ACN acetonitrile
- t-Bu tert-butyl
- DCM dichloromethane
- DIAD diisopropyl azodicarboxylate
- DMF dimethylformamide
- DMA dimethylacetamide
- DMAP 4-dimethylaminopyridine
- DMP tert-2,2-dimethoxypropane
- DMSO dimethyl sulfoxide
- Et ethyl
- HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] pyridinium 3-oxid hexafluorophosphate)
- LAH lithium aluminum hydride
- Me methyl
- MeCN acetonitrile
- NCS N-chlorosuccinimide
- PCC pyridinium chlorochromate
- PE petroleum ether
- Ph phenyl
- STAB sodium triacetoxyborohydride
- TEA triethylamine
- TFA trifluoroacetic acid
- TFAA trifluoroacetic anhydride
- THF tetrahydrofuran
- TLC thin layer chromatography
- TMS trimethylsilyl
- TsOH p-toluenesulfonic acid
-
- Methyl 2-amino-4-methoxybenzo[d]thiazole-6-carboxylate (Compound 1a): To a solution of methyl 4-amino-3-methoxybenzoate (20 g, 110 mmol) in acetic acid (340 mL) was added NaSCN (35.8 g, 330 mmol) and Br2 (26.2 g, 165 mmol) sequentially. The mixture was stirred overnight at room temperature. The mixture was concentrated under vacuum. The residue was suspended in 100 mL of water. The pH value of the mixture was adjusted to 8 with NaOH (2 M). The solids were collected and dried under vacuum. This resulted in 22.5 g of the title compound as a yellow solid (crude product). LC-MS (ESI, m/z): [M+H]+=239.1.
- Methyl 2-chloro-4-methoxybenzo[d]thiazole-6-carboxylate (Compound INT-001): To a suspension of Compound 1a (22.5 g, 94 mmol) in MeCN (320 mL) was added CuCl2 (25 g, 188 mmol). The mixture was stirred for 5 min at room temperature before 3-methylbutyl nitrite (16.5 g, 141 mmol) was added dropwise at room temperature. The reaction was stirred for another 1 h at 60° C. The reaction was then quenched by the addition of 60 mL of water. The resulting mixture was extracted with ethyl acetate several times. The organic layers were combined. The organic phase was washed with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:5). This resulted in 13 g (54%) of the title compound as a yellow solid. LC-MS (ESI, m/z): [M+H]+=258.2.
- Following the procedure described above for Scheme 1 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following common intermediates were prepared as shown in Table 1.
- Methyl 2-mercaptobenzo[d]oxazole-6-carboxylate (Compound 2a): To a stirring solution of methyl 4-amino-3-hydroxybenzoate (5 g, 29.91 mmol) in pyridine (60 mL) was added ethoxy(potassiosulfanyl)methanethione (5 g, 31.19 mmol). The resulting solution was stirred for 5 h at 115° C. The reaction was quenched with water. The resulting solution was extracted with 3'30 mL of dichloromethane. The organic layers were combined and washed successively with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. This resulted in 3.5 g (56%) of the title compound as a yellow solid.
- Methyl 2-chlorobenzo[d]oxazole-6-carboxylate (Compound INT-011): To a suspension of Compound 2a (1 g, 4.78 mmol) in thionyl dichloride (5 mL) was added DMF (0.1 mL). The resulting solution was stirred for 15 min at 80° C. The reaction solution was concentrated under vacuum. The crude was diluted with DCM and washed successively with saturated NaHCO3 solution, water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (23:77). This resulted in 520 mg (51%) of the title compound as a white solid.
- Methyl 2-chloro-1H-indole-5-carboxylate (Compound 3a): To a solution of phosphoryl trichloride (4 mL) was added methyl 2-oxo-2,3-dihydro-1H-indole-5-carboxylate (500 mg, 2.62 mmol). The resulting solution was stirred for 30 min at 50° C. The resulting solution was diluted with 10 mL of ethyl acetate. The resulting solution was washed successively with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The crude product was applied onto a silica gel column with ethyl acetate/petroleum ether (1:9). This resulted in 0.15 g (27%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=210.0.
- Methyl 2-chloro-1-methyl-1H-indole-5-carboxylate (Compound INT-012): To a solution of Compound 3a (150 mg, 0.72 mmol) in THF (5 mL) was added sodium hydride (71 mg, 2.96 mmol) batchwise at 0° C. The mixture was stirred for 30 min at room temperature then CH3I (254 mg, 1.79 mmol) was added. The mixture was stirred for 6 h at room temperature. The reaction was quenched by adding 5 mL of water. The resulting solution was extracted with 3×5 mL of ethyl acetate and the organic layers were combined. The resulted organic phase was washed successively with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:10). This resulted in 125 mg (78%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=224.0.
- Following the procedure described above for Scheme 3 and substituting the appropriate reagents, starting material and purification method known to those skilled in the art, the following common intermediate was prepared.
-
- Methyl 2-[4-[(tert-butoxy) carbonyl] piperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate (Compound 4a): To a solution of methyl 2-chloro-4-methoxy-1,3-benzothiazole-6-carboxylate (1 g, 3.88 mmol) in DMSO (10 mL) was added tert-butyl piperazine-1-carboxylate (720 mg, 3.87 mmol) and potassium carbonate (800 mg, 5.79 mmol). The resulting solution was stirred for 2 h at 120° C. The reaction was diluted with water and extracted with 3×50 mL of dichloromethane. The organic layers were combined and washed with water and brine, then dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:5). This resulted in 1.5 g of the title compound as a yellow solid. LC-MS (ESI): [M+H]+=408.2.
- Methyl 4-methoxy-2-(piperazin-1-yl) benzo[d]thiazole-6-carboxylate (Compound 4b): To a solution of Compound 4a (1.5 g, 3.7 mmol) in dichloromethane (10 mL) was added a solution of HCl in dioxane (10 mL, 4M). The resulting solution was stirred for 2 h at room temperature. The reaction mixture was concentrated under vacuum and the residue dissolved in methanol. The pH value of the solution was adjusted to 6-7 with potassium carbonate and the solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 1.01 g of the title compound as a white solid. The resulted product used directly without further purification. LC-MS (ESI): [M+H]+=308.3.
- Methyl 2-(4-[[1-(2,6-dichlorophenyl)-4-(propan-2-yl)-1H-pyrazol-5-yl]methyl] piperazin-1-yl)-4-methoxy-1,3-benzothiazole-6-carboxylate (Compound 4c): To a solution of Compound 4b (131 mg, 0.43 mmol) and 1-(2,6-dichlorophenyl)-4-(propan-2-yl)-1H-pyrazole-5-carbaldehyde (100 mg, 0.35 mmol) in dichloromethane (5 mL) was added NaOAc (96 mg, 0.71 mmol). The mixture was stirred for 1 h at room temperature then NaBH(OAc)3 (300 mg, 1.42 mmol) was added. The resulting solution was stirred overnight at room temperature. The mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:3). This resulted in 125 mg (51%) of the title compound as a white oil. LC-MS (ESI, m/z): [M+H]+=574.1.
- 2-(4-[[1-(2,6-Dichlorophenyl)-4-(propan-2-yl)-1H-pyrazol-5-yl]methyl]piperazin-1-yl)-4-methoxy-1,3-benzothiazole-6-carboxylic acid (Compound II-03): To a solution of Compound 4c (80 mg, 0.14 mmol) in a mixed solvent of methanol (1 mL) and tetrahydrofuran (1 mL) was added a solution of sodium hydroxide (49 mg, 1.23 mmol) in water (1 mL). The resulting solution was stirred for 2 h at 50° C. The pH value of the solution was adjusted to 5 with hydrogen chloride (2 N). The mixture was concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (15:1). This resulted in 27.1 mg (35%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=560.2. 1H NMR (400 MHz, DMSO-d6, ppm): δ 7.96 (s, 1H), 7.69-7.67 (m, 3H), 7.58-7.54 (m, 1H), 7.40 (s, 1H), 3.87(s, 3H), 3.41 (s, 2H), 3.34-3.36 (m, 4H), 3.01-2.94 (m, 1H), 2.34-2.31 (m, 4H), 1.23 (d, J=7.2 Hz, 6H).
- tert-Butyl 3-[[1(tert-butyldiphenylsilyl)oxy]methyl]piperazine-1-carboxylate (Compound 5a): To a solution of tert-butyl 3-(hydroxymethyl) piperazine-1-carboxylate (1 g, 4.62 mmol) in dichloromethane (10 mL) was added 1H-imidazole (629 mg, 9.24 mmol). This was followed by addition of a solution of TBDPSCl (1.18 mL, 1.30 mmol) in dichloromethane (10 mL) dropwise with stirring. The mixture was allowed warm to room temperature and stirred for 3 h. The resulting solution was extracted with 3×50 mL of dichloromethane and the organic layers were combined. The resulting mixture was washed with 3x50 mL of sodium bicarbonate and 1×50 mL of brine. The resulting mixture was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (7:3). This resulted in 1.4 g (67%) of the title compound as a light yellow oil. LC-MS (ESI, m/z): [M+H]+=455.3.
- Methyl 2-[4-[(tert-butoxy)carbonyl]-2-[[(tert-butyldiphenylsilyl)oxy]methyl]piperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate (Compound 5b): To a solution of Compound 5a (455 mg, 1.0 mmol) in DMSO (10 mL) was added methyl 2-chloro-4-methoxy-1,3-benzothiazole-6-carboxylate (223 mg, 0.87 mmol) and potassium carbonate (207 mg, 1.50 mmol). After stirring for 3 h at 120° C., the resulting mixture was diluted with ethyl acetate (100 mL). The resulted mixture was washed with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:4). This resulted in 300 mg (44%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=676.2.
- Methyl 2-(2-[[(tert-butyldiphenylsilyl)oxy]methyl]piperazin-1-yl)-4-methoxy-1,3-benzothiazole-6-carboxylate (Compound 5c): To a solution of Compound 5b (300 mg, 0.44 mmol) in dioxane (5 mL) was added a solution of hydrogen chloride in dioxane (5 mL, 4M). After stirring for 1 h at room temperature, the resulting mixture was concentrated under vacuum. The resulted solids were washed with ethyl acetate and dried under vacuum. This resulted in 120 mg (47%) of the title compound as a light yellow oil. LC-MS (ESI, m/z): [M+H]+=576.3.
- Methyl 2-(2-[[(tert-butyldiphenylsilyl)oxy]methyl]-4-[[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methyl]piperazin-1-yl)-4-methoxy-1,3-benzothiazole-6-carboxylate (Compound 5d): To a solution of Compound 5c (100 mg, 0.17 mmol) and 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carbaldehyde (49.39 mg, 0.17 mmol) in dichloromethane (5 mL) was added sodium acetate (14.6 mg, 0.18 mmol). After stirring for 30 min, NaBH(OAc)3 (111 mg, 0.52 mmol) was added. The resulting solution was stirred for 16 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:4). This resulted in 72.4 mg (49%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=843.1.
- Methyl 2-(4-[[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methyl]-2-(hydroxymethyl)piperazin-1-yl)-4-methoxy-1,3-benzothiazole-6-carboxylate (Compound 5e): To a solution of Compound 5d (70 mg, 0.08 mmol) in ethanol (10 mL) was added hydrogen chloride (2 mL, 6M). The resulting solution was stirred for 16 h at room temperature. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (2:1). This resulted in 30 mg (60%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=605.2.
- 2-(4-[[3-(2,6-Dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methyl]-2-(hydroxymethyl)piperazin-1-yl)-4-methoxy-1,3-benzothiazole-6-carboxylic acid (Compound II-07): Into a 25-mL round-bottom flask, was placed a solution of Compound 5e (100 mg, 0.17 mmol) in methanol (4 mL), then a solution of sodium hydroxide (64 mg, 1.60 mmol) in water (2 mL) was added. After stirring for 2 h at 50° C., the mixture was concentrated under vacuum. The residue was applied onto a silica gel column with CH3CN/H2O (4:1). This resulted in 16.1 mg (16%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=591.3. 1H-NMIR (300 MHz, CDCl3, ppm): δ 7.99 (s, 1H), 7.67-7.51 (m, 4H), 4.62-4.22 (m, 5H), 4.04 (s, 3H), 3.93-3.68 (m, 3H), 3.37-3.33 (m, 1H), 2.88-2.73 (m, 3H), 1.48 (brs, 6H).
- tert-Butyl 4-[[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methyl]-3,3-dimethylpiperazine-1-carboxylate (Compound 6a): To a solution of tert-butyl 3,3-dimethylpiperazine-1-carboxylate (150 mg, 0.70 mmol) in dichloromethane (5 mL) was added 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carbaldehyde (180 mg, 0.63 mmol) and sodium acetate (87 mg, 1.06 mmol). The mixture was stirred for 1 h at room temperature. Then STAB (404 mg, 1.91 mmol) was added. The resulting solution was stirred overnight at room temperature. The reaction was then quenched by adding water (15 mL). The resulting mixture was extracted with 5×5 mL of dichloromethane and the organic layers were combined. The organic phase was washed successively with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:10). This resulted in 0.116 g (38%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=482.4.
- 1-[[3-(2,6-Dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methyl]-2,2-dimethylpiperazine (Compound 6b): To a solution of Compound 6a (116 mg, 0.24 mmol) in dioxane was added a solution of hydrogen chloride in dioxane (3 mL, 4M). The resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 0.09 g (98%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=382.1.
- Methyl 2-(4-[[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methyl]-3,3-dimethylpiperazin-1-yl)-4-methoxy-1,3-benzothiazole-6-carboxylate (Compound 6c): To a solution of methyl 2-chloro-4-methoxy-1,3-benzothiazole-6-carboxylate (88 mg, 0.34 mmol) in DMSO (3 mL) was added Compound 6b (90 mg, 0.24 mmol) and potassium carbonate (107 mg, 0.77 mmol). The resulting solution was stirred for 3 h at 120° C. The reaction was then quenched by the addition of water (5 mL). The resulting solution was extracted with 5×5 mL of ethyl acetate and the organic layers were combined. The organic phase was washed successively with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:3). This resulted in 0.11 g (77%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=603.2.
- 2-(4-[[3-(2,6-Dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methyl]-3,3-dimethylpiperazin-1-yl)-4-methoxy-1,3-benzothiazole-6-carboxylic acid (Compound II-22): To a solution of Compound 6c (110 mg, 0.18 mmol) in a mixed solvent of methanol/tetrahydrofuran/water (3 mL, 1:1:1) was added sodium hydroxide (37 mg, 0.93 mmol). The resulting solution was stirred for 2 h at 50° C. The pH value of the solution was adjusted to 5 with hydrogen chloride (2 N). The mixture was concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (15:1). This resulted in 0.05 g (47%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=589.2. 1H NMR (400 MHz, DMSO-d6, ppm): δ 7.96 (d, J=1.6 Hz, 1H), 7.64-7.62 (m, 2H), 7.57-7.53 (m, 1H), 7.38 (d, J=1.2 Hz, 1H), 3.88 (s, 3H), 3.48 (s, 2H), 3.39-3.27 (m, 3H), 3.00 (s, 2H), 2.44-2.42 (m, 2H), 1.33-1.30 (d, J=6.8 Hz, 6H), 0.75 (s, 6H).
- (R)-tert-Butyl 2-methyl-4-(trifluoromethylsulfonyloxy)-5,6-dihydropyridine-1(2H)-carboxylate (Compound 7a): To a solution of N-[(1,1-difluoroethane) sulfinyl]-1,1,1-trifluoro-N-phenylmethanesulfinamide (213 mg, 1.0 mmol) in THF (3 mL) was added HMDSLi (1.1 mL, 1.1mmol) dropwise at −78° C. under N2 atmosphere. The mixed was stirred for 30 min at −78° C., then a solution of tert-butyl (2R)-2-methyl-4-oxopiperidine-1-carboxylate (393 mg, 1.1 mmol) in THF (2 mL) was added dropwise. The resulting mixture was stirred for 2 h at −78° C. The reaction was then quenched by the addition of 5 mL of water. The resulting solution was diluted with ethyl acetate. The resulted mixture was washed with water and brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 300 mg of the title compound as a colorless oil (crude product).
- (R)-tert-Butyl 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (Compound 7b): To a solution of 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (100 mg, 0.39 mmol) in dioxane (2 mL) was added Compound 7a (110 mg, 0.32 mmol), Pd(dppf)Cl2 (66 mg, 0.09 mmol) and potassium acetate (81 mg, 0.83 mmol). The mixture was stirred overnight at 80° C. under N2 atmosphere. The resulting mixture was diluted with ethyl acetate. The resulted mixture was washed with water and brine. The residue was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was applied onto a silica gel column with ethyl acetate/petroleum ether (27:73). This resulted in 100 mg (79%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=324.2.
- 4-(Chloromethyl)-3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole (Compound 7c): To a solution of [3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl] methanol (500 mg, 1.75 mmol) in dichloromethane (5 mL) was added sulfurous dichloride (225 mg, 1.89 mmol) and DMF (0.5 mL). The resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:9). This resulted in 460 mg (86%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=304.3.
- (R)-tert-Butyl 4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl) methyl)-2-methyl-5,6-dihydropyridine-1(2H)-carboxylate (Compound 7d): To a solution of Compound 7b (240 mg, 0.74 mmol) and Compound 7c (150 mg, 0.49 mmol) in dioxane (4 mL) was added tetrakis(triphenylphosphane) palladium (58 mg, 0.05 mmol), sodium carbonate (159 mg, 1.49 mmol) and water (1 mL). The resulting solution was stirred for 4 h at 80° C. under N2 atmosphere. The mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (23:77). This resulted in 80 mg (35%) of the title compound as a yellow oil. LC-MS (ESI, m/z): [M+H]+=465.4.
- (2R)-tert-Butyl 4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl) methyl)-2-methylpiperidine-1-carboxylate (Compound 7e): To a solution of Compound 7d (150 mg, 0.32 mmol) in ethyl acetate (3 mL) was added PtO2 (22.7 mg, 0.10 mmol). The mixed was stirred overnight at room temperature under H2 atmosphere. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 120 mg (80%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=467.0.
- 3-(2,6-Dichlorophenyl)-5-isopropyl-4-(((2R)-2-methylpiperidin-4-yl) methyl) isoxazole (Compound 7f): To a solution of Compound 7e (120 mg, 0.26 mmol) in dioxane (3 mL) was added a mixture of hydrogen chloride in dioxane (5 mL, 4M). The mixture was stirred for 1 h at room temperature then concentrated under vacuum. This resulted in 70 mg (74%) of the title compound as a yellow solid. LC-MS (ESI, m/z): [M+H]+=367.0.
- Methyl 2-((2R)-4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl) methyl)-2-methylpiperidin-1-yl)-4-methoxybenzo[d]thiazole-6-carboxylate (Compound 7g): To a solution of methyl 2-chloro-4-methoxy-1,3-benzothiazole-6-carboxylate (70 mg, 0.27 mmol) in DMSO (3 mL) was added Compound 7f (99 mg, 0.27 mmol) and potassium carbonate (112 mg, 0.80 mmol). The mixture was stirred for 2 h at 120° C. The reaction was then quenched by the addition of water. The resulting solution was diluted with EA. The resulting mixture was washed with water and brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (25:75). This resulted in 70 mg (44%) of the title compound as a yellow solid. LC-MS (ESI, m/z): [M+H]+=588.2.
- 2-((2R)-4-((3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl) methyl)-2-methylpiperidin-1-yl)-4-methoxybenzo[d]thiazole-6-carboxylic acid (Compound II-45): To a solution of Compound 7g (70 mg, 0.12 mmol) in a mixture of THF (1 mL), water (1 mL) and methanol (1 mL) was added sodium hydroxide (24 mg, 0.60 mmol). The resulting solution was stirred for 1 h at 50° C. The pH value of the solution was adjusted to 6 with hydrogen chloride (2 M). The solids were filtered out. The reaction mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions: Column, SunFire Prep C18 OBD Column, 19*150mm, Sum; mobile phase: Water (0.1% TFA) and ACN (60% ACN up to 67% in 10 min); Detector, UV 254/220 nm. This resulted in 3.9 mg (6%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=573.7. 1HNMR (400 MHz, DMSO-d6, ppm): δ 7.94 (s, 1H), 7.71-7.69 (m, 2H), 7.63-7.59 (m, 1H), 7.39 (s, 1H), 4.35 (s, 1H), 3.87 (s, 3H), 3.31-3.23 (m, 2H), 3.10-3.04 (m, 1H), 2.34-2.26 (m, 1H), 2.19-2.10 (m, 1H), 1.63-1.45 (m, 3H), 1.33-1.24 (m, 7H), 1.16-1.08 (m, 1H), 1.05-1.03 (d, J=6.8 Hz, 3H).
- Methyl 2-(1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-methoxybenzo[d]thiazole-6-carboxylate (Compound 8a): To a solution of methyl 2-chloro-4-methoxy-1,3-benzothiazole-6-carboxylate (300 mg, 1.16 mmol) and tent-butyl 4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate (543 mg, 1.76 mmol) in a mixed solvent of dioxane (4 mL) and water (1 mL) was added Pd(dppf)Cl2 (87.7 mg, 0.12 mmol) and sodium carbonate (372 mg, 3.51 mmol). The resulting solution was stirred for 3 h at 80° C. under N2 atmosphere. The filtrate was concentrated under vacuum after filtration. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (21:79). This resulted in 340 mg (72%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=405.2
- Methyl 2-(1-(tert-butoxycarbonyl) piperidin-4-yl)-4-methoxybenzo[d]thiazole-6-carboxylate (Compound 8b): To a solution of Compound 8a (340 mg, 0.84 mmol) in ethyl acetate (6 mL) was added PtO2 (76 mg, 0.33 mmol). The resulting solution was stirred overnight at 30° C. under H2 atmosphere. The solids were filtered out. The filtrate was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (28:72). This resulted in 250 mg (73%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=407.2.
- Methyl 4-methoxy-2-(piperidin-4-yl) benzo[d]thiazole-6-carboxylate (Compound 8c): Into a 50-mL round-bottom flask was placed Compound 8b (250 mg, 0.62 mmol, 1.00 equiv), hydrogen chloride/dioxane (10 mL). The resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 180 mg (96%) of the title compound as a white solid. LC-MS (ES, m/z): [M+H]+=307.1.
- Methyl 2-(1-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl) methyl) piperidin-4-yl)-4-methoxybenzo[d]thiazole-6-carboxylate (Compound 8d): To a solution of Compound 8b (135 mg, 0.44 mmol), and 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carbaldehyde (125 mg, 0.44 mmol) in dichloromethane (3 mL) was added sodium acetate (37 mg, 0.45 mmol). The mixture was stirred for 30 min then NaBH(OAc)3 (280 mg, 1.32 mmol) was added. The resulting solution was stirred overnight at room temperature. The solids were filtered out. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (32:68). This resulted in 130 mg (51%) of the title compound as colorless oil. LC-MS (ESI, m/z): [M+H]+=574.3.
- 2-(1-((3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl) methyl) piperidin-4-yl)-4-methoxybenzo[d]thiazole-6-carboxylic acid (Compound II-47): To a solution of Compound 8d (130 mg, 0.23 mmol) in a mixed solvent of THF (1 mL) and methanol (1 mL) was added a solution of sodium hydroxide (45 mg, 1.13 mmol) in water (0.5 mL). The resulting solution was stirred for 1 h at 50° C. The pH value of the solution was adjusted to 6 with hydrogen chloride (2 N). The resulting mixture was concentrated under vacuum. The residue was applied onto a C18 column with H2O/CH3CN (35:65). This resulted in 35.7 mg (28%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=560.0. HNMR (300 MHz, DMSO-d6, ppm): δ 8.25 (s, 1H), 7.59 (s, 1H), 7.42-7.38 (m, 3H), 4.12 (s, 3H), 3.29 (brs, 3H), 3.15 (brs, 1H), 2.89 (brs, 2H), 2.09-1.85 (m, 4H), 1.75-1.56 (m, 2H), 1.43 (d, J=6.6 Hz, 6H).
- 5-Bromo-7-(trifluoromethoxy) benzo[d]thiazol-2-amine (Compound 9a): To a solution of 4-bromo-2-(trifluoromethoxy) aniline (5.00 g, 19.53 mmol) in acetic acid (60 mL) was added NaSCN (6.33 g,78.12 mmol) batchwise at room temperature. The mixture was stirred for 30 min then a solution of Br2 (6.24 g, 39.0 mmol) in acetic acid (10 mL). The resulting mixture was stirred for 8 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was suspended in water. The pH value of the mixture was adjusted to 9 with solid Na2CO3. The solids were collected by filtration and washed with water, dried under vacuum. This resulted in 5.70 g (93%) of the title compound as an orange solid (crude product). LC-MS (ESI, m/z): [M+H]+=315.
- 5-Bromo-2-chloro-7-(trifluoromethoxy) benzo[d]thiazole (Compound 9b): To a suspension of Compound 9a (4.40 g, 14.05 mmol) in MeCN (60 mL) was added CuCl2 (3.77 g, 28.02 mmol). The mixture was stirred for 30 min before 3-methylbutyl nitrite (2.47 g, 21.10 mmol) was added dropwise at room temperature. The resulting mixture was stirred for 8 h at room temperature. The solid was filtrated out, the resulted filtrate was diluted with ethyl acetate. The mixture was washed with water and brine. The resulting mixture was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:3). This resulted in 840 mg (18%) of the title compound as a light yellow solid.
- (R)-4-((4-(6-Bromo-4-(trifluoromethoxy) benzo[d]thiazol-2-yl)-3-methylpiperazin-1-yl) methyl)-5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazole (Compound 9c): To a solution of Compound 9b (150 mg, 0.45 mmol) in DMSO (5 mL) was added K2CO3 (62.1 mg, 0.45 mmol) and (3R)-1-[[5-cyclopropyl-3 -(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-3-methylpiperazine (110 mg, 0.30 mmol). The mixture was stirred for 12 h at 120° C. The mixture was diluted with water. The mixture was extracted with ethyl acetate several times. The organic layers were combined and washed with water and brine. The residue was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:3). This resulted in 160 mg (79%) of the title compound as an off-white solid. LC-MS (ESI, m/z): [M+H]+=663.3.
- (R)-Methyl 2-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl) methyl)-2-methylpiperazin-1-yl)-4-(trifluoromethoxy) benzo[d]thiazole-6-carboxylate (Compound 9d): To a solution of Compound 9c (160 mg, 0.24 mmol) and triethylamine (1.5 mL) in methanol (5 mL) was added Pd(dppf)Cl2 (20 mg, 0.027 mmol). The mixture was stirred for 48 h at 80° C. under CO (20 atm). The solid was filtered out after cooling to room temperature. The filtrate was concentrated and applied onto a silica gel column with ethyl acetate/petroleum ether (1:3). This resulted in 120 mg (77%) of the title compound as an off-white solid. LC-MS (ESI, m/z): [M+H]+=641.0.
- 2-[(2R)-4-[[5-Cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-4-(trifluoromethoxy)-1,3-benzothiazole-6-carboxylic acid (Compound VII-04): To a solution of Compound 9d (120 mg, 0.19 mmol) in methanol (4 mL) was added a solution of sodium hydroxide (50 mg) in water (2 mL). The mixture was stirred for 4 h at 50° C. The pH of the mixture was adjusted to 2 with HCl (2M). The residue was extracted with ethyl acetate several times. The organic layers were combined and concentrated under vacuum after dried over anhydrous sodium sulfate. The crude product was purified by Prep-HPLC with the following conditions (2#-AnalyseHPLC-SHIMADZU(HPLC-10)): Column, XSelect CSH Prep C18 OBD Column, 5 um,19*150 mm; mobile phase, Water (0.05% HCl) and ACN (60% ACN up to 85% in 7 min); Detector, UV 254/220 nm. This resulted in 3.1 mg (3%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=627.0. 1HNMR (400 MHz, DMSO-d6, ppm): δ 8.23 (s, 1H), 7.91 (s, 1H), 7.44-7.36 (m, 2H), 7.34-7.32 (m, 1H), 4.33-3.75 (brs, 2H), 3.50-3.23 (m, 3H), 2.97-2.88 (m, 1H), 2.69-2.58 (m, 1H), 2.39-2.31 (m, 1H), 2.25-2.18 (m, 1H), 2.03-1.95 (m, 1H), 1.32-1.25 (m, 2H), 1.18-1.02 (m, 5H).
- 4-(Chloromethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole (Compound 10a): To a solution of [5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl] methanol (1 g, 3.52 mmol) in DCM (7 mL) was added SOCl2(460 mg, 3.87 mmol) and DMF (2 drops). The resulting solution was stirred for 1 h at room temperature. The reaction was quenched by the addition of water. The resulting mixture was diluted with DCM and washed with water and brine. The mixture was dried over anhydrous sodium sulfate. The mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:5). This resulted in 1 g (94%) of the title compound as an orange oil. LCMS (ESI, m/z): [M+H]+=302.1.
- (R)-tert-Butyl 4-((3-(2,6-dichlorophenyl)-5-cyclopropylisoxazol-4-yl) methyl)-5,6-dihydro-6-methylpyridine-1(2H)-carboxylate (Compound 10b): To a solution of tert-butyl(2R)-2-methyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate ((220 mg, 0.68 mmol) in a mixture of dioxane (3 mL) and H2O (1 mL) was added Compound 10a (280 mg, 0.93 mmol), Pd(PPh3)4 (20 mg, 0.02 mmol) and Na2CO3 (231 mg, 2.16 mmol). The resulting solution was stirred for 3 h at 80° C. under N2 atmosphere. The mixture was diluted with ethyl acetate and washed with water and brine. The mixture was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:4). This resulted in 80 mg (crude product) of the title compound as an orange oil. LCMS (ESI, m/z): [M+H]+=463.3.
- (2R)-4-[[5-Cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methyl-1,2,3,6-tetrahydropyridine (Compound 10c): To a solution of Compound 10b (50 mg, 0.11 mmol) in dioxane (4 mL) was added a solution of hydrogen chloride in dioxane (6 mL, 4M). The resulting solution was stirred for 1 h at room temperature. The mixture was concentrated under vacuum. This resulted in 35 mg (89%) of the title compound as a light yellow oil. LCMS (ESI, m/z): [M+H]+=363.2.
- Methyl 2-[(2R)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methyl-1,2,3,6-tetrahydropyridin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate (Compound 10d): To a solution of methyl 2-chloro-4-methoxy-1,3-benzothiazole-6-carboxylate (100 mg, 0.33 mmol) in DMSO (3 mL) was added K2CO3 (138 mg, 0.99 mmol) and Compound 10c (120 mg, 0.33 mmol). The resulting solution was stirred for 3 h at 120° C. The reaction was quenched by the addition of water. The resulting mixture was extracted with ethyl acetate several times. The organic layers were combined and washed with water and brine. The residue was dried over anhydrous sodium sulfate. The mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:1). This resulted in 50 mg (26%) of the title compound as a yellow solid. LCMS (ESI, m/z): [M+H]+=584.2.
- 2-[(2R)-4-[[5-Cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methyl-1,2,3,6-tetrahydropyridin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylic acid (Compound II-46): To a solution of Compound 10d (30 mg, 0.05 mmol) in a mixture of methanol (1 mL) and tetrahydrofuran (1 mL) was added a solution of sodium hydroxide (10 mg, 0.25 mmol) in water (1 mL). The resulting solution was stirred for 2 h at 50° C. The pH value of the solution was adjusted to 6-7 with hydrogen chloride (2 N). The resulting mixture was concentrated under vacuum. The residue was applied onto a reversed column with ACN: H2O (4:6). This resulted in 2 mg (7%) of the title compound as a white solid. LCMS (ESI, m/z): [M+H]+=570.3. 1HNMR (400 MHz, DMSO-d6, ppm): δ 8.00-7.98 (m, 1H), 7.64-7.52 (m, 3H), 7.38 (s, 1H), 5.15 (s, 1H), 5.03 (s, 1H), 4.30 (s, 1H), 3.97 (s, 3H), 3.22-2.97 (m, 3H), 2.29-2.25 (m, 1H), 2.18-2.12 (m, 1H),1.90-1.78 (m, 1H), 1.13-1.06 (m, 7H).
- (R)-Methyl 2-(4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)-4-chlorobenzo[d]thiazole-6-carboxylate (Compound 11a): To a solution of methyl 2,4-dichloro-1,3-benzothiazole-6-carboxylate (50 mg, 0.19 mmol) in DMSO (2 mL) was added tert-butyl (3R)-3-methylpiperazine-1-carboxylate (38 mg, 0.19 mmol) and potassium carbonate (79 mg, 0.57 mmol). The mixture was stirred for 2 h at 120° C. The reaction solution was diluted with ethyl acetate. The resulted mixture was washed with water and brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (27:73). This resulted in 30 mg (37%) of the title compound as a white solid. LCMS (ESI, m/z): [M+H]+=426.3.
- (R)-Methyl 2-(4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)-4-(prop-1-en-2-yl) benzo[d]thiazole-6-carboxylate (Compound 11b): To a solution of Compound 11a (30 mg, 0.07 mmol) in dioxane (1 mL) was added potassium isopropenyltrifluoroborate (31 mg, 0.21 mmol), Pd2(dba)3.CHCl3 (4 mg, 0.005 mmol), dppf (4 mg, 0.01 mmol) and cesium carbonate (69 mg, 0.21 mmol). The mixture was stirred for 3 hat 150° C. under N2 atmosphere. The mixture was diluted with ethyl acetate and further washed with water and brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:4). This resulted in 30 mg (crude) of the title compound as a solid. LCMS (ESI, m/z): [M+H]+=432.0
- (R)-Methyl 2-(4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)-4-isopropylbenzo[d]thiazole-6-carboxylate (Compound 11c): To a solution of Compound 11b (30 mg, 0.07 mmol) in methanol (2 mL) was added Pd-C (15 mg, 10%, w %). The mixture solution was stirred for 2 h at room temperature under H2 atmosphere. The filtrate was concentrated under vacuum after filtration. This resulted in 28 mg (93%) of the title compound as a white solid. LCMS (ESI, m/z): [M+H]+=434.2.
- (R)-Methyl 4-isopropyl-2-(2-methylpiperazin-1-yl) benzo[d]thiazole-6-carboxylate (Compound 11d): To a solution of Compound 11c (30 mg, 0.07 mmol) in dioxane (2 mL) was added a solution of hydrogen chloride in dioxane (2 mL, 4M). The mixture was stirred for 1 h at room temperature. The mixture was concentrated under vacuum. This resulted in 20 mg (87%) of the title compound. LCMS (ESI, m/z): [M+H]+=334.2.
- (R)-Methyl 2-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl) methyl)-2-methylpiperazin-1-yl)-4-isopropylbenzo[d]thiazole-6-carboxylate (Compound 11e): To a solution of Compound 11d (20 mg, 0.06 mmol) in dichloromethane (1 mL) was added 5-cyclopropyl-3-(2,6-dichlorophenyl)-4,5-dihydro-1,2-oxazole-4-carbaldehyde (20 mg, 0.07 mmol) and sodium acetate (6 mg, 0.07 mmol). The mixed was stirred for 30 min at room temperature then NaBH(OAc)3 (40 mg, 0.24 mmol) was added. The reaction was stirred overnight at room temperature. The resulting mixture was diluted with DCM and washed with water and brine. The residue was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:3). This resulted in 35 mg (97%) of the title compound as a white solid. LCMS (ESI, m/z): [M+H]+=599.3.
- (R)-2-(4-((5-Cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl) methyl)-2-methylpiperazin-1-yl)-4-isopropylbenzo[d]thiazole-6-carboxylic acid (Compound VII-01): To a solution of Compound 11e (35 mg, 0.06 mmol) in a mixed solution of THF (1 mL), methanol (1 mL) and water (1 mL) was added sodium hydroxide (12 mg, 0.30 mmol). The resulting mixture was stirred for 1 h at 50° C. The pH value of the solution was adjusted to 6 with hydrogen chloride (2 N). The mixture was concentrated under vacuum. The residue was applied onto a C18 gel column with ACN/H2O (62:38). This resulted in 6.8 mg (20%) of the title compound as a white solid. LCMS (ESI, m/z): [M+H]+=585.1. 1HNMR (400 MHz, DMSO-d6, ppm): δ 8.18-8.17 (m, 1H), 7.83-7.72 (m, 1H), 7.66-7.64 (m, 2H), 7.57-7.55 (m, 1H), 4.18-4.17 (m, 1H), 3.79-3.78 (m, 1H), 3.56-3.51 (m, 1H), 3.29-3.17 (m, 3H), 2.82-2.79 (m, 1H), 2.68-2.60 (m, 1H), 2.38-2.34 (m, 1H), 2.28-2.24 (m, 1H), 1.97-1.92 (m, 1H), 1.27-1.25 (m, 6H), 1.18-1.09 (m, 4H), 0.98-0.95 (m, 3H).
- Following the procedure described above for Scheme 4-9 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared.
-
TABLE 2 LC-MS 1HNMR Compound A* B Scheme (M + H)+ (ppm) II-01 4 561.2 CD3OD-d4: δ 8.05 (s, 1H), 7.68-7.54 (m, 4H), 4.25 (s, 2H), 4.02 (s, 3H), 3.62-3.60 (m, 1H), 3.34-3.32 (m, 8H), 1.49 (d, J = 6.9 Hz, 6H). II-02 4 559.2 DMSO-d6: δ 7.99 (s, 1H), 7.65-7.62 (m, 2H), 7.58-7.53 (m, 1H), 7.39 (d, J = 1.2 Hz, 1H), 3.89 (s, 3H), 3.40 (brs, 4H), 3.34 (s, 2H), 2.38-2.34 (m, 5H), 1.18-1.09 (m, 4H). II-04 4 562.1 DMSO-d6: δ 12.75 (s, 1H), 8.83 (m, 2H), 7.99 (m, 1H), 7.38 (s, 1H), 3.88 (s, 3H), 3.52-3.34 (m, 7H), 2.36 (s, 4H), 1.35-1.33 (d, J = 7.2 Hz, 6H). II-05 4 577.3 DMSO-d6: δ 12.75 (s, 1H), 7.99 (s, 1H), 7.71-7.64 (m, 2H), 7.55-7.53 (m, 2H), 7.38 (s, 1H), 3.88 (s, 3H), 3.56- 3.32 (m, 7H), 2.35 (brs, 4H), 1.34-1.23 (d, J = 6.8 Hz, 6H). II-06 4 574.9 DMSO-d6: δ 7.97 (s, 1H), 7.73-7.71 (m, 1H), 7.67-7.65 (m, 1H), 7.63-7.54 (m, 2H), 7.38 (s, 1H), 3.87 (s, 3H), 3.40-3.32 (m, 6H), 2.37-2.33 (m, 5H), 1.14-1.07 (m, 4H). II-08 4 575.1 DMSO-d6,: δ 12.68 (brs, 1H), 7.97 (d, J = 1.5 Hz, 1H), 7.66-7.63 (m, 2H), 7.57-7.51 (m, 1H), 7.37 (d, J = 1.5 Hz, 1H), 4.12 (brs, 1H), 3.87 (s, 3H), 3.74-3.70 (m, 1H), 3.38- 3.34 (m, 1H), 3.21-3.16 (m, 3H), 2.78-2.73 (m, 1H), 2.57- 2.55 (m, 1H), 2.23-2.18 (m, 1H), 1.87-1.86 (m, 1H), 1.36- 1.32 (m, 6H), 0.93-0.91 (d, J = 6.6 Hz, 3H). II-09 4 573.3 CD3OD-d4: δ 7.98 (s, 1H), 7.57-7.46 (m, 4H), 4.24 (brs, 1H), 3.99 (s, 3H), 3.88-3.84 (m, 1H), 3.34 (s, 2H), 2.93- 2.90 (m, 1H), 3.66 (d, J = 10.8 Hz, 1H), 2.35-2.29 (m, 2H), 2.04-1.94 (m, 2H), 1.19 (t, J = 2 Hz, 4H), 1.08 (d, J = 7.8 Hz, 3H). II-10 4 575.2 DMSO-d6: δ 12.73 (s, 1H), 7.98 (s, 1H), 7.66-7.63 (m, 2H), 7.57-7.52 (m, 1H), 7.37 (s, 1H), 4.20-4.10 (m, 1H), 3.88 (s, 3H), 3.80-3.68 (m, 1H), 3.42-3.35 (m, 1H), 3.25- 3.1 (m, 3H), 2.81-2.72 (m, 1H), 2.60-2.55 (m, 1H), 2.25- 2.15 (m, 1H), 1.92-1.80 (m, 1H), 1.40-1.30 (m, 6H), 0.93 (d, J = 6.6 Hz, 3H). II-11 4 573.2 DMSO-d6: δ 12.75 (s, 1H), 8.00 (s, 1H), 7.66-7.50 (m, 3H), 7.38 (s, 1H), 4.21-4.09 (m, 1H), 3.89 (s, 3H), 3.82- 3.74 (s, 1H), 3.40-3.33 (m, 2H), 3.23-3.10 (m, 1H), 2.85- 2.75 (m, 1H), 2.60-2.54 (m, 1H), 2.40-2.30 (m, 1H), 2.28- 2.20 (m, 1H), 1.98-1.86 (m, 1H), 1.22-1.10 (m, 4H), 0.95 (d, J = 6.6 Hz, 3H). II-12 4 575.2 DMSO-d6: δ 7.96-7.95 (m, 1H), 7.65-7.63 (m, 2H), 7.56- 7.51 (m, 1H), 7.38-7.37 (m, 1H), 4.14-4.13 (m, 1H), 3.88 (s, 3H), 3.75-3.72 (m, 1H), 3.43-3.40 (m, 1H), 3.31-3.12 (m, 3H), 2.78-2.74 (m, 1H), 2.51-2.50 (m, 1H), 2.27-2.19 (m, 1H), 1.91-1.83 (m, 1H), 1.36-1.34 (m, 6H), 0.91 (d, J = 6.5 Hz, 3H). II-13 4 573.2 DMSO-d6: δ 12.75 (s, 1H), 7.99 (d, J = 1.2 Hz, 1H), 7.65 (d, J = 8.0 Hz, 2H), 7.57-7.53 (m, 1H), 7.37 (d, J = 1.2 Hz, 1H), 4.31-4.12 (m, 1H), 3.88 (s, 3H), 3.81-3.61 (m, 1H), 3.29-3.28 (m, 2H), 3.18-3.11 (m, 1H), 2.82-2.80 (m, 1H), 2.59-2.50 (m, 1H), 2.36-2.34 (m, 1H), 2.25-2.23 (m, 1H), 1.93-1.92 (m, 1H), 1.15-1.11 (m, 4H), 0.99-0.90 (m, 3H). II-14 4 574.3 DMSO-d6: δ 12.62 (s, 1H), 7.98 (s, 1H), 7.69-7.67 (m, 3H), 7.57-7.52 (m, 1H), 7.37 (s, 1H), 4.16 (s, 1H), 3.87 (s, 3H). 3.75-3.71 (m, 1H), 3.35-3.32 (m, 2H), 3.24- 3.17 (m, 1H), 3.00-2.96 (m, 1H), 2.76-2.73 (m, 1H), 2.44 (s, 1H), 2.26-2.22 (m, 1H), 1.93-1.87 (m, 1H), 1.27-1.21 (m, 6H), 1.21-0.71 (m, 3H). II-15 4 574.2 DMSO-d6: δ 7.96 (d, J = 1.6 Hz, 1H), 7.70-7.68 (m, 3H), 7.58-7.54 (m, 1H), 7.38 (d, J = 1.6 Hz, 1H), 4.15 (s, 1H), 3.88 (s, 3H), 3.74-3.69 (m, 1H), 3.39-3.32 (m, 2H), 3.24-3.17 (m, 1H), 3.02-2.95 (m, 1H), 2.76-2.68 (m, 1H), 2.48-2.45 (m, 1H), 2.34-2.23 (m, 1H), 1.94-1.87 (m, 1H), 1.28-1.22 (m, 6H), 0.92 (d, J = 6.8 Hz, 3H). II-16 4 589.3 DMSO-d6: δ 12.8 (s, 1H), 8.01 (s, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.55-.51 (m, 1H), 7.39 (s, 1H), 3.91 (s, 3H), 3.41-3.35 (m, 1H), 3.22 (s, 2H), 2.90 (s, 1H), 2.74 (s, 1H), 2.39 (s, 2H), 2.19 (s, 2H), 1.36-1.33 (m, 12H). II-17 4 587.3 CD3OD-d4: δ 8.02-7.99 (m, 1H), 7.61-7.46 (m, 4H), 4.00 (s, 3H), 3.40-3.33 (m, 3H), 2.52-2.10 (m, 4H), 3.24 (s, 2H), 1.41 (d, J = 6.9 Hz, 6H), 1.15-1.00 (m, 2H), 0.75-0.65 (m, 2H). II-18 4 589.2 DMSO-d6: δ 12.72 (s, 1H), 7.96 (s, 1H), 7.66-7.50 (m, 3H), 7.37 (s, 1H), 3.88 (s, 3H), 3.86-3.75 (m, 2H), 3.41- 3.30 (m, 1H), 3.28-3.00 (m, 3H), 2.77-2.62 (m, 2H), 2.16- 2.11 (m, 1H), 1.89-1.78 (m, 1H), 1.42-1.30 (m, 8H), 0.62 (t, J = 7.5 Hz, 3H). II-19 4 603.2 DMSO-d6: δ 12.75 (s, 1H), 7.96 (s, 1H), 7.69-7.50 (m, 3H), 7.36 (s, 1H), 4.10-3.93 (m, 1H), 3.87 (s, 3H), 3.60- 3.33 (m, 2H), 3.30-3.03 (m, 3H), 2.88-2.68 (m, 2H), 2.10- 2.00 (m, 1H), 1.92-1.75 (m, 2H), 1.33 (t, J = 6.6 Hz, 6H), 0.70 (d, J = 6.9 Hz, 3H), 0.61 (d, J = 6.6 Hz, 3H). II-20 4 589.1 DMSO-d6: δ 7.95 (d. J = 1.2 Hz, 1H), 7.65-7.63 (m, 2H), 7.55-7.53 (m, 1H), 7.40 (s, 1H), 3.88 (s, 3H), 3.66-3.62 (m, 1H), 3.51-3.34 (m, 4H), 3.15-3.07 (m, 1H), 2.72-2.68 (m, 1H), 2.27-2.26 (m, 1H), 2.19-2.16 (m, 1H), 1.42-1.40 (m, 1H), 1.35-1.32 (m, 6H), 1.23-1.20 (m, 1H), 0.66 (t, J = 7.2 Hz, 3H). II-21 4 587.3 DMSO-d6: δ 7.97 (s, 1H), 7.64-7.62 (m, 2H), 7.57-7.53 (m, 1H), 7.40 (s, 1H), 3.88 (s, 3H), 3.68-3.65 (m, 1H), 3.54- 3.50 (m, 3H), 3.23-3.09 (m, 2H), 2.77-2.73 (m, 1H), 2.37- 2.22 (m, 3H), 1.47-1.43 (m, 1H), 1.25-1.21 (m, 1H), 1.15- 1.08 (m, 4H), 0.65 (t, J = 7.6 Hz, 3H) II-23 6 587.2 DMSO-d6: δ 12.70 (s, 1H), 7.97 (d, J = 1.2 Hz, 1H), 7.64-7.62 (m, 2H), 7.58-7.53 (m, 1H), 7.37 (d, J = 1.6 Hz, 1H), 3.88 (s, 3H), 3.48 (s, 2H), 3.31 (d, J = 4.8 Hz, 2H), 3.02 (s, 2H), 2.50-2.47 (m, 2H), 2.33-2.27 (m, 1H), 1.15- 1.11 (m, 4H), 0.75 (s, 6H). II-24 6 575.2 DMSO-d6: δ 12.73 (s, 1H), 7.98 (d, J = 1.2 Hz, 1H), 7.64-7.62 (m, 2H), 7.57-7.53 (m, 1H), 7.38 (d, J = 1.2 Hz, 1H), 3.88 (s, 3H), 3.70- 3.55 (m, 3H), 3.38-3.33 (m, 1H), 3.21-3.16 (m, 1H), 3.00 (d, J = 14 Hz, 1H), 2.71-2.66 (m, 2H), 2.40-2.34 (m, 1H), 2.13-2.10 (m, 1H), 1.34- 1.31 (m, 6H), 0.75 (m, 3H). II-25 6 573.3 DMSO-d6: δ 12.75 (s, 1H), 7.99 (s, 1H), 7.64-7.62 (m, 2H), 7.57-7.53 (m, 1H), 7.38 (d, J = 0.8 Hz, 1H), 3.88 (s, 3H), 3.72-3.56 (m, 3H), 3.21- 3.16 (m, 1H), 3.08 (d, J = 13.6 Hz, 1H), 2.73-2.68 (m, 2H), 2.50 (s, 1H), 2.42-2.13 (m, 2H), 1.23-1.08 (m, 4H), 0.76 (d, J = 6.4 Hz, 3H). II-26 6 575.2 DMSO-d6: δ 12.75 (s, 1H), 7.99 (s, 1H), 7.65-7.54 (m, 3H), 7.44-7.38 (m, 1H), 3.89 (s, 3H), 3.70-3.56 (m, 3H), 3.21-3.16 (m, 1H), 2.30-2.27 (m, 1H), 2.71-2.60 (m, 2H), 2.38 (s, 2H), 2.21-2.11 (m, 1H), 1.47-1.32 (m, 6H), 1.75 (s, 3H). II-27 4 573.0 CD3OD-d4: δ 7.95 (d, J = 1.2 Hz, 1H), 7.55-7.46 (m, 4H), 3.97 (s, 3H), 3.84 (d, J = 14 Hz, 1H), 3.74-3.69 (m, 2H), 3.29-3.25 (m, 1H), 3.11 (d, J = 14 Hz, 1H), 3.86-3.76 (m, 2H), 2.45-2.42 (m, 1H), 2.28- 2.17 (m, 2H), 1.17 (d, J = 6.8 Hz, 4H), 0.85 (d, J = 6.4 Hz, 3H). II-28 4 575.1 DMSO-d6: δ 7.96 (s, 1H), 7.65-7.64 (m, 2H), 7.57-7.55 (m, 1H), 7.39 (m, 1H), 3.87 (s, 3H), 3.68 (m, 4H), 3.16 (s, 1H), 2.99-2.96 (m, 1H), 2.68- 2.66 (m, 2H), 2.24 (m, 1H), 2.12 (m, 1H), 1.35-1.31 (m, 6H), 0.75 (s, 3H). II-29 4 603.2 DMSO-d6: δ 7.98 (s, 1H), 7.49 (s, 1H), 7.40-7.38 (m, 2H), 7.33-7.30 (m, 1H), 3.92- 3.82 (m, 4H), 3.71-3.67 (m, 1H), 3.32-3.23 (m, 2H), 3.09- 2.84 (m, 3H), 2.62 (s, 2H), 2.11 (s, 2H), 1.42-1.36 (m, 5H), 0.90 (s, 3H), 0.52 (s, 3H). II-30 6 587.0 DMSO-d6: δ 7.95-7.94 (m, 1H), 7.62-7.55 (m, 3H), 7.40- 7.38 (m, 1H), 3.87 (s, 3H), 3.67 (s, 2H), 3.60-3.50 (m, 2H), 3.40-3.32 (m, 3H), 2.79- 2.71 (m, 2H), 1.35 (d, J = 6.9 Hz, 6H), 0.47-0.45 (m, 2H), 0.15-0.18 (m, 2H). II-31 4 591.3 CD3OD-d4: δ 8.03 (s, 1H), 7.61-7.59 (m, 3H), 7.58 (m, 1H), 4.39-4.20 (m, 3H), 4.11- 4.09 (m, 4H), 3.33-3.32 (m, 1H), 3.12-3.09 (m, 4H), 2.03 1.96 (m, 6H), 1.26-1.24 (m, 3H), 1.15 (s, 3H). II-32 4 589.2 DMSO-d6: δ 7.93 (d, J = 1.2 Hz, 1H), 7.64 (d, J = 8.4 Hz, 2H), 7.57-7.55 (m, 1H), 7.37 (d, J = 1.2 Hz, 1H), 4.15 (s, 1H), 3.87 (s, 3H), 3.22-3.57 (m, 5H), 2.91-2.89 (m, 1H), 2.80-2.51 (m, 1H), 2.23-2.19 (m, 1H), 1.37-1.34 (m, 6H), 0.98-0.89 (m, 3H), 0.85-0.75 (m, 3H). II-33 4 591.2 DMSO-d6: δ 7.92 (d, J = 1.2 Hz, 1H), 7.88-7.62 (m, 2H), 7.58-7.51 (m, 1H), 7.37 (s, 1H), 4.16 (s, 1H), 3.66 (s, 3H), 3.56-3.38 (m, 3H), 3.28- 3.21 (m, 2H), 2.90-2.88 (m, 1H), 2.78-2.74 (m, 1H), 2.23- 2.19 (m, 1H), 1.36-1.34 (m, 6H), 0.93 (m, 3H), 0.78 (m, 3H). II-34 6 587.2 CDCl3: δ 8.00 (s, 1H), 7.61- 7.51 (m, 1H), 7.50-7.39 (m, 2H), 7.33-6.91 (m, 1H), 4.29 (s, 1H), 4.01 (s, 3H), 3.65- 3.61 (m, 1H), 3.54-3.49 (m, 2H), 3.31-3.26 (m, 1H), 3.04 2.90 (m, 1H), 2.89-2.85 (m, 1H), 2.26-2.19 (m, 1H), 2.18 2.12 (m, 1H), 1.40-1.21 (m, 2H), 1.20-1.10 (m, 2H), 1.09- 1.03 (m, 3H), 0.97-0.90 (m, 3H). II-35 6 587.1 DMSO-d6: δ 7.95 (s, 1H), 7.67-7.64 (m, 2H), 7.59-7.55 (m, 1H), 7.41-7.35 (m, 1H), 4.21-4.12 (m, 1H), 3.93-3.86 (m, 4H), 3.70-3.67 (m, 1H), 2.86-2.73 (m, 2H), 2.71-2.62 (m, 1H), 2.42-2.32 (m, 1H), 2.25-2.16 (m, 2H), 1.18-1.08 (m, 7H), 0.91-0.90 (d, J = 6.0 Hz, 3H) II-36 4 585.0 CDCl3: δ 7.96 (s, 1H), 7.48- 7.41 (m, 1H), 7.39-7.31 (m, 2H), 7.29-7.26 (m, 1H), 4.49- 4.31 (m, 2H), 3.89-3.24 (m, 3H), 3.24 (s, 2H), 2.64-2.61 (m, 2H), 2.38-2.35 (m, 2H), 2.16-2.07 (m, 1H), 1.81-1.71 (m, 2H), 1.70-1.68 (m, 2H), 1.23-1.22 (m, 2H), 1.16-1.07 (m, 2H). II-37 6 585.1 CDCl3: δ 8.01 (s, 1H), 7.60- 7.51 (m, 1H), 7.40-7.38 (m, 2H), 7.29-7.26 (m, 1H), 4.02 (s, 3H), 3.69-3.66 (m, 2H), 3.49-3.34 (m, 2H), 3.25-3.15 (m, 4H), 2.28-2.19 (m, 1H), 1.86-1.75 (m, 2H), 1.67-1.53 (m, 2H), 1.47-1.21 (m, 2H), 1.19-1.06 (m, 2H). II-38 4 599.2 DMSO-d6: δ 12.73 (s, 1H), 7.99 (d, J = 1.2 Hz, 1H), 7.65-7.63 (m, 2H), 7.56-7.52 (m, 1H), 7.38 (d, J = 1.2 Hz, 1H), 3.89 (s, 3H), 3.75-3.50 (m, 4H), 3.34-3.33 (m, 2H), 2.74-2.73 (m, 2H), 2.46- 2.42 (m, 1H), 1.71-1.6 (m, 3H), 1.49-1.47 (m, 2H), 1.36- 1.35 (m, 1H), 1.15-1.10 (m, 4H). II-39 4 615.2 DMSO-d6: δ 8.01 (s, 1H), 7.56-7.51 (m, 1H), 7.40-7.32 (m, 3H), 4.15-3.74 (m, 5H), 3.52-3.46 (m, 1H), 3.25-3.20 (m, 1H), 2.94-2.92 (m, 1H), 2.68-2.64 (m, 1H), 2.38-2.30 (m, 1H), 2.12-2.07 (m, 1H), 1.90-1.85 (m, 1H), 1.78-1.63 (m, 1H), 1.40-1.26 (m, 10H), 1.06-0.75 (m, 2H), 0.45-0.36 (m, 1H). II-40 4 575.3 DMSO-d6: δ 8.05 (s, 1H), 7.55 (s, 1H), 7.40-7.38 (m, 2H), 7.32-7.30 (m, 1H), 4.05 (s, 3H), 3.68 (s, 3H), 3.37 (s, 2H), 3.32-3.25 (m, 1H), 2.68- 2.66 (m, 2H), 2.53-2.50 (m, 2H), 1.83-1.80 (m, 2H), 1.48 (s, 1H), 1.41-1.40 (d, J = 5.3 Hz, 6H). II-41 4 589.2 CDCl3: δ 8.05-8.00 (m, 1H), 7.61-7.32 (m, 4H), 4.52-3.87 (m, 6H), 3.64-3.17 (m, 3H), 2.89-2.50 (m, 2H), 2.34-1.95 (m, 2H), 1.45-1.17 (m, 11H). II-42 4 587.2 CDCl3: δ 8.05 (m, 1H), 7.61- 7.57 (m, 1H), 7.51-7.32 (m, 3H), 4.06-3.87 (m, 6H), 3.64- 3.40 (m, 1H), 3.39-16 (m, 2H), 2.89-2.53 (m, 3H), 2.50- 1.95 (m, 2H), 1.45-1.38 (m, 8H), 1.28-1.17 (m, 3H). II-43 7 560.1 CDCl3: δ 8.01 (s, 1H), 7.61 (s, 1H), 7.46-7.34 (m, 3H), 4.19-4.14 (m, 2H), 4.02 (s, 3H), 3.18-3.11 (m, 1H), 3.09- 2.96 (m, 2H), 2.25 (d, J = 9.1 Hz, 2H), 1.66 (m, 2H), 1.39 (d, J = 6.2 Hz, 7H), 1.25-1.13 (m, 2H). II-44 7 559.2 CD3OD-d4: δ 7.95 (d, J = 1.2 Hz, 1H), 7.68-7.50 (m, 5H), 4.13 (d, J = 13.2 Hz, 2H), 3.97 (s, 3H), 3.03-2.86 (m, 3H), 2.51 (d, J = 7.6 Hz, 2H), 1.68-1.54 (m, 3H), 1.30-1.22 (m, 8H). II-48 8 546.3 DMSO-d6: δ 13.13 (s, 1H), 8.21 (s, 1H), 7.62-7.49 (m, 4H), 3.98 (s, 3H), 3.75 (s, 1H), 3.44-3.40 (m, 2H), 2.73 (s, 3H), 2.29 (s, 2H), 1.98 (s, 1H), 1.33-1.29 (m, 7H). II-49 7 559.2 CD3OD-d4: δ 8.75 (s, 2H), 8.02 (d, J = 1.2 Hz, 1H), 7.61 (d, J = 1.2 Hz, 1H), 4.18-4.15 (d, J = 12.0 Hz, 2H), 4.03 (s, 3H), 3.33-3.32 (m, 2H), 2.44- 2.42 (d, J = 8.0 Hz, 2H), 2.26-2.20 (m, 1H), 1.82-1.79 (d, J = 12.0 Hz, 2H), 1.63- 1.58 (m, 1H), 1.39-1.28 (m, 2H), 1.29-1.26 (d, J = 12.0 Hz, 4H). II-50 7 574.2 CD3OD-d4: δ 7.98 (s, 1H), 7.68-7.64 (m, 1H), 7.58-7.51 (m, 4H), 4.12-4.08 (d, J = 12.0 Hz, 2H), 4.00 (s, 3H), 3.08-3.03 (m, 2H), 2.50-2.49 (d, J = 4.0 Hz, 2H), 2.20-2.16 (m, 1H), 1.69-1.66 (d, J = 12.0 Hz, 2H), 1.58-1.54 (m, 1H), 1.28-1.14 (m, 6H). II-51 7 572.1 DMSO-d6: δ 12.7 (s, 1H), 7.97 (s, 1H), 7.71-7.58 (m, 3H), 7.37 (s, 1H), 4.38 (s, 1H), 3.88 (s, 3H), 3.07-3.26 (m, 1H), 2.14-2.35 (m, 3H), 1.68-1.40 (m, 5H), 1.21-1.00 (m, 8H). *It is to be understood that ring A attaches to the thiazole ring at the open valence on the left-hand side of ring A and to the B-ring at the open valence on the right-hand side of ring A. -
TABLE 3 LC-MS Compound A* B X Scheme (M + H)+ 1HNMR (ppm) III-01 S 4 531.2 DMSO-d6: δ 12.62 (s, 1H), 8.36 (s, 1H), 7.86 (d, J = 8.1 Hz, 1H), 7.65-7.53 (m, 3H), 7.46 (d, J = 8.4 Hz, 1H), 3.41 (s, 4H), 3.34 (s, 2H), 3.27 (s, 1H), 2.35 (s, 4H), 1.35 (d, J = 6.9 Hz, 6H). III-02 S 4 531.3 CD3OD-d4: δ 8.32 (s, 1H), 7.98-7.95 (m, 1H), 7.58-7.50 (m, 4H), 3.56-3.48 (m, 4H), 3.42 (s, 2H), 2.50-2.46 (m, 4H), 2.34-2.28 (m, 1H), 1.20- 1.17 (m, 4H). III-03 S 6 543.1 CDCl3: δ 8.30 (s, 1H), 8.12- 7.92 (m, 1H), 7.60-7.46 (m, 1H), 7.41-7.39 (m, 2H), 7.33- 7.28 (m, 1H), 4.18 (s, 1H), 3.97-3.71 (m, 1H), 3.48-3.22 (m, 3H), 2.98-2.81 (m, 1H), 2.69-2.53 (m, 1H), 2.25- 2.16 (m, 1H), 2.21-2.12 (m, 1H), 2.01-1.92 (m, 1H), 1.30- 1.21 (m, 2H), 1.18-1.02 (m, 5H). III-04 S 6 543.1 CDCl3: δ 8.33 (s, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.51-7.41 (m, 1H), 7.39-7.34 (m, 2H), 7.31-7.26 (m, 1H), 3.82-3.78 (m, 1H), 3.71-3.67 (m, 2H), 3.35-329 (m, 1H), 2.99 (m, 1H), 2.86-2.79 (m, 2H), 2.46- 2.42 (m, 1H), 2.20-2.05 (m, 2H), 1.18-1.10 (m, 4H), 0.86 (d, J = 6.3 Hz, 3H). III-05 S 6 543.1 DMSO-d6: δ 8.31 (s, 1H), 7.82 (d, J = 9.9 Hz, 1H), 7.64-7.57 (m, 2H), 7.55-7.54 (m, 1H), 7.40 (d, J = 8.5 Hz, 1H), 3.72-3.67 (m, 3H), 3.32- 3.15 (m, 1H), 3.06 (m, 1H), 2.72-2.70 (m, 2H), 2.62-2.35 (m, 2H), 2.22-2.01 (m, 1H), 1.22-0.95 (m, 4H), 0.75 (d, J = 6 Hz, 3H). III-06 S 6 543.1 CDCl3: δ 8.33 (s, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.51-7.41 (m , 1H), 7.39-7.34 (m, 2H), 7.31-7.26 (m, 1H), 3.82-3.78 (m, 1H), 3.71-3.67 (m, 2H), 3.35-3.29 (m, 1H), 3.02-2.97 (m, 1H), 2.86-2.79 (m, 2H), 2.46-2.42 (m, 1H), 2.20-2.05 (m, 2H), 1.31-1.29 (m, 2H), 1.16-1.03 (m, 2H), 0.86 (d, J = 6.3 Hz, 3H). III-07 S 6 557.1 CDCl3: δ 8.30 (s, 1H), 8.02 (d, J = 8.7 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.43-7.31 (m, 2H), 7.30-7.26 (m, 1H), 4.30- 4.15(m, 1H), 3.63-3.48 (m, 3H), 3.47-3.28 (m, 1H), 3.06- 3.05 (m, 1H), 2.90-2.85 (m, 1H), 2.24-2.20 (m, 1H), 2.19- 2.13 (m, 1H), 1.30-1.26 (m, 2H), 1.16-1.05 (m, 5H), 0.92 (d, J = 6.6 Hz, 3H). III-08 S 7 530.1 CDCl3: δ 8.33 (s, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.54-7.52 (m, 1H), 7.46-7.43 (m, 2H), 7.38-7.33 (m, 1H), 4.16-4.12 (m, 2H), 3.18-2.98 (m, 3H), 2.27 (d, J = 7.2 Hz, 2H), 1.75-1.71 (m, 2H), 1.40-1.31 (m, 7H), 1.25-1.19 (m, 2H). III-09 S 4 515.3 CDCl3: δ 8.00-7.94 (m, 2H), 7.40-7.32 (m, 4H), 3.55 (brs, 4H), 3.29 (brs, 3H), 2.42 (brs, 4H), 1.43 (d, J = 6.9 Hz, 6H). *It is to be understood that ring A attaches to the thiazole/oxazole ring at the open valence on the left-hand side of ring A and to the B-ring at the open valence on the right-hand side of ring A. -
TABLE 3I LC-MS Compound A* B Scheme (M + H)+ 1HNMR (ppm) III2-01 6 527.3 DMSO-d6: δ 12.30 (s, 1H), 8.03 (s, 1H), 7.67-7.54 (m, 4H), 7.34 (d, J = 8.7 Hz, 1H), 5.91 (s, 1H), 3.55 (s, 3H), 3.43-3.29 (m, 3H), 2.80 (brs, 4H), 2.42 (brs, 4H), 1.35 (d, J = 6.9 Hz, 6H). *It is to be understood that ring A attaches to the pyrrole ring at the open valence on the left-hand side of ring A and to the B-ring at the open valence on the right-hand side of ring A. -
TABLE 3II LC-MS Compound A* B Scheme (M + H)+ 1HNMR (ppm) III3-01 4 526.3 DMSO-d6: δ 7.94-7.87 (m, 1H), 7.75-7.53 (m, 4H), 7.40-7.33 (m, 1H), 3.58 (s, 3H), 3.34 (s, 2H), 3.17-3.08 (m, 4H), 2.43- 2.23 (m, 5H), 1.15-1.06 (m, 4H). *It is to be understood that ring A attaches to the imidazole ring at the open valence on the left-hand side of ring A and to the B-ring at the open valence on the right-hand side of ring A. -
TABLE 4 LC-MS Compound A* B Scheme (M + H)+ 1HNMR (ppm) IV-01 4 545.3 DMSO-d6: δ 12.60 (s, 1H), 8.17 (s, 1H), 7.69-7.62 (m, 3H), 7.58-7.52 (m, 1H), 3.34-3.39 (m, 4H), 3.27 (s, 2H), 2.45 (s, 3H), 2.36 (s, 4H), 1.34 (d, J = 6.9 Hz, 6H). IV-02 4 543.1 DMSO-d6: δ 12.60 (brs, 1H), 8.17-8.16 (m, 1H), 7.69 (s, 1H), 7.65-7.62 (m, 2H), 7.57-7.53 (m, 1H), 3.43-3.41 (m, 4H), 3.41-3.40 (m, 2H), 2.49 (s, 3H), 2.45-2.33 (m, 5H), 1.16-1.11 (m, 4H). IV-03 4 544.4 DMSO-d6: δ 8.18 (s, 1H), 7.69- 7.67 (m, 4H), 7.59-7.54 (m, 1H), 3.42-3.39 (m, 6H), 3.01- 2.95 (m, 1H), 2.45 (s, 3H), 2.34 (brs, 4H), 1.25-1.23 (m, 6H). IV-04 6 557.1 DMSO-d6: δ 12.59 (s, 1H), 8.16 (s, 1H), 7.68-7.62 (m, 3H), 7.56-7.49 (m, 1H), 4.14-4.06 (m, 1H), 3.83 (s, 1H), 3.32 (s, 1H), 3.23-3.13 (m, 2H), 2.82- 2.78 (m, 1H), 2.59-2.56 (m, 1H), 2.44 (s, 3H), 2.38-2.30 (m, 1H), 2.26-2.21 (m, 1H), 1.97- 1.88 (m, 1H), 1.17-1.08 (m, 4H), 0.97-0.95 (d, J = 6.6 Hz, 3H). IV-05 6 557.3 DMSO-d6: δ 12.52 (s, 1H), 8.19 (s, 1H), 7.79-7.63 (m, 3H), 7.57-7.51 (m, 1H), 4.08-4.02 (m, 1H), 3.85-3.81 (m, 1H), 3.28-3.15 (m, 3H), 2.90-2.73 (m, 1H), 2.60-2.50 (m, 1H), 2.45-2.37 (m, 4H), 2.27-2.15 (m, 1H), 2.08-1.89 (m, 1H), 1.15-1.03 (m, 4H), 0.96 (d, J = 6.6 Hz, 3H). IV-06 6 559.1 DMSO-d6: δ 12.59 (s, 1H), 8.16 (s, 1H), 7.68-7.51 (m, 4H), 3.71-3.57 (m, 3H), 3.24-3.17 (m, 1H), 3.09-3.04 (m, 1H), 2.74-2.68 (m, 2H), 2.44 (s, 3H), 2.32-2.28 (m, 2H), 2.19-2.12 (m, 1H), 1.13-1.06 (m,4H), 0.76-0.74 (d, J = 6.1 Hz, 3H). IV-07 6 557.3 DMSO-d6: δ 12.59 (brs, 1H), 8.16 (s, 1H), 7.68 (s, 1H), 7.64- 7.61 (m, 2H), 7.57-7.52 (m, 1H), 3.82-3.57 (m, 3H), 3.24- 3.16 (m, 1H), 3.09-3.04 (m, 1H), 2.75-2.65 (m, 2H), 2.44- 2.35 (m, 4H), 2.33-2.26 (m, 1H), 2 2.-2.11 (m, 1H), 1.16- 1.04 (m, 4H), 0.76-0.74 (d, J = 6.0 Hz, 3H). IV-08 6 570.8 DMSO-d6: δ 12.57 (s, 1H), 8 13 (s, 1H), 7.67-7.63 (m, 3H), 7.56-7.50 (m, 1H), 4.18 (s, 1H), 3.62-3.51 (m, 2H), 3.39-3.37 (m, 1H), 3.27-3.22 (m, 1H), 2.96-2.93 (m, 1H), 2.82-2.72 (m, 1H), 2.43 (s, 3H), 2.40-2.33 (m, 1H), 2.27-2.21 (m, 1H), 1.17-1.06 (m, 4H), 0.97-0.94 (d, J = 6.6 Hz, 3H), 0.86-0.84 (d, J = 6.5 Hz, 3H). IV-09 6 571.1 DMSO-d6: δ 8.15(s, 1H), 7.68- 7.56 (m, 4H), 4.17 (s, 1H), 3.89-3.84 (m, 1H), 3.74-3.67 (m, 1H), 2.88-2.68 (m, 3H), 2.44 (s, 3H), 2.40-2.18 (m, 3H), 1.12-1.10 (m, 7H), 0.90-0.88 (d, J = 5.9 Hz, 3H). IV-10 7 544.1 DMSO-d6: δ 8.15 (s, 1H), 7.69- 7.67 (m, 3H), 7.61-7.57 (m, 1H), 4.03-4.00 (m, 2H), 3.33- 3.25 (m, 1H), 3.01-2.96 (m, 2H), 2.44 (s, 3H), 2.33-2.25 (m, 2H), 1.62-1.59 (m, 2H), 1.36- 1.32 (m, 1H), 1.32-1.30 (d, J = 6.8 Hz, 6H), 1.23-1.16 (m, 2H). *It is to be understood that ring A attaches to the thiazole ring at the open valence on the left-hand side of ring A and to the B-ring at the open valence on the right-hand side of ring A. -
TABLE 5 LC-MS Compound R1 A* B Scheme (M + H)+ 1HNMR (ppm) V-01 Me 6 557.2 DMSO-d6: δ 8.20 (s, 1H), 7.79-7.76 (m, 2H), 7.64- 7.62 (m, 1H), 7.25-7.22 (m, 1 H), 4.16 (s, 1H), 3.76-3.71 (m, 1H), 3.28-3.20 (m, 4H), 2.81-2.77 (m, 1H), 2.54- 2.50 (m, 4H), 2.37-2.36 (m, 1H), 1.95-1.92 (m, 1H), 1.13-1.06 (m, 4H), 0.96- 0.94 (m, 3H). V-02 F 6 561.2 DMSO-d6: δ 13.10 (s, 1H), 8.24 (m, 1H), 7.64 (m, 2H), 7.53-7.50 (m, 1H), 7.23- 7.19 (m, 1H), 4.15 (s, 1H), 3.75 (m, 1H), 3.19-3.15 (m, 3H), 2.80-2.77 (m, 1H), 2.50-2.49 (m, 1H), 2.34- 2.32 (m, 1H), 2.24-2.21 (m. 1H), 1.95-1.92 (m, 1H), 1.16-1.11 (m, 4H), 0.96- 0.93 (m, 3H). *It is to be understood that ring A attaches to the thiazole ring at the open valence on the left-hand side of ring A and to the B-ring at the open valence on the right-hand side of ring A. -
TABLE 6 LC-MS Compound A* B Scheme (M + H)+ 1HNMR (ppm) VI-01 4 549.1 CDCl3: δ 8.09 (s, 1H), 5 7.73 (d, J = 10.2 Hz, 1H), 7.41-7.39 (m, 2H), 7.34-7.26 (m, 1H), 3.50-3.47 (m, 4H), 3.33-3.23 (m, 3H), 2.39-2.43 (m, 4H), 1.42-1.38 (m, 6H). VI-02 4 546.7 DMSO-d6: δ 12.94 (brs, 1H), 8.23-8.22 (m, 1H), 7.65-7.52 (m, 4H), 3.45-3.43 (m, 4H), 3.32-3.30 (m, 2H), 2.39-2.34 (m, 5H), 1.15-1.09 (m, 4H). VI-03 4 548.0 DMSO-d6: δ 8.18 (s, 1H), 7.69- 7.67 (m, 3H), 7.59-7.54 (m, 2H), 3.41 (s, 6H), 3.01-2.94 (m, 1H), 2.34 (s, 4H), 1.25 (d, J = 6.8 Hz, 6H). VI-04 6 561.0 DMSO-d6: δ 8.15 (s, 1H), 7.63 (d, J = 8 Hz, 2H), 7.57-7.52 (m, 2H), 4.16 (s, 1H), 3.77 (d, J = 10.8 Hz, 1H), 3.31-3.24 (m, 2H), 3.23-3.16 (m, 1H), 2.82 (d, J = 11.6 Hz, 1H), 2.67-2.56 (m, 1H), 2.39-2.32 (m, 1H), 2.26-2.22 (m, 1H), 1.96-1.90 (m, 1H), 1.17-1.11 (m, 4H), 1.10-0.95 (m, 3H). VI-05 6 561.3 CD3OD-d4: δ 8.19 (s, 1H), 7.70-7.55 (m, 4H), 4.69-4.50 (m, 1H), 4.28-4.02 (m, 3H), 3.79-3.35 (m, 3H), 3.24-2.85 (m, 2H), 2.60-2.40 (m, 1H), 1.38-1.30 (m, 7H). VI-06 6 561.1 DMSO-d6: δ 8.17 (d, J = 1.2 Hz, 1H), 7.65-7.54 (m, 4H), 3.72-3.60 (m, 3H), 3.26-3.20 (m, 1H), 3.09 (d, J = 13.6 Hz, 1H), 2.76-2.71 (m, 2H), 2.44- 2.40 (m, 1H), 2.34-2.30 (m, 1H), 2.20-2.14 (m, 1H), 1.15- 1.09 (m, 4H), 0.75 (d, J = 6.4 Hz, 3H). VI-07 6 561.1 DMSO-d6: δ 8.12 (s, 1H), 7.65- 7.56 (m, 2H), 7.55-7.53 (m, 2H), 3.72-3.59 (m, 3H), 3.28- 3.17 (m, 1H), 3.09 (d, J = 13.6 Hz, 1H), 2.75-2.70 (m, 2H), 2.42-2.41 (m, 1H), 2.33- 2.29 (m, 1H), 2.19-2.10 (m, 1H), 1.14-1.07 (m, 4H), 0.76 (d, J = 6.0 Hz, 3H). VI-08 6 575.3 DMSO-d6: δ 8.13 (s, 1H), 7.65 (d, J = 8 Hz, 2H), 7.56-7.52 (m, 2H), 4.16 (s, 1H), 3.60-3.53 (m, 2H), 3.39-3.35 (m, 1H), 3.32- 3.23 (m, 1H), 2.96 (d, J = 2.8 Hz, 1H), 2.83-2.78 (m, 1H), 2.40-2.33 (m, 1H), 2.24 (d, J = 10.8 Hz, 1H), 1.15-1.08 (m, 4H), 0.96 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.4 Hz, 3H). VI-09 6 575.1 DMSO-d6: δ 8.13 (s, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.57-7.52 (m, 2H), 4.17 (s, 1H), 3.61-3.53 (m, 2H), 3.39-3.35 (m, 1H), 3.32-3.23 (m, 1H), 2.96 (s, 1H), 2.83-2.79 (m, 1H), 2.40-2.33 (m, 1H), 2.24 (d, J = 11.6 Hz, 1H), 1.16-1.08 (m, 4H), 0.96 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.4 Hz, 3H). VI-10 6 575.3 CD3OD-d4: δ 8.21 (s, 1H), 7.70-7.60 (m, 1H), 7.57-7.53 (m, 3H), 4.69-4.34 (m, 2H), 4.20-3.91 (m, 2H), 3.64-3.31 (m, 2H), 3.22-2.81 (m, 2H), 2.51-2.44 (m, 1H), 1.59-1.44 (m, 3H), 1.33-1.12 (m, 7H). VI-11 7 548.1 DMSO-d6: δ 8.15 (s, 1H), 7.67 (d, J = 7.6 Hz, 2H), 7.62-7.57 (m, 2H), 4.02 (d, J = 12.4 Hz, 2H), 3.05-2.95 (m, 2H), 2.33- 2.25 (m, 2H), 1.63 (d, J = 11.6 Hz, 2H), 1.38-1.31 (m, 7H), 1.24-1.20 (m, 3H). *It is to be understood that ring A attaches to the thiazole ring at the open valence on the left-hand side of ring A and to the B-ring at the open valence on the right-hand side of ring A. -
TABLE 7 LC-MS Compound R2 A* B Scheme (M + H)+ 1HNMR (ppm) VII-02 Cl 6 579.1 DMSO-d6: δ 8.23 (s, 1H), 7 81 (s, 1H), 7.65-7.62 (m, 2H), 7.56-7.51 (m, 1H), 4.16 (s, 1H), 4.36-4.34 (m, 1H), 3.84-3.79 (m, 1H), 3.20-3.16 (m, 2H), 2.82-2.56 (m, 3H), 2.37-2.23 (m, 1H), 1.93-1.90 (m, 1H), 1.15-1.12 (m, 4H), 0.98-0.95 (d, J = 6.6 Hz, 3H). VII-03 CF3 9 611.0 DMSO-d6: δ 8.46 (s, 1H), 8.32 (s, 1H), 7.45-7.36 (m, 2H), 7.34-7.31 (m, 1H), 4.41-3.88 (brs, 2H), 3.48-3.21 (m, 3H), 2.96-2.90 (m, 1H), 2.69-2.61 (m, 1H), 2.38-2.31 (m, 1H), 2.19-2.11 (m, 1H), 2.06-1.97 (m, 1H), 1.32-1.26 (m, 2H), 1.18-1.01 (m, 5H). VII-05 Cl 4 593.1 DMSO-d6: δ 12.98 (s, 1H), 8.32 (s, 1H), 7.82-7.51 (m, 5H), 4.18 (s, 1H), 3.83 (s, 1H), 3.49-3.36 (m, 2H), 3.17-3.12 (m, 1H), 2.79 (d, J = 10.4 Hz, 1H), 2.64 (d, J = 11.2 Hz, 1H), 2.40- 2.31 (m, 1H), 2.23- 2.16 (m, 1H), 2.01- 1.96 (m, 1H), 1.22- 0.85 (m, 7H). *It is to be understood that ring A attaches to the thiazole ring at the open valence on the left-hand side of ring A and to the B-ring at the open valence on the right-hand side of ring A. - tert-Butyl (2S)-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazine-1-carboxylate (Compound 12a): To a solution of tert-butyl (2S)-2-methylpiperazine-1-carboxylate (400 mg, 2.00 mmol) in dichloromethane (6 mL) was added acetic acid (120 mg, 2.0 mmol) and 5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carbaldehyde (562 mg, 1.99 mmol). After the mixture was stirred for 30 min, NaBH(OAc)3 (1.3 g, 6.13 mmol) was added. The resulting solution was stirred overnight at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (30:70). This resulted in 670 mg (72%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=466.2.
- (S)-5-Cyclopropyl-3-(2,6-dichlorophenyl)-4-((3-methylpiperazin-1-yl) methyl) isoxazole (Compound 12b): To a solution of Compound 12a (620 mg, 1.3 mmol) in dioxane (4 mL) was added a solution of HCl in dioxane (8 mL, 4M). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 48 mg (98%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=366.2.
- (S)-Methyl 2-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl) methyl)-2-methylpiperazin-1-yl)-7-methoxybenzo[d]thiazole-5-carboxylate (Compound 12c): To a solution of Compound 12b (100 mg, 0.27 mmol) in DMSO was added potassium carbonate (162 mg, 1.16 mmol) and methyl 2-chloro-7-methoxy-1,3-benzothiazole-5-carboxylate (143 mg, 0.55 mmol). The resulting solution was stirred for 2 h at 120° C. The reaction was then quenched by the addition of 5 mL of water. The resulting solution was diluted with 50 mL of ethyl acetate. The resulted mixture was washed with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (24:76). This resulted in 120 mg (75%) of the title compound as a light yellow solid. LC-MS (ESI, m/z): [M+H]+=587.2.
- (S)-2-(4-((5-Cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl) methyl)-2-methylpiperazin-1-yl)-7-methoxybenzo[d]thiazole-5-carboxylic acid (Compound 12d): To a solution of Compound 12c (100 mg, 0.17 mmol) in a mixed solvent of tetrahydrofuran/methanol/H2O (5 mL, 1:1:1) was added sodium hydroxide (30 mg, 0.75 mmol). The resulting solution was stirred for 3 h at 50° C. The pH value of the solution was adjusted to 6 with hydrogen chloride (2 N). The resulting solution was extracted with dichloromethane 3 times and the organic layers were combined. The organic phase was washed successively with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with dichloromethane/methanol (15:1). This resulted in 60 mg (61%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=573.2.
- (S)-2-(4-((5-Cyclopropyl-3-(2,6-dichlorophenyl) isoxazol-4-yl) methyl)-2-methylpiperazin-1-yl)-7-methoxybenzo[d]thiazole-5-carboxamide (Compound VIII-04): To a solution of Compound 12d (60 mg, 0.1 mmol) in DMF (2 mL) was added CDI (18 mg, 0.11 mmol) at room temperature. NH3.H2O (0.1 ml, 25%, w %) was added into the mixture solution after stirred for 1 h. The resulting solution was stirred for another 2 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a reverse column with H2O/CH3CN (60:40). This resulted in 6.4 mg (13%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=572.1. 1HNMR (300 MHz, DMSO-d6, ppm): δ 7.91 (s, 1H), 7.70-7.58 (s, 3H), 7.40 (s, 1H), 4.44 (s, 1H), 4.02-3.97 (m, 3H), 3.88 (s, 3H), 3.25 (s, 1H), 3.11 (s, 1H), 2.98-2.81 (m, 2H), 2.72-2.66 (m, 2H), 1.30-1.15 (m, 7H).
- Methyl 2-[(2R)-4-[[5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate (Compound 13a): To a solution of methyl 4-methoxy-2-[(2R)-2-methylpiperazin-1-yl]-1,3-benzothiazole-6-carboxylate (110 mg, 0.34 mmol) and 5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)-1,2-oxazole-4-carbaldehyde (116 mg, 0.41 mmol) in dichloromethane (6 mL) was added NaOAc (93 mg, 0.68 mmol). The mixture was stirred for 1 h at room temperature then NaBH(OAc)3 (291 mg, 1.37 mmol) was added. The resulting mixture was stirred overnight at room temperature. The mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:4). This resulted in 150 mg (74%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=588.1.
- 2-[(2R)-4-[[5-Cyclopropyl-3-(3,5-dichloropyridin-4-yl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxylic acid (Compound 13b): To a solution of Compound 13a (150 mg, 0.25 mmol) in a mixed solvent of methanol (2 mL) and tetrahydrofuran (2 mL) was added a solution of sodium hydroxide (51 mg, 1.28 mmol) in water (2 mL). The resulting solution was stirred for 2 h at 50° C. The pH value of the mixture was adjusted to 5 with hydrogen chloride (2 N). The mixture was concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (15:1). This resulted in 90 mg (61%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=574.1.
- 2-[(2R)-4-[[5-Cyclopropyl-3-(3,5-dichloropyridin-4-yl)-1,2-oxazol-4-yl]methyl]-2-methylpiperazin-1-yl]-4-methoxy-1,3-benzothiazole-6-carboxamide (Compound VIII-03): To a solution of Compound 13b (90 mg, 0.16 mmol,) in DMF (3 mL) was added CDI (25 mg, 0.15 mmol). Ammonia water (0.2 mL) was added one portion after the mixture was stirred for 30 min. The resulting mixture was stirred for 2 h at room temperature. The reaction solution was concentrated under vacuum. The residue was applied onto a C18 column with ACN/H2O (1:1). This resulted in 48.8 mg (54%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=573.2. 1HNMR (400 MHz, CD3OD-d4, ppm): δ 8.70 (d, J=0.8 Hz, 2H), 7.83 (d, J=1.6 Hz, 1H), 7.43 (d, J=1.6 Hz, 1H), 4.20-4.17 (m, 1H), 3.99 (s, 3H), 3.85 (d, J=12.4 Hz, 1H), 3.43-3.20 (m, 3H), 2.86 (d, J=11.2 Hz, 1H), 2.61 (d, J=11.2 Hz, 1H), 2.36-2.25 (m, 2H), 2.05-2.01 (m, 1H), 1.19-1.05 (m, 4H), 0.94-0.92 (d, J=6.5 Hz, 3H).
- Following the procedure described above for Scheme 12 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared.
-
TABLE 8 LC-MS Compound A* B (M + H)+ 1HNMR (ppm) VIII-01 560.3 CDCl3: δ 7.67 (d, J = 1.5 Hz, 1H), 7.43-7.41 (m, 2H), 7.36-7.31 (m, 2H), 4.03 (s, 3H), 3.50 (brs, 4H), 3.30 (brs, 2H), 2.43 (brs, 4H), 1.44 (d, J = 6.9 Hz, 6H). VIII-02 572.1 DMSO-d6: δ 7.88 (s, 2H), 7.65-7.62 (m, 2H), 7.58-7.51 (m, 1H), 7.38 (s, 1H), 7.27 (s, 1H), 4.13 (s, 1H), 3.87 (s, 3H), 3.75-3.71 (m, 1H), 3.28 (s, 1H), 3.23-3.11 (m, 2H), 2.81-2.72 (m, 1H), 2.58-2.57 (m, 1H), 2.39- 2.20 (m, 1H), 1.95-1.86 (m, 1H), 1.17-1.07 (m, 4H), 0.94-0.92 (d, J = 6.5 Hz, 3H). VIII-05 572.3 DMSO-d6: δ 7.89 (s, 2H), 7.64-7.51 (m, 3H), 7.38 (s, 1H), 7.26 (s, 1H), 3.87 (s, 3H), 3.72-3.54 (m, 3H), 3.18-3.03 (m, 2H), 2.73-2.69 (m, 2H), 2.41-2.26 (m, 2H), 2.17-2.07 (m, 1H), 1.16-1.04 (m, 4H), 0.75- 0.73 (d, J = 6 Hz, 3H). VIII-06 572.2 DMSO-d6: δ 7.88 (s, 2H), 7.64-7.61 (m, 2H), 7.57-7.51 (m, 1H), 7.38 (s, 1H), 7.26 (s, 1H), 3.87 (s, 3H), 3.72- 3.54 (s, 3H), 3.18-3.15 (m, 1H), 3.11-3.03 (m, 1H), 2.74-2.63 (m, 2H), 2.41-2.36 (m, 1H), 2.33-2.31 (m, 1H), 2.18-2.10 (m, 1H), 1.17- 1.04 (m, 4H), 0.76-0.74 (d, J = 6 Hz, 3H). VIII-07 586.2 DMSO-d6: δ 7.86 (s, 2H), 7.65-7.63 (m, 2H), 7.56-7.51 (m, 1H), 7.37 (s, 1H), 7.25 (s, 1H), 4.15-4.13 (s, 1H), 3.87 (s, 3H), 3.57-3.52 (m, 2H), 3.27-3.22 (m, 1H), 2.97-2.93 (m, 1H), 2.84-2.72 (m, 1H), 2.42-2.33 (m, 1H), 2.27-2.19 (m, 1H), 1.15- 1.06 (m, 4H), 0.93 (d, J = 6.9 Hz, 3H), 0.86 (d, J = 6.3 Hz, 3H). *The A-ring is to be understood as attaching to the thiazole ring at the open valence on the left-hand side and to the B-ring at the open valence on the right-hand side. - 2-(4-((3-(2,6-Dichlorophenyl)-5-isopropylisoxazol-4-yl) methyl) piperazin-1-yl)-4-methoxybenzo[d]thiazole-6-carbonitrile (Compound IX-01): To a solution of Compound VIII-01 (700 mg, 1.25 mmol) in dichloromethane (5 mL) was added TEA (252 mg, 2.50 mmol). After cooling to 0° C., TFAA (529 mg, 5.45 mmol) in DCM (2 mL) was added in dropwise. The resulting solution was stirred for 15 min at 0° C. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (94:6). This resulted in 500 mg (74%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=542.3. H-NMR (300 MHz, DMSO-d6, ppm): δ 7.92 (s, 1H), 7.64-7.62 (m, 2H), 7.57-7.52 (m, 1H), 7.27 (s, 1H), 3.88 (s, 3H), 3.39 (brs, 4H), 3.34-3.26 (m 3H), 2.34 (brs, 4H), 1.34 (d, J=6.9 Hz, 6H).
- 3-(2,6-Dichlorophenyl)-5-isopropyl-4-((4-(4-methoxy-6-(1H-tetrazol-5-yl) benzo[d]thiazol-2-yl) piperazin-1-yl) methyl) isoxazole (Compound IX-02): To a solution of Compound IX-01 (100 mg, 0.18 mmol) in toluene (3 mL) was added azidotrimethylsilane (42.5 mg, 0.37 mmol) and tetrabutylammonium fluoride (94 mg, 0.36 mmol). The resulting solution was stirred for 18 h at 85° C. The reaction was quenched by the addition of 10 mL of water. The resulting mixture was extracted with 3*20 mL of ethyl acetate and the organic layers were combined. The resulted mixture was washed with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The crude product was purified by a reverse chromatography with H2O/CH3CN (39:61). This resulted in 2.8 mg (3%) of the title compound as a white solid. LC-MS (ESI, m/z): [M+H]+=585.2. 1H-NMR (300 MHz, DMSO-d6, ppm): δ 8.01 (s, 1H), 7.64-7.63 (m, 2H), 7.57-7.52 (m, 2H), 3.95 (s, 3H), 3.45-3.37 (m, 5H), 3.27 (s, 2H), 2.35 (brs, 4H), 1.34 (d, J=6.9 Hz, 6H).
- tert-Butyl 4-(5-bromo-1-benzothiophen-2-yl) piperazine-1-carboxylate (Compound 15a): To a solution of 5-bromo-2-iodo-1-benzothiophene (500 mg, 1.47 mmol) and tent-butyl piperazine-1-carboxylate (412 mg, 2.21 mmol) in dioxane (5 mL) was added Pd2(dba)3.CHCl3 (77 mg, 0.074 mmol), Xantphos (85 mg, 0.15 mmol) and Cs2CO3 (1.2 g, 3.68 mmol). The resulting solution was stirred overnight at 60° C. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:10). This resulted in 200 mg (34%) of the title compound as a yellow solid. LCMS (ESI, m/z): [M+H]+=397.1.
- 1-(5-Bromo-1-benzothiophen-2-yl) piperazine (Compound 15b): To a solution of Compound 15a (200 mg, 0.50 mmol) in dioxane (3 mL) was added a solution of hydrogen chloride in dioxane (6 mL, 4 M). The resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 120 mg (80%) of the title compound as a yellow solid. LCMS (ESI, m/z): [M+H]+=296.9.
- 1-(5-Bromo-1-benzothiophen-2-yl)-4-[[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methyl] piperazine (Compound 15c): To a solution of Compound 15b (150 mg, 0.50 mmol) and 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carbaldehyde (143 mg, 0.50 mmol) in dichloromethane (10 mL) was added acetic acid (30 mg, 0.50 mmol). The reaction was stirred at r.t. for 30 min, then NaBH(OAc)3 (318 mg, 1.5 mmol) was added into the mixture. The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:10). This resulted in 180 mg (63%) of the title compound as a white solid. LCMS (ESI, m/z): [M+H]+=566.2.
- 2-(4-[[3-(2,6-Dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methyl]piperazin-1-yl)-1-benzofuran-5-carboxylic acid (Compound X-01): To a solution of Compound 15c (80 mg, 0.14 mmol) in tetrahydrofuran (1 mL) was added a solution of n-BuLi in hexane (0.056 mL, 0.14 mmol) at −78° C. The resulting solution was stirred for 30 min at this temperature. CO2 gas was bubbled into the mixture at −78° C. until saturated. The mixture was allowed warm to room temperature and stirred for another 1 h. The reaction was then quenched by the addition of 1 mL of water. The pH value of the mixture was adjusted to 3 with HCl (2 N). The resulting solution was extracted with 3x5 mL of dichloromethane and the organic layers were combined. The resulted mixture was washed with water and brine. The residue was concentrated under vacuum after dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column with dichloromethane/methanol (20:1). This resulted in 40 mg (53%) of the title compound as a white solid. LCMS (ESI, m/z): [M+H]+=530.3. 1H NMR (300 MHz, DMSO-d6, ppm): δ 12.67 (s, 1H), 8.05 (s, 1H), 7.80-7.74 (s, 1H), 7.66-7.50 (s, 4H), 6.37 (s, 1H), 3.45-3.35 (s, 1H), 3.28 (s, 2H), 3.06-2.98 (m, 4H), 2.42-2.34 (m, 4H), 1.34 (d, J=6.9 Hz, 6H).
- The compounds of the present technology may be assayed using the following procedures and show or will be shown to have FXR binding activity.
-
- HEK293T
- pGL4.35[luc2P/9XGAL4 UAS/Hygro]
- pBIND-FXR Vector
- DMEM medium, high glucose
- Fetal Bovine Serum (FBS, heat-inactivated)
- Penicillin-Streptomycin (10000 U/m1,100 ml)
- DMEM, High Glucose, HEPES, no Phenol Red
- Opti-MEM® I Reduced Serum Medium
- Steady-Glo™ Luciferase Assay System
- TransIT-293 Transfection Reagent
- GW4064 as a positive control
-
- 1. Hek293T cells were plated at 1.1*106/ml into a 100 mm dish.
- 2. Cells were transfected with 8.4 μg of pBind-FXR, 1.26 μg of the reporter vector pGL4.35 (Promega). Cells were incubated at 37° C. under 5% CO2 atmosphere.
- 3. All of compounds were 3-fold serial diluted from 10 mM stock for 10 doses in DMSO.
- 4. Transfer compound dilutions into 384 well assay plates using liquid workstation.
- 5. Seed 25 ul HEK293T cells into 384 well assay plate (prepared step 4) at 0.6*105/ml. Cells were incubated at 37° C. under 5% CO2 atmosphere overnight.
- 6. Add 25 ul steady-Glo™ Luciferase Assay Reagent into each well of 384-well assay plate.
- 7. Record the luminescence value on Envision 2104 plate reader.
- 8. Calculate EC50 by fitting % Activity values and log of compound concentrations to nonlinear regression (dose response—variable slope) with Graphpad 5.0.
-
- LanthaScreen™ TR-FRET Farnesoid X Receptor Coactivator Assay
- GW4064 as a positive control
-
- 1. All of compounds were 3-fold serial diluted from 10 mM stock for 10 doses in DMSO.
- 2. Dilute each 100× agonist serial dilution to 2× using Complete Coregulator buffer G.
- 3. Transfer 10 μl of each of the 2× agonist serial dilutions to 384 well assay plates.
- 4. Add 5 μl of 4× FXR-LBD to 384 well assay plates.
- 5. Add 5 μl of 4× peptide/4× antibody solution to 384 well assay plates.
- 6. Incubate at room temperature protected from light.
- 7. Read the plate at wavelengths of 520 nm and 495 nm on Envision 2104 plate reader.
- 8. Calculate the TR-FRET ratio by dividing the emission signal at 520 nm by the emission signal at 495 nm.
- 9. Calculate EC50 by fitting % Activity values and log of compound concentrations to nonlinear regression (dose response—variable slope) with Graphpad 5.0.
- Results of the above assays with the present compounds are shown in Table 9.
-
TABLE 9 FXR Coactivator and Transactivation Assays FXR FXR Transactivation Coactivator Assay Assay Compound (EC50) (EC50) II-01 B A II-02 A A II-03 B A II-04 B A II-05 A A II-06 A — II-07 C — II-08 A A II-09 A A II-10 B — II-11 B A II-12 A — II-13 A A II-14 C — II-15 A — II-16 B A II-17 C — II-18 A A II-19 B A II-20 B A II-21 B — II-22 B A II-23 C — II-24 A A II-25 B — II-26 A A II-27 A — II-28 B A II-29 C — II-30 B A II-31 C — II-32 A A II-33 B A II-34 A — II-35 C — II-36 A — II-37 B — II-38 C — II-39 B — II-40 B A II-41 C — II-42 B A II-43 B A II-44 C — II-45 A — II-46 — A II-47 — B II-48 — B II-49 C — II-50 A — II-51 — A III-01 B — III-02 C — III-03 A — III-04 C — III-05 C — III-06 C — III-07 A — III-08 C — III-09 C B III2-01 — A III3-01 — C IV-01 A A IV-02 A — IV-03 B — IV-04 A — IV-05 C — IV-06 B — IV-07 C — IV-08 A — IV-09 C — IV-10 B — V-01 B — V-02 A — VI-01 B A VI-02 A — VI-03 B — VI-04 A A VI-05 C — VI-06 B — VI-07 B — VI-08 C — VI-09 A — VI-10 C — VI-11 C — VII-01 A A VII-02 A — VII-03 A — VII-04 A — VII-05 — A VIII-01 B A VIII-02 A A VIII-03 B — VIII-04 C — VIII-05 A — VIII-06 C — VIII-07 B — IX-01 C — IX-02 C — X-01 C — A: EC50 = 10 nM to 100 nM; B: EC50 = 101 nM-400 nM C: EC50 = 401 nM-5 uM - While certain embodiments have been illustrated and described, a person with ordinary skill in the art, after reading the foregoing specification, can effect changes, substitutions of equivalents and other types of alterations to the compounds of the present technology or salts, pharmaceutical compositions, derivatives, prodrugs, metabolites, tautomers or racemic mixtures thereof as set forth herein. Each aspect and embodiment described above can also have included or incorporated therewith such variations or aspects as disclosed in regard to any or all of the other aspects and embodiments.
- The present technology is also not to be limited in terms of the particular aspects described herein, which are intended as single illustrations of individual aspects of the present technology. Many modifications and variations of this present technology can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods within the scope of the present technology, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the appended claims. It is to be understood that this present technology is not limited to particular methods, reagents, compounds, compositions, labeled compounds or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only, and is not intended to be limiting. Thus, it is intended that the specification be considered as exemplary only with the breadth, scope and spirit of the present technology indicated only by the appended claims, definitions therein and any equivalents thereof.
- The embodiments, illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising,” “including,” “containing,” etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the claimed technology. Additionally, the phrase “consisting essentially of” will be understood to include those elements specifically recited and those additional elements that do not materially affect the basic and novel characteristics of the claimed technology. The phrase “consisting of” excludes any element not specified.
- In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
- As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as “up to,” “at least,” “greater than,” “less than,” and the like, include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member.
- All publications, patent applications, issued patents, and other documents (for example, journals, articles and/or textbooks) referred to in this specification are herein incorporated by reference as if each individual publication, patent application, issued patent, or other document was specifically and individually indicated to be incorporated by reference in its entirety. Definitions that are contained in text incorporated by reference are excluded to the extent that they contradict definitions in this disclosure.
- Other embodiments are set forth in the following claims, along with the full scope of equivalents to which such claims are entitled.
Claims (34)
1. A compound according to formula I
stereoisomers, and/or salts thereof wherein
L and M are independently selected from N and CR7, provided that at least one of L and M is N;
Z is a substituted or unsubstituted C1-C4 alkylene group;
W is
D is N or CR9;
G4 is CR13; G1, G2, G3 are selected from the group consisting of CH and CR11;
Q is O, S, or NR12;
R1 and R2 are independently H, OH, halo, CN, carboxyl, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, or hydroxyalkyl group;
R3 is a substituted or unsubstituted alkyl or cycloalkyl group;
R4 is CN, SO3H, CONRaRb, SO2NRaRb, NHSO2Rb, SO2NHCORa, CO2Rc, or a substituted or unsubstituted tetrazolyl or 1,2,4-oxadiazol-5(4H)-one-3-yl group;
R7 is H, OH, halo, CN, carboxyl, amido, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, or aminoalkyl group;
R9 is H, halo, or a substituted or unsubstituted C1-C6 alkyl, or O—(C1-C6 alkyl) group;
R10 at each occurrence is independently halo, CO2Rc, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group, or, when n is 2 or 3, two of the R10 groups together may be a substituted or unsubstituted C2-C5 alkylene, heteroalkylene, alkenylene or heteroalkenylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached;
R11 at each occurrence is independently OH, halo, CF3, CN, carboxyl, NRaRb, or a substituted or unsubstituted alkyl, alkoxy group, or phenyl group;
R12 is H or a substituted or unsubstituted C1-C6 alkyl group; and
R13 is halo, or a substituted or unsubstituted C1-C6 alkyl, or O—(C1-C6 alkyl) group;
Ra at each occurrence is independently H, or a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, or SO2-alkyl group;
Rb at each occurrence is H or a substituted or unsubstituted alkyl, or haloalkyl group;
Rc is H or a substituted or unsubstituted alkyl, alkenyl, alkynyl, or cycloalkyl group;
n is 0, 1, 2, 3, or 4; and
r and t are each independently 1, 2, or 3.
2. The compound of claim 1 , wherein Z is an unsubstituted C1-C4 alkylene group.
6. The compound of claim 5 according to Formula IA, wherein L is N.
7. The compound of claim 6 wherein n is 2 or 3 and two of the R10 groups together are a substituted or unsubstituted C2-C5 alkylene, heteroalkylene, alkenylene or heteroalkenylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached.
8. The compound of claim 7 wherein two of the R10 groups together are a substituted or unsubstituted C2-C5 alkylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached.
9. The compound of claim 5 according to formula IA, wherein L is CR7.
10. The compound of claim 9 , wherein n is 0.
11. The compound of claim 9 , wherein n is 1 or 2.
12. The compound of claim 11 wherein R10 at each occurrence is independently halo, CO2Rc, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group.
13. The compound of claim 3 according to Formula IB, wherein M is CR7.
14. The compound of claim 13 , wherein n is 0.
15. The compound of claim 13 , wherein n is 1 or 2.
16. The compound of claim 15 wherein R10 at each occurrence is independently halo, CO2Rc, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group.
17. The compound of claim 5 , wherein R4 is CO2H, CN, CONH2, SO2NH2, or a substituted or unsubstituted CO2—C1-C6 alkyl, CO2—C3-C6 cycloalkyl, CONH—C1-C6 alkyl, CONH—C3-C6 cycloalkyl, NH—SO2—C1-C6 alkyl, or tetrazolyl group.
18. The compound of claim 17 , wherein R4 is CO2H, CONH2, or a tetrazolyl group.
19. The compound of claim 5 , wherein R1 and R2 are independently halo, CN, CO2Re, NReRf, or a substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl group; and
wherein Re and Rf at each occurrence are independently H or a substituted or unsubstituted C1-C6 alkyl group.
20. The compound of claim 19 , wherein R1 and R2 are both Cl.
21. The compound of claim 5 , wherein R3 is a substituted or unsubstituted C1-C6 alkyl or C3-C6 cycloalkyl group.
22. The compound of claim 5 , wherein R3 is an isopropyl or cyclopropyl group.
24. The compound of claim 23 , wherein R11 at each occurrence is independently halo, CF3, or a substituted or unsubstituted alkyl, alkoxy, or phenyl group.
25. The compound of claim 23 , wherein R13 is F, or a substituted or unsubstituted C1-C3 alkyl, or O—(C1-C3 alkyl) group.
26. The compound of claim 25 , wherein R13 is F, CH3, or O—CH3.
27. The compound of claim 23 , wherein q is 0.
28. A compound selected from the group consisting of compounds II-17, II-30, II-36, II-37, II-38, II-39, II-43, II-44, II-45, I-46, II-47, II-48, II-49, I-50, II-51, III-08, IV-10, and VI-11.
29. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
30. A pharmaceutical composition comprising an effective amount of the compound of claim 1 for treating an FXR-mediated disorder or condition selected from the group consisting of liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, and renal disease.
31. The pharmaceutical composition of claim 30 wherein the disorder or condition is a liver disease selected from the group consisting of primary biliary cirrhosis (PBC), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, and liver cirrhosis.
32. A method of treatment comprising administering an effective amount of a compound of of claim 1 , or administering a pharmaceutical composition comprising an effective amount of a compound of claim 1 , to a subject suffering from an FXR-mediated disorder or condition selected from the group consisting of liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, and renal disease.
33. The method of claim 32 , wherein the disorder or condition is a liver disease selected from the group consisting of primary biliary cirrhosis (PB C), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, and liver cirrhosis.
34. A method comprising modulating FXR by contacting FXR with an effective amount of a compound of claim 1 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/108,644 US20210079006A1 (en) | 2016-11-04 | 2020-12-01 | Nitrogen-containing heterocyclic compounds as fxr modulators |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610974016.1 | 2016-11-04 | ||
CN201610974016.1A CN108017636A (en) | 2016-11-04 | 2016-11-04 | Nitrogen-containing heterocycle compound as FXR conditioning agents |
US201662424813P | 2016-11-21 | 2016-11-21 | |
PCT/US2017/058802 WO2018085148A1 (en) | 2016-11-04 | 2017-10-27 | Nitrogen-containing heterocyclic compounds as fxr modulators |
US201916346807A | 2019-05-01 | 2019-05-01 | |
US17/108,644 US20210079006A1 (en) | 2016-11-04 | 2020-12-01 | Nitrogen-containing heterocyclic compounds as fxr modulators |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/346,807 Continuation US10919903B2 (en) | 2016-11-04 | 2017-10-27 | Nitrogen-containing heterocyclic compounds as FXR modulators |
PCT/US2017/058802 Continuation WO2018085148A1 (en) | 2016-11-04 | 2017-10-27 | Nitrogen-containing heterocyclic compounds as fxr modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210079006A1 true US20210079006A1 (en) | 2021-03-18 |
Family
ID=62076166
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/346,807 Active US10919903B2 (en) | 2016-11-04 | 2017-10-27 | Nitrogen-containing heterocyclic compounds as FXR modulators |
US17/108,644 Abandoned US20210079006A1 (en) | 2016-11-04 | 2020-12-01 | Nitrogen-containing heterocyclic compounds as fxr modulators |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/346,807 Active US10919903B2 (en) | 2016-11-04 | 2017-10-27 | Nitrogen-containing heterocyclic compounds as FXR modulators |
Country Status (9)
Country | Link |
---|---|
US (2) | US10919903B2 (en) |
EP (1) | EP3535260B1 (en) |
JP (1) | JP7208909B2 (en) |
KR (1) | KR102553578B1 (en) |
CN (2) | CN108017636A (en) |
AU (1) | AU2017354873C1 (en) |
CA (1) | CA3042400A1 (en) |
DK (1) | DK3535260T3 (en) |
WO (1) | WO2018085148A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107427527B (en) | 2015-03-31 | 2021-01-26 | 英安塔制药有限公司 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
TW201808283A (en) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | Nitrogen-containing tricyclic compounds and uses thereof in medicine |
KR20190056436A (en) | 2016-10-04 | 2019-05-24 | 이난타 파마슈티칼스, 인코포레이티드 | Isoxazole analogs as FXR agonists and methods for their use |
WO2018081285A1 (en) | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
CN110128432B (en) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | Nitrogenous tricyclic compound and application thereof in medicine |
WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
CN111825667B (en) * | 2019-04-19 | 2023-07-25 | 中国科学院上海药物研究所 | FXR small molecule agonist and preparation method and application thereof |
EP3957640A4 (en) * | 2019-04-19 | 2022-12-14 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Fxr small molecule agonist and preparation method therefor and use thereof |
WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US20220265614A1 (en) | 2019-07-23 | 2022-08-25 | Novartis Ag | Treatment comprising fxr agonists |
AU2020319052A1 (en) | 2019-07-23 | 2022-01-27 | Novartis Ag | Combination treatment of liver diseases using FXR agonists |
US20220340668A1 (en) | 2019-09-03 | 2022-10-27 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
JP2022548617A (en) | 2019-09-19 | 2022-11-21 | ノバルティス アーゲー | Treatments including FXR agonists |
WO2021064575A1 (en) | 2019-09-30 | 2021-04-08 | Novartis Ag | Treatment comprising the use of fxr agonists |
CN114929218A (en) | 2019-12-20 | 2022-08-19 | 诺华股份有限公司 | Treatment of liver diseases using integrin inhibitor combinations |
CA3176946A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
CN112083113B (en) * | 2020-07-09 | 2021-06-15 | 苏州旭辉检测有限公司 | Biological sample analysis method of spiro compound |
KR20230053620A (en) | 2020-08-06 | 2023-04-21 | 가셔브룸 바이오, 인크. | Heterocyclic GLP-1 agonists |
CN116406360A (en) | 2020-08-28 | 2023-07-07 | 加舒布鲁姆生物公司 | Heterocyclic GLP-1 agonists |
WO2022078380A1 (en) * | 2020-10-13 | 2022-04-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
WO2023137135A1 (en) * | 2022-01-17 | 2023-07-20 | Hepagene Therapeutics (HK) Limited | Solid forms of a benzthiazole-piperazinyl-oxazole compound and methods of use thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
CN101374834B (en) * | 2006-02-03 | 2011-12-14 | 伊莱利利公司 | Compounds and methods for modulating FXR |
BRPI0812851A2 (en) * | 2007-07-02 | 2014-09-30 | Glaxosmithkline Llc | COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT OF A DISEASE AND CONDITION IN AN INDIVIDUAL, PROCESS FOR PREPARING A COMPOUND, AND USE OF A COMPOUND |
TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
EP2110374A1 (en) * | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
JP2014500318A (en) * | 2010-12-20 | 2014-01-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Compositions and methods for modulating farnesoid X receptor |
CN103391937A (en) * | 2010-12-20 | 2013-11-13 | Irm责任有限公司 | Compositions and methods for modulating farnesoid x receptors |
CU24152B1 (en) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS |
JP6366721B2 (en) * | 2013-09-11 | 2018-08-01 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and pharmaceutical compositions for treating hepatitis B virus infection |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
SG11201704340VA (en) * | 2014-12-18 | 2017-07-28 | Novartis Ag | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
CN106946867B (en) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | FXR receptor modulators and its preparation method and application |
US11110083B2 (en) * | 2016-02-22 | 2021-09-07 | Novartis Ag | Methods for treating liver disorders using FXR agonists |
WO2017189651A1 (en) * | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US11091482B2 (en) * | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
KR20190056436A (en) * | 2016-10-04 | 2019-05-24 | 이난타 파마슈티칼스, 인코포레이티드 | Isoxazole analogs as FXR agonists and methods for their use |
-
2016
- 2016-11-04 CN CN201610974016.1A patent/CN108017636A/en active Pending
-
2017
- 2017-10-27 WO PCT/US2017/058802 patent/WO2018085148A1/en unknown
- 2017-10-27 KR KR1020197015543A patent/KR102553578B1/en active IP Right Grant
- 2017-10-27 AU AU2017354873A patent/AU2017354873C1/en active Active
- 2017-10-27 DK DK17801164.9T patent/DK3535260T3/en active
- 2017-10-27 EP EP17801164.9A patent/EP3535260B1/en active Active
- 2017-10-27 CA CA3042400A patent/CA3042400A1/en active Pending
- 2017-10-27 US US16/346,807 patent/US10919903B2/en active Active
- 2017-10-27 JP JP2019544791A patent/JP7208909B2/en active Active
- 2017-10-27 CN CN201780067659.0A patent/CN109963849B/en active Active
-
2020
- 2020-12-01 US US17/108,644 patent/US20210079006A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2017354873B2 (en) | 2021-10-21 |
CA3042400A1 (en) | 2018-05-11 |
EP3535260A1 (en) | 2019-09-11 |
CN109963849A (en) | 2019-07-02 |
DK3535260T3 (en) | 2023-10-23 |
EP3535260B1 (en) | 2023-08-30 |
KR102553578B1 (en) | 2023-07-10 |
KR20190071801A (en) | 2019-06-24 |
US20190276465A1 (en) | 2019-09-12 |
AU2017354873C1 (en) | 2023-05-18 |
AU2017354873A1 (en) | 2019-05-23 |
JP2020500211A (en) | 2020-01-09 |
WO2018085148A1 (en) | 2018-05-11 |
CN109963849B (en) | 2023-03-28 |
US10919903B2 (en) | 2021-02-16 |
CN108017636A (en) | 2018-05-11 |
JP7208909B2 (en) | 2023-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10919903B2 (en) | Nitrogen-containing heterocyclic compounds as FXR modulators | |
US10899723B2 (en) | Heterocyclic containing cyclopropyl FXR modulators | |
WO2021078301A1 (en) | Protein degrading agent and use thereof in treatment of diseases | |
RU2507202C2 (en) | Novel phenylpyrazinones as kinase inhibitors | |
EP3426674A1 (en) | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | |
MX2015006038A (en) | Pyrrolidine gpr40 modulators. | |
US10829453B2 (en) | Antagonists of the kappa opioid receptor | |
US11427556B2 (en) | Urea derivatives as inhibitors of ASK1 | |
US20200031858A1 (en) | Avermectin derivatives as fxr modulators | |
WO2023154466A1 (en) | Arylbenzoisoxazole compounds as ip6k and ipmk inhibitors and methods of use thereof | |
US20210371459A1 (en) | Dimeric peptide inhibitors of apoptosis proteins | |
CA3071992A1 (en) | Glycyrrhetinic acid derivatives for treating hyperkalemia | |
US11034679B2 (en) | Agonists of the mu opioid receptor | |
WO2019099203A1 (en) | Oxazole and thiazole derivatives as inhibitors of ask1 | |
US20220220152A1 (en) | Bivalent antagonists of inhibitors of apoptosis proteins | |
US20200231547A1 (en) | 2-(1,1'-biphenyl)-1h-benzodimidazole derivatives and related compounds as apelin and apj agonists for treating cardiovascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |